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II 
Abstract 
 
CD4+ T cells play a key role in orchestrating adaptive immunity. Their activation 
requires antigen presentation via MHC II proteins on antigen presenting cells (APC). 
Exosomes are membrane vesicles released by various cell types including APCs. 
APC-derived exosomes are MHC class II-positive and can induce CD4+ T cell 
responses. MHC II delivery to the cell surface and/or exosomes might be influenced 
by tetraspanins, a family of transmembrane proteins.  
We have prepared exosomes derived from Epstein-Barr virus (EBV)-infected human 
B lymphoblastoid cell lines (LCLs) and shown by Western blotting and 
immunoelectron microscopy that they contain MHC class II and tetraspanins 
including CD63, CD81 and CD82. 
Such LCLs as well as LCL-derived exosomes can mediate immunologically specific 
recognition by MHC class II matched EBV antigen-specific CD4+ T cell clones when 
directly added to the T cells. Using shRNA, we have decreased CD63 expression in 
LCLs and had been studying the effect of such downregulation on LCL as well as 
LCL-derived exosome mediated antigen presentation. Despite an unaltered level of 
MHC II, CD63low LCLs showed to be hyperstimulatory. In spite of a similar 
depletion of CD63 in exosomes derived from CD63low LCLs, the CD4+ T cell 
stimulation by these exosomes was unaltered. In search for the mechanism of this 
phenomenon we found a higher level of exosome secretion by CD63low LCLs. We 
speculate that CD63 may influence T cell stimulation by exosome trafficking as well 
as exosome release. 
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1 Introduction 
 
1.1 Immune system 
 
1.1.1 Background 
 
The immune system is comprised of the innate, evolutionary old and primitive and the 
adaptive, more advanced immune response. Both these parts of the immune system 
are either cellular or humoral and protect against disease by identifying and 
eliminating pathogens. The innate immune response involves macrophages, 
neutrophils, eosinophils, granulocytes and dendritic cells. The adaptive immune 
response is antigen specific and involves T lymphocytes and antigen presenting cells 
(APC) like dendritic cells (DC), B lymphocytes and macrophages. Evolved in the first 
jawed vertebrates the adaptive immune system is based on somatic hypermutation and 
recombination enabling the immune cells to generate a vast number of different 
antigen receptors. This variability provides a highly adaptable cellular response to 
pathogens of different kind such as viruses. The adaptive immune system includes 
primary response, occurring during first encounter to a pathogen, and secondary 
response, performed by B and T cells. These B and T cells differentiate to memory 
cells after clearing the pathogen and provide long term immunity to this pathogen.  
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1.1.2 Antigen presenting cells 
 
APCs are able to recognise pathogens by a set of pattern recognition receptors (PRR) 
like the Toll like receptors (TLR) and are among the first cells of the immune system 
to respond to invading pathogens. Once activated, APCs increase the expression of 
various co-stimulatory molecules which allow these cells to induce a T cell response.  
 
1.1.3 Dendritic cells 
 
DCs provide a link between the innate and adaptive immune system by enabling 
primary as well as secondary immune responses. Deriving from the bone marrow, 
progenitors of these cells enter the circulatory system and eventually home to 
different tissues. Stimulated by the uptake of pathogens or the recognition of 
pathogenic determinants the progenitors become mature DCs, upregulating levels of 
stimulating molecules on their cell surface, and migrate to secondary lymphoid 
tissues. Here they are responsible for T cell activation (Tsai et al. 1989).  
 
1.1.4 B lymphocytes 
 
B cells are activated by antigen binding to B cell receptors (BCR), a membrane bound 
immunoglobulin, or by T cell engagement. B cell-activation induces their 
development to antibody secreting plasma cells. Hence B cells major role in the 
immune system is to produce antibodies specific to invading pathogens and cause 
their destruction. 
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In addition to secreting antibodies, B cells can function as APC. Receptor mediated 
endocytosis leads to antigen internalisation, reprocessing of the antigen and finally 
presentation of antigen fragments on major histocompatibility complex (MHC) class 
II molecules. These complexes are recognised by specific T cells leading to the 
initiation of signalling cascades and activation of both cell types (Bonilla and Oettgen 
2010).  
 
1.1.5 T lymphocytes 
 
T lymphocyte progenitors originate in the bone marrow and migrate to the thymus for 
selection and maturation. After leaving the thymus T lymphocytes re-circulate 
through the lymphoid organs. After activation by encountering specific antigens 
presented by APCs, T lymphocytes develop to effector cells with different cell type 
specific functions. The two major T cell types are CD8+ and CD4+ cells expressing 
specific T cell receptors (TCRs) which recognise antigen derived peptides presented 
by specific MHC molecules (Rammensee 1995).    
 
1.1.6 CD8+ T cells 
 
CD8+ T cells (cytotoxic T cells) recognise and respond to foreign peptides presented 
by MHC class I on the surface of virtually all nucleated cells. Cytoplasmic antigens, 
or in the case of DCs exogenous antigens, are processed intracellularly by proteases 
and transported into the rough endoplasmatic reticulum (RER) where MHC class I 
loading occurs (Fig.1.1) (Groothuis and Neefjes 2005).  
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Figure 1.1: Antigen processing and presentation pathway for MHC class I 
Antigens presented by MHC class I are derived from intracellular proteins. a) These proteins 
are degraded by the proteasome into short peptide fragments that are then transported into the 
endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) at 
the (ER). Peptide binding to MHC class I is followed by the transportation of this complex 
through the Golgi to the surface membrane. b) Alternatively extracellular or even ER-derived 
proteins can exit the endosomal pathway to the cytosol and enter the normal MHC class I 
loading pathway. Reproduced from: (Andersen et al. 2006) 
 
MHC class I molecules derive from human leukocyte antigen (HLA)-A, -B, and -C 
loci where multiple allelic variants of the major loci ensure that a wide variety of 
peptides can be bound by the peptide binding groove. The structure of the peptide 
binding groove determines the antigen binding specificity of each molecule 
(Matsumura et al. 1992).  
Upon recognition of an epitope bound to MHC class I, naïve CD8+ T cells undergo 
clonal expansion and differentiation into effector cells (Andersen, Schrama, Thor, & 
Becker 2006;Pfeifer, Wick, Roberts, Findlay, Normark, & Harding 1993). Even 
though an interaction of the TCR with the appropriate peptide-MHC complexes is 
crucial for T cell activation, clonal expansion and differentiation, further co-
stimulatory signals are required. The best characterised for example is the interaction 
between T cell CD28 and CD80 and CD86 on the APC. When activated, CD8+ T 
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cells can kill their target cells in different ways. On one hand, they release cytotoxic 
effector molecules like perforin and granzymes which form pores in the plasma 
membrane of target cells, thereby compromising the membrane’s integrity on one 
side, and activating proteinases called caspases, on the other. These events will result 
in death of target cell. On the other hand, CD8+ T cells can induce apoptosis by 
expressing Fas-ligand (FasL) which binds to Fas on the target cell (Chavez-Galan et 
al. 2009).  
 
1.1.7 CD4+ T cells 
 
CD4+ T cells (T helper cells) play a key role in orchestrating adaptive immunity by 
regulating cellular and humoral immune responses (Khanolkar et al. 2004;Zajac et al. 
1998). They have been historically divided into two different lineages based on their 
cytokine production. T helper cells 1 (Th1 cells) are characterised by their production 
of Interferon (IFN)-γ, Interleukin (IL)-2 and Tumour necrosis factor (TNF)-α and 
evolved to enhance eradication of intracellular pathogens. Th2 cells, which instead 
evolved to enhance elimination of extracellular parasitic infections, produce the 
cytokines IL-4, IL-5 and IL-13 which are potent activators of immunoglobulin 
production and facilitate recruitment of eosinophils, a particular kind of granulocytes. 
In recent studies, Th17 cells which are so called because of their production of IL-17 
have been further characterised (Park et al. 2005). They seem to be highly 
proinflammatory and involved in autoimmune disorders (Bettelli et al. 2007;Langrish 
et al. 2005). 
Another subset of CD4+ T cells is regulatory T cells (Tregs) which can be divided 
into two different types. Natural occurring Tregs develop in the Thymus and go to the 
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periphery with a functional suppressive phenotype where they make up to 5-10% of 
the peripheral CD4+ T cell population (Wing et al. 2006). They express the 
transcription factor Forkhead box protein 3 (Foxp3) (Fontenot et al. 2003;Hori et al. 
2003) and seem to mediate the suppression in a contact dependent way. They need 
TCR interaction to become suppressive but once activated they suppress all T cells 
independently of their antigen specificity (Wing et al. 2006). Adaptive Treg cells (also 
known as Tr1 cells or Th3 cells) may originate during a normal immune response 
from mature T-cell populations under certain conditions of cytokine- and antigenic 
stimulation (Barrat et al. 2002;Maloy and Powrie 2001). So, adaptive Treg cells are 
distinguished from natural Treg cells not by their origin (the thymus), but rather by 
their requirement for further differentiation as a consequence of exposure to antigen in 
a distinct immunological context.  
 
1.1.7.1 Pathways of antigen presentation through MHC class II 
 
CD4+ T cells are stimulated by pathogen-derived exogenous peptides, presented on 
MHC class II molecules, encoded by HLA-DR, -DQ and –DP loci and expressed on 
specific APCs. After encountering antigen, APCs can internalise antigens in three 
different ways: by phagocytosis, fluid phase pinocytosis or receptor mediated 
endocytosis (Thery and Amigorena 2001). The antigen then is proteolytically 
processed into small peptide fragments and loaded onto MHC class II molecules 
which occurs in special compartments called MHC class II enriched compartments 
(MIICs) (Fig.1.2). In the ER, MHC II α and β-chains assemble into heterodimers 
forming a binding groove capable of binding antigenic peptides. Yet in the early 
stages, this binding groove is occupied by a short peptide called CLIP from the 
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transmembrane chaperon called invariant chain (Ii) (Roche and Cresswell 1990). 
CLIP prevents MHC II from premature peptide binding. From here these molecule 
complexes can either be transported directly to the cell surface via vesicles derived 
from the Trans Golgi Network (TGN) or a sorting motif in the cytoplasmic portion of 
li directs MHC II complexes to MIICs (Bakke and Dobberstein 1990;Roche et al. 
1993). Within MIICs low pH, protease activity and a chaperone called HLA-DM 
facilitate the exchange of CLIP for antigenic peptides. Also other proteins on the 
membranes of MIICs may interact with MHC II, HLA-DM (Hammond et al. 1998) 
and play a role in efficient peptide loading. Ultimately, fusion of MIIC with the 
plasma membrane is one way MHC II complexes are delivered to the surface for 
antigen presentation (Raposo et al. 1996;Wubbolts et al. 1996). An alternative way is 
MHC class II recycling which occurs by internalisation of MHC class II-peptide 
complexes via ubiquitin mediated endocytosis from the plasma membrane. This way 
of entering the endosomal pathway eventually leads to reprocessing of these MHC 
class II-peptide complexes in MIICs. In this context, where cells (APCs) naturally 
express MHC class II antigens, CD4+ T lymphocytes could potentially act as direct 
effectors in their own right and kill infected or malignant cells (Merlo et al. 2010). 
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Figure 1.2: Antigen processing and presentation pathway for MHC class II 
MHC class II heterodimers are assembled in the ER and transported by the invariant chain (li) 
through the Golgi (1) either directly to MIICs or (2) indirectly via the surface membrane 
where unbiquitination (Ub) results in re-internalisation and recycling of MHC molecules (3). 
In the MIIC, proteases degrade li leaving a small fragment called CLIP in the binding groove. 
HLA-DM later replaces CLIP with exogenous peptides before the MHC class II-peptide 
complex is integrated into the plasma membrane. Reproduced from: (Rocha and Neefjes 
2008) 
 
1.1.8 The immunological synapse (IS) 
 
The adaptive immune response relies on T cell activation by their recognition of 
antigenic peptides presented by APCs which in turn necessitates the physical 
interaction of T cell and APC. This interaction is accompanied by pronounced 
changes in T cell morphology; these include a flattening of the T cell against the APC 
which requires changes in the cytoskeleton (Delon et al. 1998;Donnadieu et al. 1994). 
For T cells early research has shown that both, the microtubule organising centre 
(MTOC) and microfilaments orientate towards the APC (Geiger et al. 1982;Kupfer et 
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al. 1986). This T cell-APC interface is termed immunological synapse or immune 
synapse (IS) as it is thought to function in the communication between the two cells 
(Bromley et al. 2001). The IS is organised into distinct domains termed 
supramolecular activation clusters (SMACs). These clusters sequester receptor-ligand 
interactions and signalling molecules and facilitate adhesion and antigen presentation 
or recognition, respectively (Grakoui et al. 1999). The SMAC is canonically 
organised into concentric rings during antigen presentation. The orientation of 
molecules involved in antigen presentation and activation such as TCRs, MHCs and 
co-stimulatory molecules are located in the of the “Bull’s eye” thermed central SMAC 
(cSMAC) within the IS; adhesion molecules such as LFA-1 and ICAM-1 are located 
within the peripheral SMAC (pSMAC) surrounding the centre (Monks et al. 1998a).  
 
1.1.9 Cancer immune evasion 
 
In the majority of cancer patients, tumours are not recognised by the immune system. 
This lack of natural induced immunity is not only due to the limited expression of 
tumour-associated antigens (TAAs) (Disis et al. 2000) but also to an active 
suppression of the adaptive immune activity by the tumour cells.  
During the process of tumour growth, the tumour microenvironment, which is 
composed of immune cells, stromal cells and the extracellular matrix, is the main site 
of immune and cancer cell interaction allowing and supporting proliferation, survival 
and cell migration of tumour cells. Not only do malignant cells survive in these 
conditions but they are also capable of mimicking some of the signalling pathways of 
the immune system which enhances tumour immune tolerance and allow them to 
escape host immune response. The major influences are imbalances in the tumour 
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microenvironment including alterations in APC-subsets. This is caused by 
deregulation of the ratios of co-stimulatory and co-inhibitory molecules and of T cells 
and regulatory T cells (Zou 2005). Additionally, cancer cells can release surface 
antigens in order to evade detection of the immune system. This energy dependent 
process may involve secretion of a specific type of microvesicles called exosomes, 
which themselves have been shown to have a potential inhibitory effect on immune 
cells in vitro (Valenti et al. 2007;Whiteside 2005).  
 
1.1.10 Cancer immunotherapy 
 
The main strategy in cancer immunotherapy is to make use of the altered or de novo 
expression of particular proteins and to target these TAAs for host immune responses. 
Expression of most TAAs is not restricted to tumour cells but these antigens are either 
over-expressed in tumour cells or only occur naturally during the foetal development. 
Despite an existing shortage of well-defined tumour antigens, several 
immunotherapeutic approaches have been used in the treatment of various cancers. 
For example, patients could be vaccinated to a certain degree using tumour cell 
lysates and irradiated tumour cells (Mitchell et al. 2002). However, this treatment is 
costly and labour intensive and inoculation the entire repertoire of cellular proteins 
risks masking TAAs and potentially generates dangerous auto-reactive immune 
responses (Moingeon 2001). Monoclonal antibodies, unmodified, chimeric or armed 
with toxins or radionuclides, recognising particular TAAs have also been approved to 
treat cancer in several trials (Waldmann 2003). Compared to passive immunisation 
active immunotherapy mostly targets the direct enhancement or modulation of the 
function of APCs. Since DCs are considered most potent in initiating immune 
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responses, therapeutic approaches involve mature DCs either loaded with tumour 
antigens (Berger and Schultz 2003) or transduced with genes that encode relevant 
tumour antigens in vitro (Dyall et al. 2001). These DCs then are re-introduced to the 
patients to stimulate cytotoxic T cell response in vivo. Tumour-antigen specific 
cytotoxic T cells were also used directly to combat particular cancers. Similar to DCs 
they can be generated ex vivo to produce an anti-tumour response after re-
administration to the patient (Yamaguchi et al. 2003). Recently Hunder et al. 
successfully treated a patient with refractory melanoma by isolating and expanding 
autologous tumour-antigen specific CD4+ T cells. They achieved a durable clinical 
remission of the tumours (Hunder et al. 2008). However, high costs, labour 
intensiveness and high specificity, limit the use of all methods involving ex vivo 
propagation and treatment of live cells in immunotherapies.  
 
1.2 Exosomes 
 
1.2.1 Definition and exosome formation 
 
Exosomes are small membrane vesicles of endocytic origin, 30 – 100nm in size, 
which are secreted by a variety of different cell types including B cells (Raposo et al. 
1996), T cells (Blanchard et al. 2002), DC (Zitvogel et al. 1998), neurons (Faure et al. 
2006), epithelial cells (Van et al. 2001) and tumour cells (Andre et al. 2004b). Recent 
studies revealed the presence of exosomes in a number of body fluids such as plasma 
(Caby et al. 2005), urine (Pisitkun et al. 2004), synovial fluid (Skriner et al. 2006), 
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malignant effusions (Andre et al. 2002), epididymal fluid (Gatti et al. 2005) and 
seminal plasma (Ronquist 2007). 
Exosomes are thought to originate from late endosomal compartments called 
mulitvesicular bodies (MVBs). They are formed by fusion of endosomes with one 
another and subsequent inward budding of the limiting endosomal membrane. MVBs 
either transport proteins for degradation to lysosomes, release their intraluminal 
vesicles into the cytoplasm as a result of a process called back fusion or fuse with the 
plasma membrane releasing its inner vesicles now called exosomes (Pan et al. 
1985;Raposo et al. 1996;Simons and Raposo 2009). The intracellular transport of 
vesicles and sorting of cargo into MVBs is orchestrated among others by Rab proteins 
and Ca
2+
 (Savina et al. 2002;Savina et al. 2003;Savina et al. 2005), by the endosomal 
sorting complexes required for transport (ESCRT) (De et al. 2004;Tamai et al. 2010), 
lipid rafts (De et al. 2003;Mincheva-Nilsson and Baranov 2010) and ubiquitination 
(Longva et al. 2002;Pisitkun et al. 2004).  
 
1.2.2 Exosome composition 
 
The composition of exosomes varies between cell types but contains some common 
components such as MHC class I, Rabs, Arp2/3, annexins (Thery et al. 
2001;Wubbolts et al. 2003a) and tetraspanins (Escola et al. 1998) as well as heat 
shock proteins (Clayton et al. 2005;Thery et al. 1999), cytoskeleton proteins like actin 
and moesin, ESCRT proteins, and CD55 and CD59, both of which have been shown 
to protect exosomes from complement lysis (Clayton et al. 2003) (Table 1.1). In 
APCs, MIICs, which represent a morphologically distinct class of MVBs, are the 
major sites for antigen loading of MHC class II molecules. Consequently, APC 
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derived exosomes bear peptide loaded MHC class II-peptide complexes in addition to 
co-stimulatory proteins such as CD54 (ICAM-1), CD80 (B7-1) and CD86 (B7-2) 
(Clayton et al. 2001;Escola et al. 1998;Lamparski et al. 2002).  
 
A                                                               B 
 
 
Figure 1.3: Exosome formation and protein composition 
A) Tracking an anti-transferrin-receptor antibody reveals the formation of exosomes. Firstly 
clathrin coated pits are observed which quickly lead to the generation of early endosomes. 
These fuse with one another and form intraluminal vesicles by invagination leading to MVBs. 
After fusion of these MVBs with the plasma membrane the intraluminal vesicles are released 
as exosomes to the extracellular environment. B) According to their origin and development 
exosomes carry several cytosolic as well as specific and general membrane proteins. 
Reproduced from: (Thery et al. 2002b) 
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Table 1.1: protein expression of exosomes according to their cell type origin  
modified from (Thery et al. 2002b) 
 
Exosomes protein Cell type 
Antigen presentation  
MHC class I B cells, Dendritic cells, Enterocytes, 
Tumours, T cells 
MHC class II B cells, Dendritic cells, Enterocytes (IFNγ-
treated), Mastocytes, T cells 
 
Integrins 
 
α4β1 Reticulocytes  
αMβ2 Dendritic cells 
β2 T cells 
αLβ2 Mastocytes 
 
Immunoglobulin-family members 
 
ICAM-1/CD54 B cells, Dendritic cells, Mastocytes 
P-selectin Platelets 
A33 antigen Enterocytes 
 
Cell surface peptidases 
 
Dipeptidylpeptidase IV/CD26 Enterocytes 
Aminopeptidase  n/CD13 Mastocytes 
 
Tetraspanins 
 
CD63 B cells, Dendritic cells, Enterocytes, 
Platelets, T cells, Mastocytes 
CD37, CD53, CD81, CD82 B cells 
CD9 Dendritic cells 
 
Heat-shock proteins 
 
HSC70 Reticulocytes, Dendritic cells, Tumours 
HSP84/90 Dendritic cells, Enterocytes 
 
Cytoskeletal proteins 
 
Actin Dendritic cells, Enterocytes, Mastocytes 
Actin-binding protein (cofilin) Dendritic cells 
Tubulin Dendritic cells, Enterocytes 
 
Membrane transport and fusion 
 
Annexins I, II, IV, V, VI Dendritic cells 
Annexin VI Mastocytes 
RAB7/RAP1B/RABGDI Dendritic cells 
 
Signal transduction 
 
GI2α/14-3-3 Dendritic cells 
CBL/LCK 
miRNA 
T cells 
T cells (Mittelbrunn et al. 2011) 
 
Metabolic enzymes 
 
Enolase 1 Enterocytes 
Thioredoxine peroxidase Dendritic cells 
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1.2.3 Exosome function in APCs 
 
As well as being present on the cell surface MHC molecules and tetraspanins are 
released from cells on exosomes. These micro-vesicles were initially discovered 
studying reticulocytes which use exosomal secretion as a pathway to remove obsolete 
proteins such as the transferrin receptor during their maturation from reticulocytes to 
erythrocytes (Pan et al. 1983). Exosomes from APCs are shown to be involved in T 
cell stimulation both in vitro (Hwang et al. 2003;Raposo et al. 1996;Utsugi-Kobukai 
et al. 2003;Vincent-Schneider et al. 2002) and in vivo (Segura et al. 2005;Thery et al. 
2002a). There is still a debate regarding how this stimulation occurs, with some 
studies showing exosomes being able to stimulate T cells directly without the 
presence of APCs (Hwang et al. 2003;Raposo et al. 1996) while others demonstrating 
that exosomes need APCs to exert their effect (Thery et al. 2002a;Vincent-Schneider 
et al. 2002). Different parameters may play a role in the efficiency of T cell 
stimulation by exosomes. Some of them are the phenotype of exosomes and of the T 
cells used, the affinity of the antigens or the doses or quality of the exosomes used. 
Hwang et al. proved that CD54 together with B7 and MHC class I/peptide complex 
on exosomes is strongly immunogenic (Hwang et al. 2003). Segura et al. showed that 
CD54 together with MHC class II is required to prime naïve T cells (Segura et al. 
2005). Referring to the exosome’s donor cell type, it is shown that exosomes from 
mature DCs are more potent inducing antigen specific T cell stimulation as compared 
to exosomes from other APCs (Segura et al. 2005;Utsugi-Kobukai et al. 2003) which 
may be due to the higher expression of the proteins CD54 and MHC II.  
Another function for exosomes might be to serve as a vehicle to transport molecules 
from one cell to another. MHC/peptide complexes are transferred between DCs 
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enabling recipient cells to efficiently stimulate T cells in an antigen specific manner 
(Andre et al. 2004a;Hsu et al. 2003). Furthermore, exosomes can be internalised by 
DCs and sorted to the endosomal compartments for reprocessing of exosomal 
proteins, which will lead to presenting their peptides on MHC class II molecules and 
stimulation of CD4+ T cells. The targeting to DCs is mediated by a number of 
exosomal proteins including milk fat globule elongation factor 8 (MFG-E8), CD11a, 
CD54, phosphatidylserine and the tetraspanins CD9 and CD81 (Morelli et al. 2004). 
Moreover, in vivo experiments demonstrated that exosome like vesicles bearing MHC 
class II can be attached to follicular DCs. As these cells do not express MHC class II 
themselves the vesicles probably derive from another cell type and may be involved 
in modulating the immune response (Denzer et al. 2000). Additionally, B cell derived 
exosomes were shown to express integrin molecules which enable them to bind to 
extracellular matrix proteins like collagen and fibronectin as well as the surface of 
activated fibroblasts giving evidence for exosomes’ ability to transfer signals at 
distances beyond the direct cell-to-cell contact (Clayton et al. 2004). Also exosomes 
secreted by mast cells are shown to have an immunological effect. They are able to 
stimulate maturation of DCs, which respond with up-regulation of MHC class II, 
CD40, CD80 and CD86. In addition, when co-incubated with splenocytes mast cell-
derived exosomes induced blast-formation, proliferation and IL-2 and IFNγ 
production (Skokos et al. 2003). More recent in vitro studies demonstrated that 
exosomes could serve as a tool for a cell-free vaccine for immunoprophylaxis against 
leishmaniasis and other infectious diseases (Schnitzer et al. 2010).  
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1.2.4 Exosomes from tumour cells 
 
During the last few years much effort has been invested to study exosomes in the 
context of tumour biology and cancer treatment. Tumour cell-derived exosomes were 
able to protect mice against establishment of the tumour (Wolfers et al. 2001). Later, 
exosomes bearing MHC class I, heat shock proteins (Hsp), CD81 and tumour antigens 
such as melanoma antigen recognised by T cells (MART1) could be purified from 
malignant effusions from cancer patients (Andre et al. 2002). In both studies these 
exosomes were able to transfer tumour specific antigens to DCs which made them 
capable to induce CD8+ T cell response. Although these features suggest tumour-
derived exosomes as a potential tool in cancer immunotherapy, in some other studies 
they were also depicted to be immunosuppressive and promote cancer tolerance. 
These exosomes were shown to inhibit CD8+ T cell cytotoxic killing (Clayton and 
Tabi 2005) and promote apoptosis of CD8+ T cells by FasL-Fas interaction 
(Abusamra et al. 2005). Likewise, tumour-derived exosomes can inhibit the 
cytotoxicity of natural killer cells (NK) by reducing their perforin release (Liu et al. 
2006) and activate differentiation of myeloid-derived suppressor cells (MDSC) which 
are shown to promote tumour progression (Xiang et al. 2008). Exosomes secreted by 
EBV-associated nasopharyngeal carcinoma cells were shown to express Galectin-9 in 
vivo. Galectin-9 binds to TIM (T cell, immunoglobulin domain and mucin domain)-3, 
an apoptosis inducing membrane receptor on mature CD4+ T cells. NPC exosomes 
induced significant apoptosis of EBV-specific CD4+ T cells and indicate their CD4+ 
T cell suppressive effect and a role in tumour tolerance (Klibi et al. 2008). 
Additionally, exosomes are proven to be involved in tumour angiogenesis by the 
expression of the tetraspanin D6.1A/CO-029 (Tspan8) (Gesierich et al. 2006) or 
  
18 
Tspan8-CD49d complex (Nazarenko et al. 2010a), proteins shown to be strong 
inducers of angiogenesis.  
 
1.2.5 Exosomes in cancer immunotherapy  
 
Even though tumour derived exosomes have been shown to exhibit inhibitory effects 
on immunity (Abusamra et al. 2005;Clayton & Tabi 2005;Liu et al. 2006) they are 
still an attractive target for immunotherapy as they represent a natural source of 
tumour antigens (Wolfers et al. 2001).  
First evidence for the anti-tumour effect was shown for tumour-peptide pulsed DC-
derived exosomes (DEX). Injected into mice they suppressed established tumour 
growth (Zitvogel et al. 1998). Since then many studies focussed on exosomes as a 
potential tool in immunotherapy. Different approaches examined either exosomes 
from tumour cells or exosomes from DCs loaded with tumour peptides as mentioned 
above (Altieri et al. 2004;Chaput et al. 2004;Hao et al. 2006b). Comparison of these 
two different potential cancer vaccines revealed tumour peptide loaded exosomes 
derived from DCs as an efficient vehicle in inducing an anti-tumour immunity (Hao et 
al. 2006a). Different approaches to improve the immunogenicity of exosomes have 
been utilised. For example, heat shocked lymphoma cells led to secretion of exosomes 
with a higher level of both, heat-shock proteins and lymphocyte proteins such as 
MHC class II, CD40 and CD86. These exosomes were more potent in inducing T cell 
responses and anti-tumour immunity when compared to exosomes from untreated 
lymphoma cells (Chen et al. 2006). Furthermore, an increase in exosomal 
immunogenicity could be achieved by tumour cells genetically modified to express 
IL-2. Their exosomes contain IL-2 which made them more efficient in inhibiting 
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tumour growth when used for immunotherapeutic experiments (Yang et al. 2007). 
Additionally, the supplemental treatment with adjuvants like CpG was shown to have 
positive effects on tumour rejection (Chaput et al. 2004). Autologous DEX loaded 
with tumour peptides were used in phase 1 clinical trials for vaccination of lung 
cancer and melanoma patients. Low toxicity of the exosome treatment could be 
shown (Escudier et al. 2005;Morse et al. 2005) which allowed going to phase II 
clinical trial (Mignot et al. 2006).   
 
1.3 Tetraspanins 
 
1.3.1 Background 
 
Tetraspanins are ubiquitous surface proteins, firstly described as an distinct protein 
family in 1994 (Wright and Tomlinson 1994). Subsequent work has revealed much 
more about their structure and functions. Tetraspanins are known to be involved in 
various cellular processes including motility, invasion, fusion, signalling, maintaining 
cell morphology, immune response and even in pathogenesis of pathogenic diseases 
(Boucheix and Rubinstein 2001;Chambrion and Le 2010;Hemler 2003a;Romanska 
and Berditchevski 2010;Tarrant et al. 2003;van Spriel and Figdor 2010a).  
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1.3.2 Tetraspanin structure 
 
All members of the tetraspanin family have a characteristic structure (Fig. 1.5) 
consisting of four transmembrane domains giving rise to a small and a large 
extracellular loop (termed EC1 and EC2, respectively), a small interconnecting 
cytoplasmic loop and a short C- and N-terminal cytoplasmic tails. A distinctive 
feature of tetraspanins compared to other four-transmembrane proteins is the 
conserved Cys-Cys-Gly motif in EC2 which stabilises the three dimensional structure 
of this loop. Intracellular juxtramembrane cysteins are palmitoylated which is thought 
to facilitate tetraspanin-tetraspanin binding and together with palmitoylation of 
specific integrins it contributes to formation of tetraspanin microdomains 
(Berditchevski et al. 2002;Charrin et al. 2002;Sharma et al. 2008). It has been 
proposed that the main tertiary structure of the protein is partly stabilised by polar 
residues in the transmembrane regions (Seigneuret 2006;Stipp et al. 2003b).  
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Figure 1.4: Tetraspanin structure 
Tetraspanins are comprised of four transmembrane domains, an N- and C-terminal cytosolic 
tail, two extracellular loops (EC1 and EC2) and a short intracellular loop. EC2 can be 
separated into a constant (yellow) and a variable region (blue) where conserved cysteins, 
including the CCG motif, lead to sulphide bonds which are crucial for the correct folding of 
EC2 (Hemler 2005). Reproduced from: Hemler, 2005 
 
1.3.3 Binding partners 
  
The most important feature of tetraspanins is their ability to interact with one another 
as well as with other molecules in the cell membrane. Homophilic tetraspanin-
tetraspanin interactions (e.g. CD9-CD9) are more common than the formation of 
heterophilic complexes (e.g. CD9-CD151, CD81-CD151) (Kovalenko et al. 2004). 
Non-tetraspanin associations involve several transmembrane and also some cytosolic 
molecules  including integrins, growth factor receptors, peptidases, immunoglobulin 
superfamily members, G-protein coupled receptors and their associated G-proteins 
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and cytosolic signal transduction molecules (Table 2) (Andre et al. 
2006;Berditchevski 2001;Hemler 2005;Levy and Shoham 2005a). 
Apart from these direct interactions, creating protein-oligomers, tetraspanins associate 
with cholesterol and gangliosides (Charrin et al. 2003;Miura et al. 2004;Odintsova et 
al. 2006), enabling these small protein complexes to group together to form higher 
order protein aggregates, the tetraspanin-enriched microdomains (TERMs) (Hemler 
2003b;Hemler 2005). 
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Table 1.2: known tetraspanin partners  
Reproduced from M. Yunta, P. Lazo, 2002 and M. Yáñez-Mó et al. 2009 
 
  CD9 CD37 CD53 CD63 CD81 CD82 CD151 
Integrins α3β1 + + + + + + + 
 α4β1 + nd + + + + nd 
 α6β1 + nd + + + + + 
 α5β1 + nd nd + + + + 
 α6β1 + nd nd nd nd nd + 
 α7β1 + nd nd nd nd nd + 
 Precursor β1 + nd nd - - - nd 
 αLβ2 nd nd nd + nd + nd 
 αMβ2 nd nd nd + nd nd nd 
 αIIbβ3 + nd nd - - - - 
 α3β4 + + + + + + + 
 αvβ4 nd nd nd nd + nd nd 
 CD11/CD18 nd nd nd + nd nd nd 
         
MHC HLA-DR + + + + + + + 
 HLA-DM + nd nd + + + nd 
 HLA-DQ + + + + + + + 
 HLA-DO + nd nd + + + nd 
 MHC I nd nd + + + + nd 
         
Growth factor 
receptor 
EGF-R nd nd nd nd nd + nd 
 TGF-α + nd nd nd nd nd nd 
 HB-EGF + nd nd nd nd nd nd 
         
Immunoglobulin 
superfamily 
FRPP + nd nd nd + nd nd 
 EWI-2 + nd nd nd + nd nd 
 EWI-F + nd nd nd + nd nd 
 CD2 + nd + nd nd nd nd 
 CD4 nd nd nd nd + + nd 
 CD8 nd nd nd nd + + nd 
 CD19 + nd nd nd + + nd 
 CD20 nd nd + nd + + nd 
 CD54 (ICAM-1) + nd nd nd nd nd nd 
 CD106 (VCAM-1) nd nd nd nd nd nd + 
         
Other membrane 
proteins 
CD36 + nd nd nd nd nd nd 
 CD46 + nd nd nd + + + 
 CD21/CD19/Leu13 nd nd nd nd + nd nd 
 E-cadherin nd nd nd nd nd nd + 
 L6 nd nd nd nd nd nd + 
 Dectin-1 nd + nd + nd nd nd 
         
Signalling 
molecules 
PKC + - + - + + + 
 PI 4K + nd - + + - + 
nd: not determined 
 
1.3.4 Tetraspanins and immune responses 
 
Tetraspanins function via modulating the functions of associated proteins rather than 
exhibiting direct enzymatic activities. Tetraspanins sequester partner molecules into 
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TERMs where these molecules are influenced by the composition of the 
microdomains as well as the surrounding tissue and the maturation state of the cell. 
For example, tetraspanins influence cell adhesion, migration and spreading 
predominantly by compartmentalisation, clustering, internalisation, recycling of 
integrins and regulating integrin-dependent signalling (Berditchevski 2001;Hemler 
2005;Levy and Shoham 2005b;Stipp et al. 2003b). Since all cells of the immune 
system express tetraspanins (Tarrant et al. 2003) they also have been implicated in 
various aspects of host immunity (Table 1.3). Tetraspanins and associated molecules 
are involved in intercellular interactions involving immune cells as well as immune 
cell migration, adhesion, proliferation and signalling (Rubinstein et al. 1996). At the 
cellular level tetraspanins contribute to synapse formation (Mittelbrunn et al. 2002) 
and intracellular transport (i.e. endocytosis and exocytosis) of key immune receptors 
and associated effector proteins (Pols and Klumperman 2008) (Fig. 1.5 A). 
Tetraspanins are shown to interact with fungal pattern-recognition receptors (F-PRR) 
and may regulate their function in the response to fungal antigens by recruitment of F-
PRRs into TERMs (Figdor and van Spriel 2010). Moreover, tetraspanins are 
suggested to play a role in the defense to viral, bacterial and parasitic infections (van 
Spriel & Figdor 2010a).   
In the context of tetraspanins and their role in antigen presentation via MHC II,  
tetraspanins CD9, CD37, CD53, CD81 and CD82 are documented to interact on the 
surface with MHC class II complexes (Engering et al. 2003;Kijimoto-Ochiai et al. 
2004;Schick and Levy 1993a) (Fig. 1.5 B). It was also described that tetraspanins, 
which are abundant on MIIC can interact with HLA-DM and HLA-DO (Hammond et 
al. 1998). Given emerging roles of tetraspanin microdomains in sorting and 
trafficking of the associated proteins, it has been suggested that tetraspanins may play 
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a role in MHC transport (Vyas et al. 2007) or peptide loading (Rocha & Neefjes 2008) 
(Fig. 1.5 A). It is thought that peptide presentation by MHC molecules does not occur 
randomly but instead is a well organised process which brings MHC-peptide 
complexes into functionally potent clusters on the APC’s surface (Unternaehrer et al. 
2007). Tetraspanins are likely contributors in this process as particular multi protein 
surface complexes were shown to incorporate CD82, CD9, CD81 together with MHC 
II, CD86 and HLA-DM. Kropshofer et al. demonstrated that tetraspanin 
microdomains sequester particular subsets of MHC II molecules carrying the same 
antigenic peptide. In this way TERMs facilitate an optimal T cell stimulation by 
bringing these MHC-peptide complexes in juxtaposition to each other and generating 
stimulatory units (Kropshofer et al. 2002a). Interestingly, dendritic cells from mice 
deficient in CD37 or CD151 were hyperstimulatory (Sheng et al. 2009) (Table 1.4).  
Whilst CD151’s influence appears to be purely due to an elevated co-stimulatory 
activity, the knockout of CD37 seems to change MHC II-peptide driven activation 
signals. These data clearly indicate that CD37 has an inhibitory effect in antigen 
presentation. The authors suggested that one of the possible mechanisms may involve 
CD37-dependent sequestration of MHC II away from the clusters required for 
effective stimulation of TCR. Further underlying the versatile regulatory roles of 
tetraspanins in the immune system, Gartlan et al. showed that in vitro DCs deficient in 
the expression of CD37 and Tssc6 induced hyperproliferation of T cells. In vivo 
however, the absence of both these tetraspanins leads to a poor immune response in 
mice (Gartlan et al. 2010). This observation is suggested to be due to a deregulation of 
cytokine production in vivo caused by a simultaneous T cell hyperstimulation and 
hyperproliferation (Gartlan et al. 2010).  
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Figure 1.5: Model of tetraspanin functions and associated microdomains on MHC class 
II biology? 
A) HLA class II molecules are incorporated into TERMs on the cell surface (1) and 
can get internalised during endocytosis (2). Particularly CD63 and CD82 have the 
potential to recycle between the cell surface and MIICs (termed here as late 
endosome, (3)). Once HLA-DM-mediated peptide loading in MIICs occurs, CD63 
and CD82 also appear to keep together HLA class II clusters uniformly loaded with 
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peptide and may regulate the transport of HLA class II molecules to the surface and 
into exosomes (4). At the cell surface, mainly CD81, CD9 and to a lesser extent CD82 
and CD63 aid in preserving the clustered configuration of HLA class II–peptide 
complexes. This configuration may be maintained in the synapse after TCR 
engagement. B) In APCs (illustrated here as a B cell), tetraspanins such as CD37, 
CD63 or CD81 associate with MHC class II molecules. Similarly, exosomes (shown 
as secreted vesicles in orange), which are enriched in tetraspanins, are involved in 
antigen presentation. In T cells, CD81 and CD82 associate with CD3 and CD4. CD81 
is also reported to be distributed to the cSMAC. 
 
Table 1.3: Tetraspanins known to be expressed in blood cells and their functions 
Modified and updated from Tarrant et al. 2003 
 
Tetraspanin Expression Function 
CD9 B cells, activated T cells, Granulocytes, 
Monocytes, DCs, Megakaryocytes, 
Platelets, blood progenitors, widespread 
T cell activation, Antigen 
presentation, B cell β1-integrin 
adhesion 
CD37 B cells, T cells, Monocytes, DCs, 
Granulocytes 
B cell-T cell interaction, T cell 
activation, antigen presentation, 
receptor-trafficking, IgA 
secretion 
CD53 B cells, T cells, DCs, Monocytes, NK cells, 
Granulocytes 
Monocyte and neutrophil 
activation, T cell activation, T 
cell positive selection, B cell 
β2-integrin adhesion 
CD63 B cells, T cells, DCs, Monocytes, Platelets, 
widespread 
Antigen presentation, β2-
integrin adhesion, MHC II 
trafficking 
CD81 B cells, T cells, NK cells, DCs, Monocytes, 
blood progenitors, widespread 
B cell co-receptor, B cell-T cell 
activation, B cell-T cell 
interaction, Th2 response, β1 
and β2-integrin adhesion  
CD82 B cells, T cells, Granulocytes, Monocytes, 
CD34+ progenitors, widespread 
T cell co-stimulation, β2-
integrin adhesion, antigen 
presentation 
CD151 B cells, T cells, Granulocytes, 
Megacaryocytes, Platelets, erythroleuceia 
and T cell lines, widespread 
Neutrophil motility, co-
stimulation 
Tssc6 B cells, T cells, Granulocytes, Monocytes, 
DCs, erythroid cells, blood progenitors 
T cell activation, T cell 
proliferation 
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Table 1.4: immunological phenotypes of various tetraspanin knockdowns in mice 
 
Tetraspanin Immune cell phenotype upon knockdown Reference 
CD9 No significant phenotype on immune cells 
(Infertility due to defective fusion capacity of 
eggs), decreased exosome release in DCs 
(Chairoungdua et al. 
2010;Miyado et al. 2000) 
CD81 Hyperproliferation of T cells, deficiency in T cell 
dependent IgG production and Th2 cytokine 
secretion, enhanced B cell activation 
(Maecker and Levy 
1997;Sanyal et al. 2009) 
CD9, CD81 Enhanced cell fusion of alveolar macrophages and 
bone marrow cells after in vivo and in vitro 
stimulation, less motile macrophages and increased 
production of matrix metalloproteinase (MMP)-2, 
MMP9 
(Takeda et al. 
2003;Takeda et al. 2008) 
CD37 Hyperproliferation of T cells, impaired T cell-B 
cell interaction under sub-optimal co-stimulatory 
conditions, antigen presentation via MHC II 
(Knobeloch et al. 2000) 
Tssc6 Hyperproliferation of T cells due to increased IL2 
production, impaired Platelet function 
(Goschnick et al. 
2006;Sheng et al. 
2009;Tarrant et al. 2002) 
CD37, Tssc6 in vitro: Hyperproliferation of T cells, increased 
stimulatory capacity of DCs 
in vivo: reduced ability to produce influence-
specific T cells, mice suffer from hyperparasitemia 
(Gartlan et al. 2010) 
CD151 Hyperproliferation of T cells in response to in vitro 
mitogenic stimulation, increased co-stimulatory 
capacity of DCs 
(Sheng et al. 2009;Wright 
et al. 2004) 
CD63 Minor differences in platelet function (Schroder et al. 2009) 
 
1.4 Model System designed for this project 
 
I am using Epstein-Barr virus (EBV) antigens as a model system to explore the role of 
tetraspanin CD63 in antigen presentation to CD4+ T cells. In the human body, EBV 
infected B cells, MHC class I and II positive, establish a lifelong latent infection that 
is controlled by an anti-viral T cell response. In vitro, EBV infection of B cells leads 
to the generation of so called lymphoblastoid cell lines (LCLs) which here serve as 
APCs for EBV-antigen specific CD4+ T cells. This model was chosen since LCLs 
express a variety of tetraspanins including CD63 and EBV-derived antigens which are 
shown to be recognised by CD8+ as well as CD4+ T cells (Long et. al 2005). 
Furthermore, EBV-infection of B cells stimulates exosome-secretion (McLellan et al. 
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2009). Therefore, this system allows me to investigate the role of CD63 in the sorting 
of protein complexes and their compartmentalisation, especially in respect of MHC 
class II, and in the formation and trafficking of exosomes as well as the translocation 
of proteins into the endosomal pathway. 
 
1.5 Epstein-Barr virus 
 
Epstein-Barr virus (EBV), a γ1-herpesvirus and one of eight known human 
herpesviruses, is associated with several diseases and malignancies. EBV was 
discovered by Anthony Epstein, Yvonne Barr and Bert Achong in 1964. They grew 
cells cultured from the tumour specimens sent from Uganda by Denis Burkitt who 
described a novel childhood lymphoma endemic, now known as Burkitt’s lymphoma 
(BL), throughout equatorial Africa (Burkitt and Wright 1966). Subsequently, EBV 
was identified as the causative agent of infectious mononucleosis (IM) and has been 
implicated in the pathogenesis of an increasing number of human malignancies like 
BL, nasopharyngeal carcinoma (NPC), post transplant lymphoproliferative disease 
(PTLD), Hodgkin’s disease (HD), some cases of gastric carcinomas and T cell 
lymphoma (Rickinson and Moss 1997;Young and Rickinson 2004). 
 
1.5.1 EBV infection cycle 
 
EBV is widespread in all human populations all over the world and is carried by the 
vast majority of individuals as a life-long asymptomatic infection. Primary infection 
usually occurs during early childhood and is almost always asymptomatic. However, 
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in industrialised Western countries primary infection is becoming increasingly 
delayed and up to 50% of serologically confirmed primary EBV infection in 
adolescence and early adulthood result in IM (Khanna et al. 1995a).  
The mechanism of infection and persistence of the virus is not yet fully understood 
but basically viral transmission occurs orally followed by infection, replication and 
expression of the full range of lytic cycle genes. There is still debate about which cells 
exactly are targeted by the initial infection but it is likely that, apart from B cells, the 
oropharyngeal epithelium plays a role in it. Later, infected B cells either enter the lytic 
cycle, where EBV particles are reproduced and infect again other mucosal cells and 
lymphocytes, or enter the latent cycle, where B cells migrate back into the lymphoid 
tissue. There, B cells start undergoing proliferation in which a considerable 
percentage of these lymphocytes is eliminated by cytotoxic T cells. This leads to 
infected B cells becoming resting memory B cells and going into a latency 
programme avoiding the expression of antigens which induces CD8+ T cell response. 
EBV-infected memory B cells still keep the ability to occasionally replicate the virus 
and release it into saliva. Some of them differentiate into plasma cells which may 
enter the lytic cycle whilst migrating into peripheral tissues. These lytic cycle-derived 
EBVs are thought to be responsible for EBV-related epithelial neoplasms such as 
gastric and nasopharyngeal carcinoma (NPC), whereas EBV-associated Burkitt 
lymphoma appears to derive from germinal-centre B-cell blasts, which remain 
proliferative due to activated c-myc oncogene. EBV-associated Hodgkin’s lymphoma 
however is considered to arise from EBV-infected B cells carrying a cellular 
mutation. In immunocompromised patients, the absence of CD8+ T cells does 
possibly lead to lymphoproliferative disease (Maeda et al. 2009).  
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Figure 1.6: EBV infection cycle and its influence on development of certain cancer types  
EBV transmission occurs via saliva followed by infection of probably oropharyngeal 
epithelium and/or naïve B cells (a). Infected B cells enter the lytic cycle and infect again other 
mucosal cells and lymphocytes (b), or the latent cycle and migrate back into the lymphoid 
tissue (c). Cytotoxic T cells respond to proliferating infected B cells (d). Infected B cells turn 
into resting memory B cells with a latency expression programme avoiding CD8+ T cell 
response (e). EBV-infected memory B cells replicate the virus and release it into saliva (f). 
Some of them differentiate into plasma cells and may enter the lytic cycle whilst migrating 
into peripheral tissues (g). This is thought to be the source for EBV-related epithelial 
neoplasms such as gastric carcinoma and NPC (h). EBV-associated BL appears to derive 
from germinal-centre B-cells (i). EBV-associated HL may arise from EBV-infected B cells 
carrying a cellular mutation (j). The absence of CD8+ T cells following immunosuppression 
(k) does possibly lead to lymphoproliferative disease (l). Reproduced from: (Maeda et al. 
2009) 
 
1.5.2 EBV latent infection 
 
Primary human B cells infected with EBV in vitro transform into a proliferating and 
immortalised lymphoblastoid cell line (LCL) where the virus is represented by 
multiple copies of episomes (Nilsson et al. 1971). This infection by a non-productive 
but replication-competent virus is described as latency. Four types of latent EBV 
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infections are characterised by expression of different combinations of up to nine 
latent genes (Table 1.5). LCLs exhibit the latent state known as latency III which is 
essentially characterised by the expression of six EBV nuclear antigens, EBNA 1, 2, 
3A, 3B, 3C and LP (leader protein), three latent membrane proteins, LMP1, 2A and 
2B and two small non-polyadenylated RNAs termed EBV-encoded RNA (EBER)1 
and EBER2. Other EBV-associated malignancies show different latencies as for 
example BL-cells only express EBNA1 and EBERs which represents latency I. 
 
Table 1.5: EBV gene latency programmes, adapted from (Kuppers 2003)  
 
Latency 
programme 
EBV genes expressed Occurrence 
 EBERs EBNA1 LMP1 LMP2A EBNA2 EBNA3s, 
EBNA-LP 
 
0 + nd - + - - Memory B cells in 
peripheral blood 
I + + - - - - Burkitt lymphoma, 
PEL 
II + + + + - - Hodgkin 
lymphoma 
 
III + + + + + + PTLD 
 
IV? nd nd - nd + nd Infectious 
mononucleosis, 
PTLD 
nd: not determined 
 
1.5.3 The immune response to EBV 
 
Primary infection predominantly occurs in early childhood and with no clinically 
important symptoms. However, if infection is delayed into adolescence or beyond, it 
may result in acute IM. IM is a self limiting disease, which is generally characterised 
by a huge expansion of T cells and usually resolved through generation of a strong 
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CD8+ T cell response. In healthy carriers, EBV persists in B cells as a latent infection 
that periodically reactivates into lytic cycle. The absolute frequency of infected B 
cells lies within the normal range of 1-50 per 10
6
 peripheral blood mononuclear cells 
(PBMC) (Khan et al. 1996). Components of the EBV-specific immune system 
continually act to control the viral infection and enable a life-long, disease free co-
existence of host and pathogen in the vast majority of individuals.  
 
1.5.3.1 CD8+ T cell immune response to EBV 
 
During the acute phase of EBV infection CD8+ T cells expand dramatically and 
represent the main source of adaptive immune response (Moss et al. 1988;Steven et 
al. 1997). EBV-specific CD8+ T cells generated, mainly recognise lytic antigens 
rather than latent antigens, of which 22-50% may be directed towards individual EBV 
lytic antigens in certain IM patients (Callan et al. 1998). But following resolution of 
the primary infection, lytic and latent antigen-specific CD8+ T cells may be detected 
in healthy EBV-seropositive individuals (Tan et al. 1999).  
 
1.5.3.2 CD4+ T cell recognition of EBV-transformed cells 
 
Although CD4+ T cells are crucial for priming and maintenance of CD8+ T cell 
responses, the role of CD4+ T cells has not been studied carefully until recently and 
little is known about this facet of the EBV-response. The frequency of EBV-specific 
CD4+ T cells during primary infection is only 1.4% in average of the total CD4+ 
population and drops to even to 0.34% during persistent infection (Amyes et al. 
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2003). CD4+ T cells came into focus of recent research due to their helper role they 
play in CD8-mediated virus-specific immunity and the fact that the latent EBV-
infection occurs in cells in which the HLA class II pathway of antigen presentation is 
active. CD4+ T lymphocytes, additionally to their classical functions in the immune 
system, could potentially act as direct effectors in their own right and kill infected or 
malignant cells, when these naturally express MHC class II proteins (Merlo et al. 
2010). It is known for endogenously expressed antigens to gain entry into the HLA 
class II processing pathway in LCLs, which applies to non-EBV-related antigens 
(Chen and Wu 1998;Malnati et al. 1993;Nimmerjahn et al. 2003) as well as EBV 
latent cycle antigens (Long et al. 2005a). First observations of polyclonal CD4+ T cell 
lines being able to directly recognise and lyse LCLs (Misko et al. 1984;Moss et al. 
1988) did years later lead to the demonstration of in vitro-primed CD4+ T cell lines, 
generated from virus naïve individuals, to kill autologous LCLs (Savoldo et al. 2002).  
Identified as components of LCL-reactivated memory T cell preparations, the first 
CD4+ T cell clones to EBV latent proteins are specific for an EBNA-1 or an EBNA-2 
derived epitope, respectively (Khanna et al. 1995b;Khanna et al. 1997). Only the 
EBNA-2 specific clone however seems to be capable of killing LCLs in vitro (Khanna 
et al. 1997). Since that time, more CD4+ T cell clones recognising latent-cycle 
epitopes have been generated by various groups (Leen et al. 2001;Omiya et al. 
2002;Steigerwald-Mullen et al. 2000;Voo et al. 2002). However, only in 2005 the first 
clones which could be shown to reliably and reduceably recognise LCLs naturally 
expressing cognate antigens from the EBV genome were published (Long et al. 
2005b). This work provides CD4 epitope maps for the EBV latent-cycle antigens 
EBNA1, -2,-3A and 3C and establishes CD4+ T cell clones to 12 selected epitopes 
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from these antigens. Two of these clones recognising epitopes from the antigens 
EBNA2 or EBNA3C, respectively were used as model cell lines in this project.  
  
36 
2 Materials and Methods 
 
2.1 Cell culture 
 
DMEM 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with L-glutamine 
purchased from GIBCO or Sigma was used for culture of all adherent cells used in 
this study. 
 
RPMI 1640 
RPMI 1640 supplemented with L-glutamine (2.05mM) purchased from GIBCO or 
Sigma was used for culture of all lymphocyte cell lines.  
 
AIM-V  
Serum-free AIM-V media (GIBCO) containing L-glutamine, 50μg/ml streptomycin 
sulphate and 10μg/ml gentamycin sulphate was used to grow lymphocyte cells prior 
to purifying exosomes from the cell supernatant. This medium enables to grow cells 
without any bovine serum thus avoiding any contamination of growth media with 
exosomes or cell material of bovine origin. 
 
Foetal calf serum (FCS) 
Virus- and mycoplasma-free FCS (purchased from GIBCO) was filtered through 
0.2m pore membrane prior to aliquoting into 50ml volumes and storing at -20°C 
until use. 
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Human Serum (HS) 
Sterile male HS of type AB (virus and mycoplasma screened) was purchased from 
HD supplies, UK and stored in 25ml aliquots at -20°C until use. 
 
Penicillin-Streptomycin 
A combined solution of the antibiotics Penicillin (10
4
 units/ml) and Streptomycin 
(10mg/ml) in 0.9% NaCl was purchased from GIBCO. The solution was stored at -
20°C until use. 
 
Trypsin 
0.5% Trypsin EDTA was purchased from GIBCO diluted 1:10 in EDTA solution 
(0.5mM), aliquoted in 5ml volumes and stored at -20°C until use. 
 
MLA 
Supernatant of the Gibbon cell line MLA-144, which spontaneously releases IL-2, 
was used as a source of growth stimulus to supplement T cell media. Cells were 
cultured in RPMI 1640, 10% FCS without further feeding. After 2 weeks the cell 
supernatant was harvested by centrifugation at 1600rpm for 10min, followed by 
filtration through a 146mm 0.2μm membrane (PALL). MLA supernatant was stored 
at -20°C in 60ml aliquots until use. 
 
IL-2 
Lyophilised powder (Peprotech) was reconstituted in water at concentration of 10
5
 
IU/ml, filtered through 0.2μm membrane and stored at -20°C in 500μl aliquots. 
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Cyclosporin A (CSA) 
CSA (Sandimmun, Sandoz) was stored in -20°C and reconstituted in RPMI 1640 to a 
stock concentration of 10μg/ml. 
 
Phosphate buffered saline (PBS) 
10 tablets (OXOID) were dissolved per litre sterile water and autoclaved if required 
sterile (NaCl 8g/l; KCl 0.2g/l; Na2HPO4 1.44g/l; KH2PO4 0.24g/l; pH 7.4). 
 
CFSE 
Carboxyfluorescein succinimidyl ester, stored at -20°C (5µM, 20µM or 40µM, 
respectively) 
 
2.1.1 Cryopreservation and recovery of cryopreserved cells 
 
Cell to be cryopreserved were centrifuged at 1200-1500 rpm for 10min and 
resuspended in freezing media: RPMI 1640 containing 20% FCS and 10% DMSO. 
The cells were transferred into sterile plastic cryovials (Nunc) in 1ml aliquots and 
placed in a -70°C freezer overnight in a Mr. Frosty (Nalgene) which allows gradual 
lowering the temperature of the cell suspension. The following day the frozen cells 
were transferred into a freezer containing liquid nitrogen for long-term storage. Cell 
were recovered from such storage by fast-thawing at 37°C in a water bath and 
transferred to a 15ml tube (Sarstedt) filled with 10ml RPMI 1640 plus 10% FCS using 
a 10ml (Corning) pipette. After allowing cell suspension to stand for 1min, they were 
pelleted by centrifugation at 1200-1500rpm and resuspended in the appropriate 
growth medium for culture.  
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2.1.2 Mycoplasma Test 
 
Cells were routinely tested for mycoplasma infection using MycoAlert Mycoplasma 
Detection Kit (Lonza). In cases of contamination cells were either discarded or treated 
using Mycoplasma Removal Agent (MP Biomedicals) according to the protocol 
supplied by the manufacturer. 
 
2.1.3 Transfection of eukaryotic cells by electroporation 
 
For the standard procedure for electroporation, the relevant cells, including LCLs, 
were resuspended in 400 μL of complete medium with DNA or RNA in a cuvette. 
After 10-min incubation at 25 °C, the culture was pulsed with 230 V at 975 μF using a 
Bio-Rad Gene Pulser II. Transfected cells were cultured in complete medium with 
10% FBS for 4–5 days. Every 5–8 days, viable cell numbers were determined by 
hemocytometry based on trypan blue exclusion. Cultures were then split, and total 
viable cell numbers were calculated relative to the initial culture.  
 
2.1.4 Blood donors 
  
Blood was donated by healthy laboratory personnel, the EBV status of whom was 
identified by serological staining for IgG antibodies to the viral capsid antigen. 
Additionally, buffy coats were obtained from Birmingham Blood Transfusion 
Service, Vincent Drive, Edgbaston, Birmingham.  
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2.1.5 Generation of lymphoblastoid cell lines 
  
LCLs were generated by in vitro transformation of the B cells from donors who had 
previously donated blood in the past. 5-10x10
6
 PBMCs were centrifuged at 1600rpm 
to remove all media then resuspended in a 500μl aliquot of the prototype 1 B95.8 or 
the prototype 2 strain Ag876 virus and incubated at 37°C with 5% CO2, flicking every 
15min. After 1hr the cells were washed and resuspended in a 48-well plate (Iwaki) in 
RPMI 1640 with L-glutamine, 10% FCS and penicillin/streptomycin, with the 
addition of 0.1μg/ml cyclosporine A for the first 2 weeks to suppress T cell activity. 
LCL cultures were subsequently split and re-fed with medium twice weekly. 
According to its individual donor, each LCL is labelled with “PER” standing for 
person followed by an anonymous three digit code.   
CD4+ T cell clones specific for defined epitopes within EBNA 2 or 3C were used. 
Overall, the experiments involved CD4+ T cell clones to two different EBNA-derived 
epitopes identified along with their HLA class II-restricting alleles in Table I.  
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Table 2.1: T cell clones with their EBV derived antigens and HLA restriction used in 
these experiments. 
 
EBV Antigen                Epitope 
Coordinates 
Epitope 
Sequence 
HLA 
Restriction 
Clone 
EBNA2 276-295 PRSTVFYNIPPMPLPPSQL DR52b c93 (CD4+) 
EBNA3C 386-400 SDDELPYIDPNMEPV DQ5 c38 (CD4+) 
BMLF1 259-267 GLCTLVAML A2 c6   (CD8+) 
LMP2 340-349 SSCSSCPLSK A11 c24 (CD8+) 
EBNA1 77-96 GLRALLARSHVERTTDEGTW DR1 c4   (CD4+) 
bold: T cell clones capable of recognising LCL PER241 
 
2.1.6 Lentiviral transduction of LCLs 
 
2.1.6.1 Vectors   
 
The vectors pLV-THM, psPAX2 and pMD2.G were provided by D. Trono (Geneva, 
Switzerland); the vector pLV-THM allows for direct cloning of shRNAs 
(http://tronolab.epfl.ch/). 
The oligonucleotides containing the shRNAs sequences (Table 2.6.1) were cloned 
into the plasmid pSuperior puro purchased from OligoEngine (Seattle, WA). 
pSuperior puro is under the control of the H1 PolIII promoter and enables to use the 
EcoRI-ClaI sites to replace the H1 promoter in pLVTHM with the H1-shRNA 
cassette from pSuperior puro.  
 
Table 2.2: used shRNA constructs 
 
target protein Target sequences 
CD63 a 5′-GGTTTTTCAATTAAACGGA 
CD63 b 5′-GGAGAACTATTGTCTTATG 
CD81 5’-ATCTGGAGCTGGGAGACAA 
CD82 5’-TGTAGTCTTCGGAATGGACGTGC 
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2.1.6.2 Verification of RNA Interference 
 
Efficacy of RNA Interference (RNAi) was verified by transfection of Hela cells using 
electroporation. Hela cells were detached and electroporated with a single pulse at 
250V and 250µF using GenePulser Xcell electroporation system (BioRad) and 7-
10µg of pSuperior including the respective shRNA fragment. The efficacy of 
knocking–down was assessed 48 hours later by flow cytometry.  
 
2.1.6.3 Lentivirus production 
 
We used VSV-G pseudotyped lentivirus to deliver gene–specific shRNAs. For 
silencing, lentiviral particles were produced by transfecting (FuGene6, Roche 
Diagnostics, Indianapolis, IN) 30% confluent 10cm
2
 tissue culture dish of HEK293T 
cells with a plasmid mix containing the vector shRNA-pLVTHM encoding the 
specific shRNAs, the packaging construct psPAX2 and the envelope plasmid 
pMD2G-VSVG (DNA-ratio: 49:37:14). Fresh medium was added 16 hours after 
transfection. Virus-containing supernatants were harvested every 24 hours and filtered 
through a 0.45μm filter (Millipore, Billerica, MA). For control purposes we generated 
an LCL transduced with the lentivirus which does not carry any shRNA construct. 
 
2.1.6.4 Target cell transduction 
 
Virus-containing supernatant was pooled to an amount of up to 12ml and 
ultracentrifuged at 19500rpm (SW40Ti, Beckman Coulter) for 2hrs at 4°C. 
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Meanwhile target LCLs were plated into a 24 well plate at a density of 5x10
5
 
cells/well. After removing as much medium from the cells as possible the 
resuspended virus was mixed with the cells in the presence of polybrene (8g/ml, 
Sigma) and incubated overnight until fresh medium was added.     
 
2.2 Assays on living or fixed cells 
 
Triton X-100 permeabilisation buffer 
For cell permeabilisation in immunofluorescence experiments 0.1% Triton X-100 
(Sigma) was prepared in Tris-buffered saline (TBS) (10 mM Tris, pH 7.5/150 mM 
NaCl/1 mM KCl).  
 
CHAPS permeabilisation buffer 
CHAPS (Sigma) was solubilised to 1% in 30 mM Tris-Cl pH 7.5, 150 mM NaCl and 
diluted dependent on the purpose. For permeabilisation in immunofluorescence 
experiments a 0.1% solution in PBS was used. 
 
Brij 98 
1% Brij 98 detergent was diluted in PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM 
sodium phosphate dibasic, 2 mM potassium phosphate monobasic, pH 7.4 + 40µM 
CaCl2, 100µM MgCl2). The exact procedure includes melting Brij 98 in the water 
bath and adding 5ml Brij 98 into 500ml buffer of above composition. 
 
Human IFNγ 
Human IFNγ (2000 pg/ml) was purchased from R&D Systems.  
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Wash buffer (ELISA) 
PBS/0.05% Tween (0.5ml in 1l) 
 
Coating buffer (ELISA) 
0.1M Na2HPO4, adjusted to pH9 with 0.1M NaH2PO4 
 
Blocking buffer (ELISA) 
1% BSA/PBS filtered and then Tween added (50µ/100ml) 
 
Stopping-solution (ELISA) 
1M HCl 
 
Peptides 
Synthetic 20mer and 15mer peptides were synthesised using 9-
fluorenylmethoxycarbonyl chemistry (Alta Bioscience, University of Birmingham), 
and dissolved in dimethylsulfoxide (DMSO, Sigma Aldrich). Peptides used in this 
study covered epitopes of the Epstein Barr Virus Nuclear Antigens EBNA2 or 
EBNA3c, respectively.  
 
2.2.1 IFNγ ELISA 
 
Known numbers of T cells (500, 2500, 5000) were incubated in V-bottom wells of a 
microtest plate (Nunc) with either standard numbers of autologous, HLA-matched or 
HLA-mismatched LCLs. In other experiments T cells were incubated either with 
LCLs premixed with previously purified LCL-derived exosomes or with exosomes 
  
45 
alone. In all settings LCLs were prepulsed for 1hr with 5μM peptide or an equivalent 
concentration of DMSO solvent as a control and then washed six times with washing 
buffer. In blocking assays, LCLs or exosomes were preincubated with different 
concentration of monoclonal antibodies (MAbs) specific for HLA-DR (L243; ATCC 
clone HB-55), HLA-DQ (SPV-L3; Serotec) for 1 h before addition of T-cells to the 
assay. 
The supernatant medium harvested approximately after 18hrs was assayed for IFNγ 
by ELISA (Endogen) following the manufacturer’s recommended protocol. 96-well 
Maxisorp plates (Nunc) were coated with 50μl of a 0.75μg/ml solution of a mouse 
IgG1K anti-human IFNγ mAb (Pierce, Endogen) overnight at 4°C. The following 
morning the antibody was flicked out of the wells which were subsequently blocked 
at RT for 1hr with 1% BSA, 0.05% Tween 20 in PBS. The plates were then washed 6 
times in washing buffer (0.05% Tween 20 in PBS) and 50μl of neat (or diluted) 
supernatant from the T cell assay was added to each well for 2-4 hrs at RT. After 
incubation the supernatant was discarded, plates washed 6 times in washing buffer, 
and a biotinylated mouse IgG1K anti-human IFNγ mAb (Pierce, Endogen) was added 
at 0.375μg/ml and left at RT for 1-2hrs. The wells were washed and supplemented 
with an Extravidin peroxidise conjugate (Sigma) for a further 30min. After a final 10 
washes of the plate in washing buffer, 100μl of the developing TMB (3,5’,5,5’-
tetramethyl benzidine, Tebu-Bio laboratories) solution was added and left at RT for 
20min to allow the colour to develop. 100μl 1M HCl was added to each well to stop 
the reaction and the absorbencies were read at 450nm using an automated 
spectrophotometer (Wallac Victor 1420 Multilabel Counter). All results represent the 
mean of duplicate or triplicate wells. 
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2.2.2 Analysis of co-stimulatory activity of LCLs 
 
Nunc C96 MicroWell™ Plates (Maxisorp, cat# 430341) were coated overnight with 
an α-CD3 mAb antibody (OKT3) in the concentration 0, 0.5, 1 and 2mg/ml in coating 
buffer. These plates were then used to co-culture CD4+ T cells with either CD63low 
a, b or the control LCLs for 18 hours at 37°C. After this incubation period 
supernatants were harvested and directly analysed for IFNγ by ELISA assays.   
 
2.2.3 Flow cytometry 
 
Cells (~1x10
6
) were transferred to U-bottom 96-well plate and incubated with a 
control or a primary antibody for 1hr at 4°C. The cells were washed three time with 
PBS and were incubated with either fluorescein isothiocyanate- (FITC) or 
phycoerytrin- (PE) conjugated secondary antibody (polyclonal Goat anti-mouse 
Immunoglobulins, Dako) diluted 1:300 in BSA/PBS for 1hr at 4°C in the dark. Cells 
were washed several times in PBS and resuspended in 500μl PBS for analysis on 
EPICS XL Flow Cytometer (Coulter) using System II software (Coulter). The mean 
fluorescence intensity was calculated by subtraction of the average intensity of the 
control antibody (non-specific binding, α-rat PtdIns 4-kinase (4C5G) IgG1) from the 
target antibody value. 
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2.2.4 Peptide binding assay 
 
Cells (3x10
5
) in 50µl complete medium were added to 150µl PBS containing 
biotinylated peptide SDD or PRS (50µM final concentration, Alta Bioscience) and 
incubated at 37°C for 4 hours. Subsequently the cells were incubated PE-conjugated 
streptavidin (Sigma) in a dilution 1:300 for up to 1 hour at 4°C. As greater sensitivity 
was desired, staining of cells via incubating with biotinylated peptide was conducted 
as described above. But after adding PE-conjugated streptavidin, incubation with 
biotinylated α-PE antibody (BD Biosciences) did occur, which finally allowed us to 
add an additional layer of PE-conjugated streptavidin. 
 
2.2.5 Immunofluorescence microscopy 
 
Cells or LCL-T cell conjugates were cytospun onto polylysine-coated slides 
(SurgiPath Europe) and then immediately fixed with 4% paraformaldeyde in PBS for 
10 min and permeabilised with either 1% Triton X-100, CHAPS (0.05%) or Brij 98 
for 5 min. Cells were then blocked with 10% heat inactivated goat serum in PBS for 
1-2 hours and stained with primary antibody and subsequently after washing 3 times 
with PBS fluorochrome-conjugated secondary antibodies at room temperature for 1 
hour each time. After washing 3 times with PBS cells were stained with Hoechst 
33342 for 5 min and slides were mounted with Slow Fade
®
, Antifade kit (Invitrogen) 
and examined using a Nikon E600 microscope.  
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2.2.6 Confocal Microscopy to analyse immune synapses 
 
LCLs and T cells were washed twice in PBS and mixed 1:1 in PBS before spinning 
them down, discarding the supernatant and resuspending the pellet in the remaining 
amount of supernatant (app. 20µl). The cells were then incubated at 37ºC for 30 min 
to allow conjugate formation and then gently resuspended in PBS to achieve a 
concentration of 1x10
5
 cells/ml. After being cytospun onto slides (500 rpm) and fixed 
and permeabilised as described above, cells stained and mounted as described above. 
Confocal images were acquired using a Carl Zeiss LSM510 microscope with a 63× 
oil-immersion objective (Plan-APOCHROMAT, Zeiss) and analyzed using LSM 
Image software. 
 
2.3 Protein analysis 
 
10x Running buffer 
To prepare 10x running buffer for SDS-PAGE 144g glycine, 30.3g Tris 
(tris(hydroxymethyl)aminomethane)  and 10g SDS (sodium dodecyl sulphate) were 
dissolved in 1L dH2O. 
 
10x Transfer buffer 
To prepare 10x transfer buffer for Western blotting 200ml of 10x Tris/Glycine 
(0.25M Tris, 1.92M glycine, Geneflow) was mixed with 400ml methanol and topped 
up to 2L with dH2O. 
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Triton X-100 buffer 
Triton X-100 lysis buffer was prepared by mixing 250μl CaCl2 (1mM), 250μl MgCl2 
(2mM) and 5ml Triton X-100 (Sigma) and topping up to 500ml with 1x PBS. 
 
Laemmli buffer 
Solution contains 5% w/v SDS, 40% v/v glycerol, 0.005% w/v bromphenol blue and 
0.25 M w/v Tris HCl, pH6.8; additionally 5% v/v 2-mercaptoethanol if reduced 
conditions were required 
 
Acrylamide 
Purchased from Geneflow 
 
Bio-Rad Dc protein assay kit 
Bio-Rad Dc protein assay Reagent A, B, S purchased from Bio-Rad Laboratories 
 
MES 
2-(N-Morpholino)ethanesulfonic acid hemisodium salt, 4-Morpholineethanesulfonic 
acid hemisodium salt (C6H13NO4S·0.5Na); purchased from Sigma-Aldrich 
 
2.3.1 Determining protein concentration 
 
Protein concentration of lysate samples or exosomes was determined using a DC 
protein assay kit (Biorad) according to the manufacturers operating recommendations. 
BSA was used to prepare protein standards at serial dilutions from 2mg/ml to 
32.5μg/ml.  
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2.3.2 Preparation of protein extracts 
 
Preparing cell lysates, cells were spun down and washed twice in PBS before 
transferred to ice cold Triton X-100 lysis buffer. The suspension was rotated at 4°C 
for a few hours until the remaining cell debris was pelleted at 13,000rpm and the 
supernatant used for further analysis. Exosomes were simply resuspended in PBS, 
mixed with the appropriate amount of Laemmli buffer and prepared for further 
analysis. 
 
2.3.3 SDS-PAGE (Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis) 
 
Cell lysates and exosome samples were mixed 1:3 (v/v) with 4x Laemmli buffer and 
boiled at 95°C for 5min prior to loading onto a SDS-PAGE. Proteins were then 
separated using a Biorad minigel system. The acrylamide concentration of the 
stacking gel was 5% whereas the concentration of the running gel depended on the 
particular protein of interest and its molecular weight. Prestained molecular weight 
markers (6-175kDa, NEB) were run alongside the protein samples. Electrophoresis 
was conducted at 15-22mA in running buffer. 
 
2.3.4 Western blotting 
 
After electrophoresis the gel was equilibrated in transfer buffer and laid onto 
nitrocellulose membrane (Amersham). Both were wrapped between two layers of 
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Whatman paper and all these layers together placed into a blotting cassette. After the 
transfer performed at 60V for 2hrs, the membrane was blocked for 1hr in 5% milk at 
room temperature on the shaker and washed three times for approximately 10min in 
PBS-Tween-80 followed by incubation with the first antibody (commonly overnight 
at 4°C). The next morning the antibody solution was taken off, the membrane washed 
again in PBS-Tween and incubated with the secondary antibody (e.g. goat anti-mouse 
IgG HRP-conjugated, 1:20000, Sigma) for 1hr at RT. The membrane was washed the 
last time before detecting the protein using a chemiluminescence kit (Western 
Lighting
TM
, Perkin Elmer Life Sciences).  
 
2.3.5 Analysis of HLA class II dimers using immunoblotting 
  
Cells were lysed at 5 x 10
6
/ml in 1% Trion X-100 buffer, pH 7.2, 1.0 mM PMSF, 1.0 
µg/ml leupeptin, and 1.0 µg/ml pepstatin for 30 min at 4°C. To detect HLA-DR αβ-
dimers, total cell lysate was mixed with the appropriate volume of 4x non-reducing 
SDS laemmli buffer and incubated for 30 min at room temperature. To detect HLA-
DR β-monomers, total cell lysate was mixed with an appropriate volume of 4x 
reducing SDS sample buffer and boiled for 10 min. Samples were electrophoresed on 
a 12% SDS-polyacrylamide gel and subsequently transferred to nitrocellulose. 
Immunoblotting was carried out as described above. Following monoclonal antibodies 
were used to detect HLA class II: DA6-14, SPC-L3 or L243. 
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2.3.6 Fractionation in sucrose density gradient 
 
Cells centrifuged at 200 x g for 3 min, and washed once with PBS. Sodium carbonate 
(pH 11.0) buffer (100 mM) supplemented with 10µg/ml aprotinin, 10µg/ml leupeptin 
and 2mM PMSF was mixed with the pelleted cells. Lysates were prepared using the 
detergents Triton X-100, CHAPS or Brij98 or were homogenised using Dounce 
homogenizer (15 strokes) and a sonicator (4×20 s bursts, 1 min interval, power 10). 
The resulting homogenate was mixed with equal volume of 90% (w/v) sucrose 
prepared in 25 mM MES buffer (pH 6.5), and overlaid with 2 vol. of 35% (w/v) 
sucrose and followed by 1 vol. of 5% sucrose (w/v; both in MES). Samples were 
centrifuged at 55000 x g for 16–18 h at 4 °C. Then, 400 µl aliquots were collected 
from the top of the tube. The pellet was dissolved in Laemmli buffer supplemented 
with protease inhibitors. Equal amounts of each fraction were mixed with 4× Laemmli 
loading buffer and the distribution of proteins was analysed by SDS/PAGE followed 
by Western blotting. Protein concentration has been measured by Bio-Rad kit. 
 
2.4 Exosome purification 
 
2.4.1 Exosome depletion of growth medium 
 
Exosomes present in FCS were removed by centrifugation at 100,000xg overnight. 
The next morning the exosomes free supernatant was harvested, sterile filtered 
through a 22μm syringe membrane filter, diluted to 10% FCS and stored at 4°C until 
use.  
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2.4.2 Differential centrifugation 
 
LCLs growing in complete media were counted, span down and plated to 150cm
2
 
flasks to enrich secreted exosomes for 48hrs. Cells were grown either in complete 
media depleted from bovine serum’s exosomes (above) or in serum free AIMV 
medium at a starting cell number of 4x10
5
 cells/ml. The supernatant was centrifuged 
at 4°C by optimised sequential centrifugation (Fig. 2.1): 1) to remove living cells at 
200xg for 4min (twice); 2) dead cells at 500xg for 8min; 3) debris at 2000xg for 
10min; 4) cell membranes at 10,000xg for 45min; 5) to pellet exosomes at 70,000xg 
for 2hrs. The pellet was resuspended in 12ml ice cold PBS and centrifuged again at 
70,000xg for 1hr. The final exosomes pellet was resuspended in PBS or medium 
depending on the procedure whether the exosomes were further purified by sucrose 
cushion centrifugation or directly used for functional assays. For sucrose cushion 
centrifugation, exosomes were resuspended in 10ml PBS and layered onto 2ml of 
sucrose/D2O (99.9% Sigma) (1.2g/ml). After spinning at 100,000xg overnight the 
cushion was carefully taken, diluted with 10ml fresh ice cold PBS and the exosomes 
sedimented a last time at 70,000xg for 1hr. This final pellet was resuspended in 40-
80μl and stored in -70°C or used immediately.  
 
2.4.3 Sucrose gradient flotation of exosomes 
 
In order to further define the grade of purification, the flotation density of LCL-
derived exosomes was determined by flotation on a sucrose gradient. Following the 
second ultracentrifugation step (see 2.6.2), the pellet was resuspended in 2.4ml of a 
2.5M sucrose/D2O, 20mM HEPES (Sigma), pH7.2 solution and filled into a SW60 
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centrifuge tube (Beckman Coulter). This solution was overlaid with 8 successive 
fractions of 200μl with concentrations ranging from 2 to 0.25mM. After 
centrifugation at 100,000xg overnight, each fraction was carefully harvested without 
disturbing underlying fractions, diluted in up to 2ml PBS, span again and the resulting 
pellet analysed by WB for exosomal marker proteins. 
 
2.4.4 Sucrose cushion flotation of exosomes 
 
In order to assure that the final pellet contains exosomes, a subsequent purification 
was conducted by flotation on a sucrose cushion. Using a centrifuge tube for SW40Ti 
(Beckman) a density cushion of 1.2g/ml, composed of 20 mM Tris/30% 
sucrose/deuterium oxide (D2O) pH 7.4 (2 ml) was overlaid with the PBS-resuspended 
exosome pellet from 2.6.2 forming a visible interphase. The samples were 
ultracentrifuged at 100,000×g and 4 °C for 75 min in a SW-40 swinging bucket rotor 
(Beckman). 
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Figure 2.1: Exosome purification by differential centrifugation and flotation on a 
sucrose cushion 
Exosomes were separated from the LCL-supernatant and concentrated by differential 
centrifugation in six single steps which, depending on the purity required, was followed by 
centrifugation on a sucrose cushion (density 1.2g/ml). Each pellet after each centrifugation 
step (1 to 7, whereas #6 represents a sample of the supernatant after spin #5) was analysed for 
protein content by Western blotting in the initial experiments performed to optimise the 
purification protocol. 
 
2.5 Electron microscopy 
 
Phosphate buffer, 0.2M, pH 7.4 
A solution of 0.2M Na2HPO4 and a solution of 0.2M NaH2PO4 are prepared 
separately. Prior to using, the two buffers are mixed in a ratio 81:19 whilst measuring 
the pH. 
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Paraformaldehyde 16% 
16g of paraformaldehyde powder (Polysciences, Inc.) is dissolved in 90ml distilled 
H2O by heating to 65°C whilst stirring. pH 7.4 is adjusted by titrating NaOH. After 
topping up to 100ml with distilled H2O, small aliquots were stored in -20°C. 
 
Grids 
Formvar/Carbon coated copper grids, 200 mesh, Agar Scientific, catalogue number 
S162 
 
Methyl cellulose 
For a final volume of 200ml, 196ml of dH2O was heated to 90°C and 4g of methyl 
cellulose (Sigma, 25 centipoises) were added while stirring. The solution was rapidly 
cooled down on ice to 10°C while stirring. Slow stirring was continued overnight at 
4°C and then stopped to let the solution “ripen” for 3 days at 4°C. 
 
Methyl cellulose/uranyl acetate, ph4 
90ml of methyl cellulose solution was mixed with 10ml of 4% uranyl acetate. This 
solution was centrifuged for 95min at 29,000rpm (4°C) and the supernatant stored at 
4°C in the dark until use. 
 
Protein A Gold (PAG) 
Protein A coated Gold particles (10 or 15nm) were purchased from Cell Microscopy 
Center (CMC), Utrecht (www.cmc-utrecht.nl) 
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2.5.1 Preparation of exosome samples 
 
Following sucrose cushion centrifugation, 5μl from a freshly prepared exosome pellet 
resuspended in up to 40μl PBS was put on a formvar carbon-coated grid (Agar 
Scientific) and left for 20-40min. The liquid was soaked up and the sample attached to 
the grid was fixed by adding a drop of 2% PFA (Park Scientific) in 0.1M phosphate 
buffer (0.081M Na2HPO4, 0.019M NaH2PO4) for 15min. The PFA was washed off by 
dipping the grid once onto a drop of 0.15% glycine in phosphate buffer and once onto 
1% BSA. Specific labelling was done by adding a drop with the first antibody (2-
20μg/ml in 1% BSA/PBS) for more than 20min onto the grid. After rinsing the grids, 
labelling with a bridging antibody (1:250 in 0.1% BSA/PBS, polycl. rabbit α-mouse 
immunoglobulins, Dako Cytomation) was conducted if necessary (Protein A binds 
only mouse IgG2a, 2b). Then onto the rinsed grids a drop of Protein A-Gold (PAG, 
CMC-Utrecht) diluted in 0.1% BSA/PBS according to company’s recommendation 
was added and left for at least 20min. The grids had to be rinsed with plain PBS 
before fixation for 5min with 1% glutaraldehyde (Sigma) needed to be done. To 
contrast the grids had to be rinsed in dH2O and put onto a drop of 
methylcellulose/uranylacetate. If double labelling was done, the specimen was taken 
after glutaraldehyde fixation and the procedure started again from the step of dipping 
the grid onto 0.15% glycine and 1% BSA. 
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Table 2.3: antibodies used for electron microscopy 
 
Antibody Source Type MW of protein 
(kDa) 
Dilution 
CD63 (6H1) (Berditchevski et al. 
1995) 
mc 40-70 20-50g/ml 
     
CD81 (M38) kindly provided by 
Dr. O. Yoshi 
mc 20 20-50g /ml 
     
CD82 (M104) kindly provided by 
Dr. O. Yoshi 
mc 60 20-50g/ml 
     
MHC I (W6/32) 
(1mg/ml) 
kindly provided by 
Prof. M. Rowe 
mc 45 20-50g/ml 
     
MHC II – DQ 
(SPV-L3) (1mg/ml) 
kindly provided by 
Dr. G. Taylor  
(Spits et al. 1983) 
mc 30 20-50g/ml 
     
MHC II – DR 
(L243) (1mg/ml) 
kindly provided by 
Dr. G. Taylor  
(Fong et al. 1981) 
mc 30 20-50ug/ml 
     
Rabbit anti-mouse Ig Dako pc  1:250 
mc: monoclonal; pc: polyclonal 
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2.6 Details of cell lines and T cell clones used in this study 
 
Table 2.4: cell lines used in this study 
 
Cell line Origin Supplier/donor Complete media 
HEK 293T Embryonic Kidney CRUK DMEM 
HeLa Cervical cancer CRUK DMEM 
HeLa CIITA Cervical cancer 1* DMEM 
KEM Burkitt lymphoma CRUK RPMI 
Ramos Burkitt lymphoma CRUK RPMI 
LCL, PER141 B lymphoplasts PER141 RPMI 
LCL, PER149 B lymphoplasts PER149 RPMI 
LCL, PER213 B lymphoplasts PER213 RPMI 
LCL, PER241 B lymphoplasts PER241 RPMI 
LCL, PER255 B lymphoplasts PER255 RPMI 
LCL, PER279 B lymphoplasts PER279 RPMI 
LCL, PER282 B lymphoplasts PER282 RPMI 
T cell, clone 38 (SDD) CD4+ PER141 T cell medium 
T cell, clone 98 (PRS) CD4+ PER141 T cell medium 
T cell, clone 4 (GLR) CD4+ PER253 T cell medium 
T cell, clone 6 (GLC) CD8+ PER141 T cell medium 
T cell, clone 24 (SSC) CD8+ PER050 T cell medium 
1*: kindly provided by Dr. M. Pegtel 
 
Table 2.5: HLA-types of LCLs and HeLa cells used in this study 
 
LCL donor MHC class I MHC class II 
 HLA-A HLA-B HLA-DR HLA-DQ 
LCL, PER241 2 27, 44 1, 11, 52b 5, 7 
LCL, PER213 1 8, 57 7, 17, 52a 2, 9 
LCL, PER141 1, 2 16, 40 1, 13, 52b 5, 7 
LCL, PER149 1, 2 44, 57 4, 7, 53 7, 9 
LCL, PER255 2, 24 27, 35 4, 53 8 
LCL, PER279 1, 3 8, 35 1, 17, 52a 2, 5 
LCL, PER282 1, 24 27, 35 9, 15, 51, 53 6, 9 
HeLa cells 68 15 1 5 
 
LCLs were grown in tissue culture vented flasks (Iwaki) in complete RPMI media in a 
humidified atmosphere at 37°C in 5% CO2. Cells were passaged by removal of 
approximately 2/3 of the old media and either splitting the cells into multiple new 
flasks or discarding a part of the cells and topping up the remaining cells with fresh 
complete media. Adherent cells used in this study were grown in complete DMEM 
under same conditions like LCLs. In order to passage cells, media was removed, cells 
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were washed twice with PBS and detached using Trypsin-EDTA (GIBCO). Cells 
were then resuspended in fresh media and replaced at a ratio of 1:3 to 1:10.  
Polyclonal T cells were grown in 24 well plates and maintained in T cell specific 
RPMI media (see above). 
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2.7 Antibodies used in this study 
 
Table 2.6: antibodies used for Western blotting and flow cytometry 
 
Antibody Source Type MW of 
protein 
(kDa) 
Dilution Reduced 
PtdIns 4-
kinase 
(4C5G) 
(Endemann et al. 
1991) 
mc 45 serum 
supernatant 
(FC) 
no 
CD37  
(MCA 483S) 
Serotec mc 40-52 1:100 no 
CD53 
(MCA 723G) 
Serotec mc 32-40 1:100 no 
CD63 (6H1) (Berditchevski et 
al. 1995) 
mc 40-70 serum 
supernatant 
(FC) 
no 
CD63  
(MX-
49.129.5) 
Santa Cruz Bio. mc 40-70 1:1000 
(WB) 
no 
CD81 (M38) kindly provided by 
Dr. O. Yoshi 
mc 20 serum 
supernatant 
no 
CD82 
(M104) 
kindly provided by 
Dr. O. Yoshi 
mc 60 serum 
supernatant 
(FC) 
no 
CD82 
(TS82b) 
kindly provided by 
Dr. E. Rubinstein 
mc 60 serum 
supernatant 
(WB) 
no 
CD151 
(5C11) 
(Berditchevski et 
al. 1997) 
mc 29 serum 
supernatant 
no 
HSP90 
(SPA830) 
Stressgen mc 90 1:1000 (WB) yes 
CD19 Cell Signaling mc 95 1:1000 (WB) yes 
CD19 
(HIB19) 
BD Pharmingen mc 95 1:500 (FC) Nd 
MHC I 
(W6/32) 
kindly provided by 
Prof. M. Rowe 
mc 45 1:800 (FC) 
1:250 (WB) 
 
yes 
MHC II  
(DA6-14) 
kindly provided by 
Prof. M. Rowe 
(Lehner and Jones 
1984) 
mc 30 1:250 (WB) yes 
MHC II – DQ 
(SPV-L3) 
kindly provided by 
Dr. G. Taylor 
(Spits et al. 1983) 
mc 30 1:800 
(FC/EM) 
Nd 
MHC II – DR 
(L243) 
kindly provided by 
Dr. G. Taylor 
(Fong et al. 1981) 
mc 30 1:800 
(FC/EM) 
Nd 
MHC I 
(ILA88, 
α-bovine)  
kindly provided by 
Dr. S. Ellis 
mc 45 1:10000 
(5ng/ml, WB) 
yes 
Calnexin  
(AF-8) 
(Hochstenbach et 
al. 1992) 
mc 90 1:50000 yes 
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Antibody Source Type MW of protein 
(kDa) 
Dilution Reduced 
ICAM-1 
(CD54) 
CR UK mc 90 1:100 yes 
Talin (8D4) Sigma mc 230 1:2000 yes 
LMP-1 (CSI-
4) 
CR UK, kindly 
provided by Prof. 
M. Rowe 
mc 63 1:50 yes 
LMP-2a 
(14B7) 
Santa Cruz, kindly 
provided by Prof. 
M. Rowe 
mc 65 1:500 yes 
EBNA2 
(PE2) 
kindly provided by 
Prof. M. Rowe 
mc 86 1:50 yes 
EBNA3c 
(E3C) 
Santa Cruz, kindly 
provided by Prof. 
M. Rowe 
mc 170 1:50 yes 
CD3 (OKT-
3) 
kindly provided by 
Dr. S. Lee 
mc 23 0-2ug/ml Nd 
α-PE e-Bioscience mc, biotin-
labelled 
240 1:40 Nd 
Syntenin Abnova mc 32 1:500 yes 
Goat anti-
mouse Ig-
HRP 
conjugated 
Dako pc HRP-
conjugated 
 1:25000 Nd 
Goat anti-
rabbit Ig 
Dako pc HRP-
conjugated 
 1:25000 Nd 
Mouse anti-
human CLIP 
BD Pharmingen mc  1:50 Nd 
Mouse anti-
human α-
tubulin  
kindly provided by 
Dr. S. Roberts 
mc  1:1000 Nd 
AlexaFluor 
594-
phalloidin 
invitrogen   1:100 Nd 
mc: monoclonal; pc: polyclonal; Nd: not determined; WB: Western blotting; FC: Flow cytometry 
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2.8 Molecular Biology 
 
Luria Broth (LB) 
LB was prepared by dissolving 5g Peptone, 2.5g yeast extract and 5g NaCl in 500ml 
sterile water. The solution was autoclaved for 20min at 15psi and 121°C. 
 
LB agar 
LB agar was prepared by addition of 7.5g agar to 500ml LB before autoclaving. 
 
Antibiotics 
Bacteria containing plasmids were seleted using ampicillin. Concentrated stocks of 
ampicillin (100mg/ml) were prepared in sterile water and stored in aliquots at - 20°C. 
Ampicillin was added to autoclaved media directly before use to make a final 
concentration of 100μg/ml. 
 
Tris/acetate buffered EDTA (TAE) 
500ml of a concentrated stock of TAE (50x) was prepared by dissolving of 121g Tris 
base in H2O and adding 28.6ml glacial acetic and 5ml 0.5M EDTA.  
 
Competent cells 
NEB 5-alpha F’Iq Competent E.coli; stored at -80°C 
 
DNA extraction kit 
QIAprep Spin Miniprep Kit, Qiagen Germany 
QIAGEN Plasmid Maxi Kit, Qiagen Germany 
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2.8.1 DNA digestion with endonuclease enzymes 
 
Plasmid DNA was diluted in sterile water and dependent on the particular purpose an 
aliquot of 0.5-5ug was taken to perform a DNA digestion by adding 5-20 Units of 
particular endonuclease restriction enzymes (Roche) and appropriate amounts of 10x 
enzyme buffers.  
 
2.8.2 Agarose gel electrophoresis 
 
Separation of DNA fragments generated by restriction enzyme digestion was 
performed by agarose gel electrophoresis containing ethidium bromide to allow 
visualisation of the DNA in a ultra-violet (UV) transilluminator. To make the gel, the 
particular amount of agarose was added to H2O and heated until boiling point in a 
microwave oven. Once the agarose solution had cooled slightly, the appropriate 
volume of 10xTAE and ethidium bromide was added and the gel was cast into a gel 
former (Geneflow). When set, the gel was submerged in an electrophoresis tank 
(Geneflow) in 1 x TAE. DNA samples were diluted in a 5x sample loading buffer 
alongside standard size markers (NEB 1kb or 100bp ladder mix). The samples were 
run at 100V and electrophoresis was stopped when the dye front migrated a desired 
distance.  
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2.8.3 DNA extraction from an agarose gel 
 
DNA fragments separated by agarose gel electrophoresis were visualised and 
photographed. DNA fragments requiring purification were excised from the gel into a 
sterile 1.5ml eppendorf tube under a UV transilluminator using a clean scalpel blade. 
The excised pieces of gel were weighed and purified using a Quiagen QIAquick Gel 
Extraction Kit according to the manufacturer’s instructions.  
 
2.8.4 DNA ligation 
 
The ligation of enzyme digested DNA fragments (generated from vector and insert 
DNAs) was performed using T4 Ligase (NEB) in 10x ligation buffer. 3:1 molar ratios 
of purified insert and vector DNA were mixed with 1μl 10x ligation buffer and topped 
up to 10μl with sterile dH2O. The mixture was either incubated at RT for several 
hours or at 16°C overnight. Ligated DNA was either used directly for transformation 
of competent bacteria or stored at -20°C until use.      
 
2.8.5 Transformation of competent bacteria 
 
Competent E.coli cells were thawed on ice. An aliquot of 14μl was transferred to a 
sterile eppendorf tube, mixed with 1μl of the ligation mixture and incubated for 30min 
on ice. After this the cells were made receptive for DNA-uptake by exposing them to 
42°C for 30sec and immediately returning to ice for 5min incubation. 200μl SOC 
medium was added to the bacteria followed by incubation for 1hr at 37°C in a shaker. 
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The cells were plated onto LB agar plates containing ampicillin (100g/ml) for 
selection of the transformed cells and incubated at 37°C overnight. 
 
2.8.6 Preparation of plasmid DNA from transformed bacteria 
 
All procedures were conducted according to “QIAprep® Miniprep Handbook” as 
briefly described: 
 
Mini-prep 
Colonies of transformed bacteria were picked into 5ml of LB medium supplemented 
with 100μg/ml ampicillin and grown overnight in a shaker at 37°C. 1.5ml of the 
culture was centrifuged in a 1.5ml eppendorf tube at 5000rpm for 3min in a bench top 
centrifuge. The supernatant was discarded and the bacteria-pellet resuspended in 
250μl P1-buffer. The suspension was mixed with 250μl P2-buffer and incubated for 
max 5min in order to lyse the bacterial cells. 350μl of buffer N3 was added to the 
lysate to neutralise the solution and precipitate insoluble bacterial material. After the 
precipitate was sedimented at 13.000rpm for 10min (bench-top centrifuge), the 
supernatant was transferred into a QIAprep spin column and centrifuged for 1min. 
The remaining DNA was washed once with 0.5ml buffer PB and once with 0.75ml 
buffer PE before eluted in 50μl sterile, deionised water.    
 
Maxi-prep 
200-300μl of an overnight bacterial culture was transferred into 200ml of LB medium 
supplemented with 100μg/ml ampicillin and grown overnight in a shaker at 37°C. The 
bacteria were pelleted and resuspended in 10ml buffer P1. 10ml buffer P2 was added 
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to bacterial suspension to lyse the cells for 5min at room temperature followed by 
neutralisation with 10ml buffer P3. After incubation for 20min on ice the precipitate 
was spun down and the supernatant was transferred into a buffer QBT-equilibrated 
QIAGEN-tip 500. The tip was washed twice with 30ml buffer QC before the DNA 
was eluted into a 50ml centrifuge tube by adding 15ml buffer QF. Thereupon, the 
DNA was precipitated with isopropanol and the remaining pellet washed with 1ml 
70% ethanol before dissolved in the required amount of sterile deionised water.     
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3 Results 
3.1 Characterisation of the model system 
 
3.1.1 Characterisation of LCLs 
 
Prior to starting immunological assays, it was important to characterise the cell lines 
selected for use in this research. EBV-transformed LCLs serve in this project as a 
model antigen presenting cell. An LCL established from a healthy laboratory donor 
(PER241) was selected on the basis of possessing both HLA-DR52b and HLA-DQ5 
and therefore able to present both of the EBV epitope peptides that were selected for 
the study. As expected, the LCL expressed high levels of MHC class I and class II 
molecules (Fig. 3.1A). The LCL also expressed the tetraspanins CD37, CD63, CD81, 
CD82 and CD151. Analysis by flow cytometry confirmed these tetraspanins were 
present at the LCL surface (Fig. 3.1B). 
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A 
 
 
B
 
 
Figure 3.1: Cell surface expression of relevant membrane proteins by LCLs 
A) Western blotting shows the total cell expression of common B cell proteins such as MHC 
I, MHC II, CD19, CD86 as well as the tetraspanins CD63 and CD81. The tetraspanin CD9 
however, could not be detected (data not shown). B) Cell surface expression was confirmed 
by flow cytometry for the proteins MHC I, II, CD19, CD37, CD63, CD81, CD82 and CD151. 
Again an antibody specific for CD9 did not result in any detectable labelling (data not 
shown). LCLs were first incubated with antigen-specific primary antibodies or, as a negative 
control, an irrelevant primary antibody before labelling with the secondary antibody, a 
polyclonal PE-conjugated anti-mouse antibody. 
CD81 
MHC I 
MHC II 
actin 
CD63 
CD19 
62 
47.5 
32.5 
CD86 
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3.1.2 Characterisation of T cells 
 
The CD4+ T cell clones selected for use in this research were also tested for their 
expression of relevant proteins. As expected, the clones expressed CD4 and also the 
tetraspanins CD53, CD63, CD81, CD82 and CD151 but not CD9 and CD37 (Fig. 
3.2).
 
Figure 3.2: Cell surface expression of CD4 and tetraspanins by CD4+ T cell clone c38 
Flow cytometry confirms CD4+ T cell clones (here: c38 (HLA-DQ5 restricted)) express CD4 
and the tetraspanins CD53, CD63, CD81, CD82, CD151. The tetraspanins CD9 and CD37 
were not detected. The same molecules were also expressed by the second CD4+ T cell clone 
c93 (HLA-DR52b restricted) (data not shown). Staining and controls are as described for Fig. 
3.1. 
 
3.1.3 Recognition of LCLs by CD4+ T cells 
 
After characterising the expression of relevant proteins by the LCL and CD4+ T cell 
clones, the ability of the LCL to activate the CD4+ T cell clones was determined. 
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Using IFNγ to measure T cell activation revealed that only the HLA-matched LCL, 
established from PER241, was capable of stimulating both CD4+ T cell clones (Fig. 
3.3). Note that recognition of the LCL by the c93 clone was relatively weak without 
peptide loading. A second HLA-mismatched LCL (PER213, see Table 2.4) did not 
stimulate the T cell clones, demonstrating the HLA specificity of T cell activation.  
 
A 
 
 
B 
 
 
Figure 3.3: Activation of CD4+ T cell clones is HLA-restricted  
The chosen HLA-matched LCL (PER241), either left unmanipulated (HLA matched, control) 
or prepulsed with epitope peptide (1x10
-5
M) and then washed (HLA matched+peptide), was 
recognised by c38, a DQ5 restricted CD4+ T cell clone (A) and c93, a DR52b restricted clone 
(B). Note that the unmanipulated LCL activates the T cells and this is increased when the 
LCL is pre-treated with synthetic epitope peptide prior to co-culture with the T cells. An 
HLA-mismatched LCL (PER213), whether untreated or peptide pulsed, did not cause any 
activation. Shown is one representative result from three experiments. Error bars show the 
mean +/- standard deviation of triplicate ELISA-wells.  
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3.1.4 Depletion of tetraspanins in LCLs  
 
3.1.4.1 Transient transfection of LCLs with siRNA 
 
To knockdown the expression of tetraspanins in LCLs, an siRNA duplex targeting a 
sequence in the open reading frame of CD63 (5’-GGTTTTTCAATTAAACGGA-3’) 
previously shown to cause a marked knockdown in other cell lines such as HeLa and 
MDA293 cells (data not shown) was first tested. A second positive control duplex 
known to knockdown maxGFP, a GFP variant encoded by a plasmid provided within 
the Nucleofector Kit (Lonza), was also included in the experiment. Both, a standard 
electroporation protocols (250V, 975µF, 4mm electrode gap) as well as commercially 
available transfection kits were tested. Cell line Nucleofector Kit (Lonza), siPORT 
NeoFX (ambion) and NanoJuice Transfection Reagent (Merck) were tested using a 
variety of conditions by changing settings for the electroporation, buffers and preset 
programs according to manufacturers’ recommendations. None of these methods 
decreased expression of CD63 or, in cells transfected with pmaxGFP, did result in any 
noticeable expression of GFP which was planned to be knocked down subsequently. 
Since both siRNA duplexes had worked in other cell lines, this result suggested that 
LCLs are inherently much harder to transfect with siRNA. 
 
3.1.4.2 Designing and cloning of shRNA constructs  
 
Since siRNA supplied exogenously to the LCLs did not appear to work in LCLs, 
another strategy to knock down the tetraspanins was investigated, this time 
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endogenously expressing shRNA. A shRNA construct targeting the same sequence in 
CD63 was designed. Despite repeated attempts it was not possible to clone the 
annealed oligonucleotide duplex directly into the lentivirus vector (pLV-THM). A 
different strategy was therefore followed. Oligonucleotide primers were designed and 
synthesised to allow the same shRNA duplex to be cloned into a different vector, 
pSuperior which would serve as a platform to firstly, test the shRNA efficacy by 
transfection into HeLa cells and, secondly, to allow subcloning of shRNA sequences 
shown to knockdown their target genes into pLV-THM. In addition to the CD63-
specific construct a further four duplexes targeting CD82, designed as described 
above, were also cloned into pSuperior. An additional pSuperior plasmid containing a 
duplex  targeting CD81 (see 2.1.6.1 for target sequence) was kindly provided by 
Fedor Berditchevski (Baldwin et al. 2008). Transfection of the pSuperior plasmids 
into HeLa cells identified one plasmid able to knockdown CD81, one able to 
knockdown CD82 and a third able to knockdown CD63 (Fig 3.4). Note that, 
especially for the CD63 construct, a small population of the HeLa cells was 
transfected and these showed only a reduction in tetraspanin expression.  
 
A 
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Figure 3.4: Assessment of shRNA knockdown efficiency cloned into pSuperior in HeLa 
cells 
HeLa cells were transfected with pSuperior containing shRNA constructs targeting sequences 
within the proteins CD81, CD82 and CD63 (see 2.1.6.1). A) Western blotting of whole cell 
lysates shows a substantial knock down of the targeted proteins CD81 and CD82. For CD63 
no Western blotting was conducted. B) Knockdown was confirmed by flow cytometry using 
antibodies against CD81, CD82 or CD63, top row: unmanipulated (wild type: wt) cells 
incubated with an irrelevant primary antibody; middle row: unmanipulated cell stained with 
antibodies specific for CD81 (left panel), CD82 (middle panel) and CD63 (right panel); 
bottom row: shRNA transduced cells stained as described above. None of these knock downs 
did affect the expression of other relevant members of the tetraspanins family including 
CD81, CD82, CD63, CD151 (data not shown).  
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3.1.4.3 Lentivirus production and LCL infection 
 
Following their identification in HeLa cells, the functional shRNA sequences were 
subcloned from pSuperior into the lentivirus vector pLV-THM. These lentiviral 
vectors were then transfected into the packaging cell line HEK293T along with the 
packaging construct psPAX2 and the envelope plasmid pMD2G-VSVG to generate 
lentiviruses. Initial experiments using GFP, which is co-expressed by the lentivirus, to 
monitor infection efficiency showed that HeLa cells were readily transduced with 
these viruses whereas the efficiency of infection of LCLs was very low (data not 
shown). Testing different HEK293 packaging cell lines, different media and different 
commercial and non-commercial transduction reagents increased the efficiency of 
LCL transduction, although levels were still low. Concentrating the lentivirus by 
centrifugation prior to LCL infection gave the largest increase in infection efficiency, 
allowing up to 30% of LCL to be infected, and was therefore used routinely. Since 
transduced cells also express GFP, fluorescence-activated cell sorting (FACS) was 
then used (Institute of Biomedical Research, IBR, Birmingham) to select infected cell 
lines. Following several rounds of infection and cell sorting two different types of 
LCLs were produced, one with low levels of CD63 (Fig: 3.5) and a second transduced 
with the same virus lacking an shRNA insert to serve as a control. In the case of 
CD81 and CD82, despite multiple rounds of infection combined with three separate 
rounds of cell sorting, LCLs with reduced levels of these proteins could not be 
established (Fig: 3.5B, C) Note that in the transfection with shRNA targeting CD82 
caused even a slight increase in the total cell lysates before sorting. The fact that the 
lentivirus infection was 100% raised the possibility that the high levels of CD81 and 
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CD82 expressed by LCLs made them resistant to knockdown by these shRNA 
molecules that had been shown to work in HeLa cells.  
 
A 
 
 
B       C 
 
 
Figure 3.5: Western blot for knock down of tetraspanins in LCL 
LCL PER241 was infected with lentivirus concentrated from HEK293T supernatant. A) LCL 
infection with shRNA constructs targeting CD63 combined with subsequent cell sorting for 
low expressing populations did lead to a stable knock down of this protein. Additional flow 
cytometry data support this observation (data not shown). B+C) Transducing the same LCL 
with lentivirus expressing shRNA targeting CD81 or CD82 did not result in stable 
knockdown of these proteins even after three separate rounds of cell sorting. For all 
experiments “control LCL” represents the LCL PER241 infected with empty pLV-THM 
whereas “LCL wt” is untreated LCL. 
 
  
77 
3.1.4.4 Knock down of CD63 in LCLs  
 
As it proved impossible to knock down CD81 and CD82 in LCL despite intensive 
efforts, these two tetraspanins were not investigated any further. I therefore focused 
on the tetraspanin, CD63, which could be knocked down in LCLs. In order to rule out 
the possibility that any results achieved with the CD63 shRNA were due to off-target 
effects, a different shRNA sequence able also to knock down CD63, was sought. Five 
other shRNA sequences, each targeting different sequences within CD63, were cloned 
into pSuperior and tested for their efficacy. The shRNA causing greatest knockdown 
of CD63 in HeLa cells was then sub-cloned into pLV-THM. Lentivirus was prepared 
and used to infect PER241 LCL and a new line was generated as described above 
with CD63 now knocked down in the same cell background by a different shRNA. 
Western blotting and flow cytometry using the original CD63low LCL (CD63low-a) 
and the newly generated line (CD63low-b) revealed that the CD63 expression level 
was even further decreased in CD63low-b (Fig. 3.6A, B). Regarding other proteins, 
Western blotting showed only minor differences in total protein expression of MHC 
II, CD82, CD19 and LMP2 between the control and CD63low cell lines. In contrast, 
flow cytometry detected a number of changes in the cell surface levels of these 
proteins. CD63low-a cells exhibited lower cell surface levels of CD82 and CD151. 
Cell surface levels of ICAM-1 in both CD63low-a and CD63low-b cell lines 
increased by 13% and 32% respectively. These discrepancies between total and cell-
surface levels could be due to differences in recognition by the antibody of epitopes in 
proteins in their cell surface context. For example, an altered distribution of ICAM 
caused by CD63 knockdown could potentially increase the availability of the 
antibody’s epitope. Another explanation for these differences could be natural 
  
78 
variation between identical cell lines grown in parallel cultures. I observed 
fluctuations in the expression of certain proteins including MHC II and CD19 
between control and CD63low cell lines over the months of monitoring. However, the 
overall picture over time was that the expression of all tested membrane proteins in 
control and CD63low LCLs oscillated around the same average value. 
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Figure 3.6: CD63 knockdown does not alter the level of other relevant cellular and viral 
proteins 
A) Total levels of relevant proteins were analysed for the two LCLs in which CD63 
expression is stably decreased, and the control LCL stably transfected with a lentivirus not 
expressing shRNA. The expression of the membrane proteins MHC class II, MHC I, ICAM-1 
and CD86 as well as the viral nuclear proteins EBNA2 and EBNA3c was unaltered upon 
CD63 knockdown. B) Surface expression of proteins including CD81, two different HLA II 
molecules (DQ and DR) and MHC I were not altered by either CD63-specific shRNA. 
Alterations were observed for CD82, CD151 and ICAM-1. Negative control (-ve ctrl) see Fig. 
3.1. 
 
3.1.5 Analysis of MHC class II distribution in LCLs by transmission electron 
microscopy (TEM)  
 
To analyse the density and distribution pattern of MHC class II on LCLs after 
knocking down CD63, cells, immunogold labelled using an antibody specific for 
HLA-DR, were quantitatively analysed by electron microscopy (Fig. 3.7A). In total 
approximately 550 gold particles, representing labelled MHC II molecules, were 
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counted for each cell line. No apparent differences could be seen in the number of 
surface-bound gold particles between the CD63 knockdown (CD63low-a) LCL and 
the control LCL (Fig. 3.7B). The distribution of surface MHC II was observed to 
mainly occur in patches. The average number of MHC II molecules present in these 
patches (Fig. 3.7C) and also the number of patches in ratio to their size was 
indistinguishable between the control and the CD63low LCL (Fig. 3.7D). 
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Figure 3.7: Analysis of quantity and distribution of surface MHC II on LCLs 
A) CD63low-a and control LCLs, were negatively stained using uranyl acetate and 
immunogold labelled using an antibody specifically recognising MHC class II-DR molecules 
(L243) (arrows). A negative control was conducted and resulted in cells without labelling 
(data not shown). B) Detailed quantification using the image processing software ImageJ 
reveals an unaltered quantity as well as surface distribution of MHC II after knocking down 
CD63 in LCL. The number of molecules was assessed in relation to the cell’s perimeter 
which was given by ImageJ in arbitrary area units. The error bars represent the mean +/- 
standard deviation of MHCs per perimeter unit counted on each analysed cell. For each cell 
line, between 4 and 5 cells were analysed for quantification purposes. C) MHC II molecules 
are organised into patches on the LCL’s outer membrane. The average amount of MHC II 
molecules per patch is similar for CD63low and control LCL. The error bars represent the 
mean +/- standard deviation of the average MHCs amount per patch per cell. D) Different 
sizes of MHC II clusters could be observed on each cell. The calculated mean distance 
between patches of similar size are similar for CD63low and control LCL. 
 
Summary 
 
This chapter has focussed on the development of an experimental system to allow the 
influence of tetraspanins on MHC II antigen processing and presentation to be 
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explored. Despite intensive efforts, it proved impossible to knockdown CD81 and 
CD82. This is likely due to the naturally high levels of these tetraspanins present in 
LCLs. Only for CD63 could an adequate depletion of proteins be achieved. This 
tetraspanin and its influence on antigen processing and presentation to CD4+ T cells 
would be the subject of the next part of the project. Importantly, the total protein 
expression of relevant proteins such as MHC II, ICAM-1, CD86 or the EBV nuclear 
proteins EBNA3c and EBNA2 was not affected by knocking down CD63 in LCLs. 
Surface expression did not vary either and analysing the surface distribution of MHC 
II on CD63low and control LCL did not reveal any change upon CD63 depletion. 
Thus, any changes in presentation to CD4+ T cells would represent changes due to 
CD63 rather than other molecules involved in antigen presentation. 
 
3.2 Exosomes from B-LCLs, purification and characterisation  
 
3.2.1 Purification of LCL-derived exosomes 
 
3.2.1.1 Optimising exosome purification: i) depletion of serum contaminants 
 
An important part of the research project was to study the contribution made by 
exosomes in the recognition of LCLs by CD4+ T cells. Therefore, it was important to 
optimise methods for purification of exosomes secreted into the culture medium by 
LCLs. Exosome purification is typically achieved by differential centrifugation. To 
optimise this method, the progress of purification was tracked by samples taken from 
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the pellets produced after each centrifugation step. These samples were studied by 
Western blotting using antibodies to human MHC II, a known exosome component. 
Apart from cellular debris, the foetal bovine serum (FBS) used as a supplement to the 
medium LCLs are cultivated in, is also a potential source of contaminants. Serum 
naturally contains bovine microvesicles, which due to their morphological 
characteristics can co-sediment with human exosomes. Firstly, the degree of 
contamination by bovine material was investigated by Western blotting using an 
antibody specific for bovine MHC class I. Bovine material was present in fractions 3 
and 4 of the differential centrifugation procedure (Fig. 3.8A; top panel, lane 1, 4) as 
well as in the final exosomal pellet (lane 6). The strength of bovine MHC I band in 
those exosomal fractions was only marginally smaller compared to human MHC I 
derived from LCLs (Fig. 3.8A; bottom panel, lane 6). In order to avoid any potential 
influence of bovine material in the planned T cell assays, all exosomal preparations 
were made from LCLs grown in bovine-microvesicle depleted medium. Such medium 
was prepared after high speed centrifugation (100 000 x g, overnight) of FBS diluted 
to 20% with RPMI. The supernatant was decanted and the pellet of bovine cell 
material, including bovine vesicles, was discarded. When using this depleted medium, 
Western blotting using anti-bovine and anti-human MHC I antibodies shows a 
substantial change in ratio of bovine to human MHC I in exosomal lysates (Fig. 
3.8B).  
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Figure 3.8: Depletion of bovine cellular material from exosomal samples 
A) The purification of exosomes was monitored for contamination with bovine cellular 
material using an anti-bovine MHC I antibody (ILA88) and an anti-human MHC I antibody 
(W6/32). Bovine MHC I could be detected in fractions 3 and four (top panel, lane 3, 4) and 
the final exosome pellet (top panel, lane 6) whereas human MHC I was seen in all fractions 
(bottom panel). B) LCL-derived exosomes from two separate experiments (1 and 2), using 
bovine-microvesicle depleted medium for culturing LCLs, were analysed for remaining 
contamination by bovine exosomes. Using anti-bovine and anti-human MHC I antibody for 
Western blotting showed a markedly reduced ratio of bovine (lane 1, 2) to human MHC I 
(lane 3, 4). 
 
3.2.1.2 Optimising exosome purification: ii) separation from cellular debris 
 
The quality and purity of exosomal preparations were regularly checked by looking 
for the presence of calnexin, a transmembrane chaperone which predominantly 
resides in the endoplasmic reticulum and known not to be present in exosomes. 
Calnexin is commonly used as a control to monitor purity of exosomal fractions (Asea 
et al. 2008;Gastpar et al. 2005;Gomes et al. 2007;Mears et al. 2004). It was found that 
the cell material contamination in exosomal fractions was substantially diminished 
after the initial spin with decreased g-force was added to the protocol to carefully 
pellet/remove live cells from the medium (Fig. 3.9A). Exosomes were used for 
functional studies only if the amount of calnexin in the exosomal samples was less 
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than 10% of that present in the cellular lysate (in samples equalised by the amount of 
protein material). Note the substantial reduction in the ratio of calnexin and MHC II 
in lane 1 (whole cell lysate) and lane 6 (exosomes). Moreover, for electron 
microscopy experiments, microvesicles and potential contaminating membrane 
fragments were separated by their specific density by flotation on a sucrose gradient. 
This gradual separation revealed a broad overlap in density of MHC II and calnexin 
containing material of unknown constitution (Fig. 3.9B, lane 3 to 8). Exosomes 
characteristically appear in densities ranging from 1.10 to 1.19 g/ml. So the MHC II 
seen in fractions of higher density derives from unknown cellular compartments. 
Later, especially for analyses by electron microscopy an even higher purity was 
achieved by floatation on sucrose cushion. This cushion was prepared to a density of 
1.2 g/ml which allows exosomes of this and lower density to remain in the cushion 
where it can be harvested while debris of higher density penetrates the cushion and 
forms a pellet.   
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Figure 3.9: Depletion of cellular debris from exosomal samples 
A) Exosomes were purified from cell supernatant by differential centrifugation in 5 separate 
steps. Lane 1:1
st
 spin, Lane 2: 2
nd
 spin to separate cells, Lane 3: sedimentation of remaining 
dead cells, Lane 4: sedimentation of cell debris, Lane 5: soluble proteins in supernatant after 
pelleting exosomes, Lane 6: exosomes (arrow: calnexin (90kDa), dashed arrow: human MHC 
II (28 kDa)). B) Exosomes were further analysed by sucrose gradient centrifugation. Cellular 
material originating from the MIIC is visualised using anti-human MHC II antibody (30kDa), 
contaminating debris using anti-human calnexin antibody (95 kDa). Characteristically 
floating on a sucrose gradient with a density range from 1.10 to 1.19 g/ml, exosomal fractions 
(lane 7 – 11) overlap with fractions containing cytoplasmatic material, represented by 
calnexin (lane 7 and 8).  
 
3.2.1.3 Characterisation of exosomes by Western blotting 
 
After optimising the protocol for purifying exosomes by differential centrifugation 
(Fig. 3.10), the distribution of proteins during the separate purification steps was 
analysed by Western blotting using antibodies against CD82, CD63, CD53, heat 
shock protein (HSP)90, CD19, MHC II, MHC I, actin and tubulin (Fig. 3.10), all of 
them known to be present in exosomes (Mears et al. 2004). Since these proteins are 
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present in cells, in the cell membrane, in membrane fragments derived from apoptotic 
or dead cells and in the membrane and lumen of exosomes, the proteins were found in 
all fraction including the cell lysate (lane 1) and the purified exosomes (lane 7), but 
not in the non sedimented fraction (lane 6) as would be expected for these proteins 
located in the membrane or lumen of exosomes.  
 
 
 
Figure 3.10: Analysis of the purification of LCL-derived exosomes 
Protein samples from each of the seven different stages of a single purification were probed 
by Western blotting using antibodies to CD82, CD63 (glycosylated form, MW: 83-30kDa), 
CD53, HSP90, CD19, MHC class II (MW: 32kDa, arrow), MHC class I, actin and tubulin. 
These proteins were not present in the unsedimented supernatant in fraction 6 but clearly seen 
in the cell lysate in fraction 1 and in the exosomal fraction (#7). 
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3.2.2 Morphological analysis of LCL-derived exosomes 
 
3.2.2.1 Transmission electron microscopy 
 
The morphology of LCL-derived exosomes was studied by electron microscopy. For 
this purpose exosomes purified by differential centrifugation were centrifuged again 
and harvested from the sucrose cushion (density 1.2g/ml). The first exosome samples 
examined by electron microscopy revealed that high proportions of vesicles had been 
damaged (Fig. 3.11A). Several months of investigation into the methodology of 
exosome purification and preparation of samples suitable for electron microscopy 
were undertaken. Among others, new centrifugation tubes were purchased, different 
procedures for cleaning these tubes after use were tested and each step of the protocol 
for preparing the exosomes for electron microscopy was assessed. Eventually, the 
major reason for the exosome damage turned out to be due to generation of air 
bubbles during resuspension of exosomal pellets by pipetting with a P200 Gilson 
fitted with a yellow 200µl pipette tip. The shear forces were sufficient to almost 
completely destroy the fragile exosomes. Conducting this resuspension very gently, 
avoiding the generation of air bubbles and hence reducing the shear force, made it 
possible to resuspend the exosome pellet without causing damage producing vesicles 
morphologically consistent with exosomes. Immunogold labelling using antibodies 
binding tetraspanin CD81, CD82 or CD63 and MHC II, showed presence of the 
proteins on exosomes and their co-localisation with MHC II molecules (Fig.3.11B). 
While LCLs in culture can release EBV virions, only a small number of the cells enter 
lytic cycle replication, no virus particles were ever observed in the EM work. 
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Figure 3.11: Vesicles visualised by transmission electron microscopy 
A) The morphology of uranyl acetate stained exosomes was analysed via TEM. First attempts 
at purification resulted in almost complete destruction of exosomes. B) After further 
optimisation of the purification method, electron microscopy confirmed vesicles of size and 
morphology consistent with exosomes (upper left). Immunogold co-labelling of tetraspanins 
CD81 (upper right), CD82 (lower left) and CD63 (lower right) together with MHC class II 
molecules confirmed their co-localisation on exosomes. Here: tetraspanins - 10nm gold 
particles (arrowhead), MHC class II - 15nm gold particles (arrow). 
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3.2.3 Functional analysis of exosomes 
 
3.2.3.1 Exosomes interact with CD4+ T cell clones 
 
Since exosomes contain MHC II, co-stimulatory proteins and adhesion proteins and 
are able to directly interact with T cells (Thery et al. 2002a) the ability of LCL-
derived exosomes to bind T cells was studied. Here, the fact that LCLs transduced by 
the control or CD63 shRNA expressing lentivirus also express GFP was taken 
advantage of. Since exosomes capture proteins of the cell’s cytoplasm they should 
contain some GFP and so be detectable by flow cytometry. Exosomes purified from 
PER241, transduced with the control lentivirus, were co-incubated with a CD4+ T 
cell clone at 4°C or 37°C for one hour. The T cells were then washed and analysed by 
flow cytometry. There was an increase in fluorescence upon incubation with 
exosomes at 4°C, a larger increase was observed when the co-incubation was 
performed at 37°C (Fig 3.12A). To increase the fluorescent signal, the LCLs 
described above were first pre-labelled with CFSE, a fluorescent dye that binds 
intracellular proteins, prior to the two day culture to allow exosomes to be secreted. 
Different concentrations of CFSE were tested for LCL-labelling. The aim was to 
maximise fluorescence while minimising toxicity, since dying cells can release 
microvesicles that are not true exosomes. Labelling the LCL with 40µM CFSE 
decreased cell viability to 55%, whereas 20µM yielded strongly fluorescent LCLs and 
exosomes with an acceptable LCL-viability of 70% after the 48 hour culture used to 
accumulate exosomes in the cell supernatant (Fig. 3.12C). A remarkable increase of T 
cell fluorescence was achieved when incubating T cells with exosomes labelled with 
20µM or 40µM CFSE at 37°C (Fig. 3.12B, right panel). At 4°C however, CFSE 
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labelling of LCLs using 5 or 20µM was apparently not sufficient to cause any 
enhancement of T cell fluorescence after co-incubating T cells with labelled 
exosomes. A shift of T cell fluorescence was only seen when incubated with 
exosomes labelled with 40µM CFSE (Fig. 3.12B). However, due to the high rate of 
cell death caused by this concentration of CFSE, the result has to be interpreted 
cautiously.  
Generally, the higher increase in fluorescence intensity of T cells when incubated 
with labelled exosomes, either GFP or CFSE labelled, at 37ºC suggests that this 
temperature allows the T cells to take up exosomes and further allows additional 
exosomes to bind at their place. At 4ºC however, these exosomes are possibly not 
taken up and only bind on the T cell’s surface. 
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Figure 3.12: Analysis of binding of exosomes to T cells by flow cytometry 
A) The CD4+ T cell clone c38 was incubated with HLA-matched GFP-containing exosomes 
purified from LCLs. After washing off remaining exosomes analysis by flow cytometry 
revealed increased fluorescence in the T cells, confirming exosomal binding to T cells. The 
negative control (-ve control) is T cells incubated with non-fluorescent exosomes. B) Staining 
LCL prior to isolating exosomes using 5 or 20µM CFSE showed a similar effect and only a 
slight shift using 40µM when incubating these exosomes with HLA-matched T cells at 4°C. 
Incubation at 37°C leads to even higher degree of fluorescence in this T cell clone. The 
negative control (-ve control) was provided by T cells incubated with unmanipulated 
exosomes. C) LCL’s viability was determined before and after the 48 hour incubation with 
CFSE using Trypan blue. The viabilities were normalised in relation to 100% viability for 
untreated cells.  
 
3.2.3.2 Exosomes are capable of stimulating CD4+ T cells 
 
After demonstrating that exosomes from PER241 could bind to the CD4+ T cell 
clone, the ability of the exosomes to activate the T cells was studied. Exosomes 
purified from HLA matched or mismatched LCLs were added directly to CD4+ T 
cells. Following overnight incubation, levels of IFNγ released by the T cells was 
measured by ELISA. Exosomes were able to stimulate CD4+ T cell clones specific 
for the EBNA2 epitope “PRS” (c93, DR52b restricted) or the EBNA 3C epitope 
“SDD” (c38, DQ5 restricted), but only when derived from a suitable HLA matched 
LCL (Fig. 3.14). The same quantity of exosomes purified from an HLA-mismatched 
LCL lacking these alleles (PER213, Table 2.4) was completely unable to activate the 
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T cell clone. This result demonstrates that exosomes are able to directly activate 
CD4+ T cell clones in a HLA restricted manner.  
 
 
Figure 3.13: Direct stimulation of CD4+ T cell clones by purified LCL-derived exosomes  
CD4+ T cell clones (5000 T cells/well) specific for the DR52b restricted epitope PRS 
(EBNA2) or the DQ5 restricted epitope SDD (EBNA 3C) were incubated with equal 
quantities of exosomes purified from LCLs either HLA matched or HLA mismatched for both 
alleles. IFNγ released by activated CD4+ T cells was analysed by ELISA. Shown is one 
representative result from at least 5 experiments. Error bars show the mean +/- standard 
deviation of triplicate ELISA-wells. 
 
3.2.3.3 Stimulation of CD4+ T cells by LCL-derived exosomes is MHC II 
dependent 
 
To confirm that the ability of LCL-derived exosomes to stimulate the CD4+ T cell 
clones was indeed MHC II restricted, T cells were exposed to exosomes in the 
absence or presence of blocking monoclonal antibodies specific for HLA-DQ or 
HLA-DR. Sensitisation of the HLA-DQ5 restricted SDD epitope was blocked by the 
HLA DQ but not the HLA-DR specific antibody (Fig. 3.14A). Likewise, sensitisation 
of the HLA-DR52b restricted PRS epitope was reduced by the HLA-DR specific 
antibody while the HLA-DQ antibody had only a minor effect (Fig. 3.14B). Note that 
as exosomes bear both DR and DQ molecules on the surface, this small reduction 
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seen following incubation with the “incorrect” antibody could be caused by non-
specific steric hindrance. 
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Figure 3.14: Analysis of MHC II-restriction of CD4+ T cell clone activation 
Antibodies specifically binding to HLA-DQ or -DR were added to exosomes at a 
concentration of 0.1 mg/ml prior to addition of T cells (5000 T cells/well) to determine the 
role of exosomal MHC class II-peptide complexes in CD4+ T cell stimulation. A) The 
activation of DQ5-specific T cell clones was reduced by adding α-DQ antibody but almost 
unaffected by the addition of α-DR52b. B) Similarly, the recognition of the DR52b-specific T 
cell clones was markedly reduced upon adding α-DR antibody. However, here the addition of 
α-DQ also caused a small decrease in HLA-DR specific T cell activation. This could be due 
to steric hindrance rather than real inhibition of the HLA-DR molecule. Shown is one 
representative result from two experiments. Error bars show the mean +/- standard deviation 
of triplicate ELISA-wells. 
 
 
 
IFNγ (pg/ml) 
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3.2.4 Analysis of exosomes derived from CD63low LCL 
 
3.2.4.1 Characterisation of CD63low LCL-derived exosomes 
 
Exosomes purified from the two CD63low LCLs, a and b, were analysed for their 
protein content and compared to exosomes derived from control LCL transduced with 
the control lentivirus that contains no shRNA sequence. CD63 was markedly reduced 
in exosomes derived from CD63low LCLs compared to the control LCL. All other 
membrane proteins tested, including MHC I, MHC II, ICAM-1 and LMP-1 were not 
affected by the knock down of CD63 in exosomes (Fig. 3.15). Interestingly, while, as 
expected, LMP-1 was present in exosomes, Western blotting also revealed the 
presence of the EBV nuclear protein EBNA2 in exosomes. Other EBV proteins 
including EBNA3c and LMP2a as well as the adhesion molecule β1-integrin subunit 
could not be detected in any of the exosomes (data not shown). 
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Figure 3.15: Characterisation of CD63low exosomes 
Western blotting of exosomal lysates using antibodies recognising CD63, CD82, MHC II, 
MHC I, ICAM-1, LMP-1 and EBNA2 demonstrated that CD63 depletion (lane 1 and 2) does 
not influence the amount of these proteins compared to the amount found in exosomes 
purified from control LCL (lane 3). 
 
3.2.4.2 Quantification of exosomal MHC II by electron microscopy  
 
To investigate the effect of CD63 knockdown on the density and distribution of MHC 
class II on individual exosomes, immunoelectron microscopy analysis was performed 
(Fig. 3.16A). The analysis involved counting up to 1500 gold particles on exosomes 
per cell line. As expected low CD63 labelling was observed on exosomes purified 
from CD63low LCLs. Double labelling experiments (CD63-MHCII) were carried out 
using an anti-HLA DR primary antibody along with a CD63-specific primary 
antibody. The lower amount of CD63 on exosomes purified from CD63low LCLs was 
confirmed by this technique. However, interestingly, in contrast to previous Western 
blotting results, the level of MHC II labelling on CD63low exosomes was about 30% 
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higher (Fig. 3.16B). Interpreting this result, it has to be taken into account that the 
quantification by TEM was conducted using exosomes purified from a single batch of 
cells per LCL. This difference in MHC II level may reflect a transient variation in 
MHC II expression as it was observed for this particular LCL over the years of 
cultivation (data not shown). Alternatively, the discrepancy with the WB data may be 
due to the differences in techniques. Immunolabelling of the exosomal surface 
measures what is available for the antibody to bind and would not recognise target 
epitopes of some of the MHC II molecules on the surface of the control exosomes if 
these are occluded by adjacent proteins. On the other hand, depletion of CD63 may 
somehow increase the avidity of MHC II to this antibody. 
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Figure 3.16: CD63 and MHC II content of control and CD63low  
A) The quantity of MHC II and CD63 molecules was determined by immunogold labelled 
exosomes analysed using the image processing software ImageJ. Antibodies specifically 
recognising CD63 and MHC class II (HLA DR) where used for immunogold labelling. B) 
Lower level of CD63 was confirmed on the CD63low-a LCL. The level of HLA DR on the 
exosome surface was about 30% lower on exosomes purified from the control LCL compared 
to the CD63low LCL. The number of molecules was assessed in relation to the exosome’s 
perimeter which was given by ImageJ in arbitrary area units. Isotype controls were used to 
check for unspecific staining. C) HLA DR single labelling of exosomes purified from a 
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different batch of the same cells as used above did not confirm this difference. However, 
conclusive quantification was not done in this analysis. 
 
3.2.4.2 Analysis of direct CD4+ T cell activation by CD63low exosomes 
 
To examine whether lower levels of CD63 on exosomes has any effect on exosomal 
antigen presentation, CD63low exosomes were tested for their ability to activate 
CD4+ T cell clones. Exosomes purified from the CD63low and the control LCL 
induced comparable levels of IFNγ production from both CD4 T cell clones, c38 
(SDD) (Fig. 3.17A) and c93 (PRS) (Fig. 3.17B).  
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Figure 3.17: CD4+ T cell stimulation induced by exosomes purified from control or 
CD63low LCLs 
Exosomes purified from control or CD63low LCLs caused a comparable degree of T cell 
activation after co-incubation with CD4+ T cell clones c38 (A) or c93 (B). Exosomes purified 
from an HLA-mismatched LCL did not stimulate any detectable IFNγ secretion by T cells. 
Note that a lower number of T cells (500 cells/well) were used in this experiment accounting 
for the lower levels of IFNγ seen in this experiment compared to earlier experiments. Shown 
are the data from a representative experiment out of three. The error bars represent the mean 
+/- standard deviation of triplicate ELISA wells.  
 
To exclude the possibility of oversaturation of the system by exosomal material, 
titration experiments were carried out. Exosomes were quantified by Bradford protein 
assay and titrated for subsequent T cell assays. 5000 cells of each CD4+ T cell clone, 
c38 and c93, were incubated overnight with 10, 30 and 55µg of exosomes purified 
from control or CD63low-a LCL in a total volume of 200µl. Comparable activation of 
c38 and c93 by control and CD63low exosomes was observed when 10, 30 or 55µg of 
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exosomes were added to the T-cell clones (Fig. 3.18). Interstingly, the T cell clone 
c38 was stimulated substantially better by the control exosomes at 10µg/reaction (Fig. 
3.18A). However, given the low reading observed at this concentration of exosomes, 
this difference is likely to be a result of an experimental error due to pipetting errors 
during setting up of the assay. Taken together, these results suggest that depletion of 
CD63 did not affect the ability of LCL-derived exosomes to stimulate T cells. 
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Figure 3.18: Analysis of direct exosomal CD4+ T cell activation by exosome-titration 
Exosomes purified from control and CD63low LCLs were quantified by Bradford protein 
assay. The amounts of 10, 30 and 55µg were given to CD4+ T cell clone c38 (A) or c93 
(5000 cell/well, respectively) (B). Exosomes purified from control LCL caused a higher 
stimulation of c38 than exosomes purified from CD63low LCL when 10µg of exosomes were 
added to T cells. Otherwise, T cell stimulation by exosomes from control and CD63low LCL 
was comparable for all tested concentrations. 
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3.2.4.3 Analysis of the capability of CD63low exosomes to sensitise a EBV-antigen 
negative LCL 
 
To investigate whether exosomes purified from control and CD63low-a LCLs are able 
to sensitise other B cells for CD4+ T cell activation we used PER282 as a mediator 
LCL. PER282 is transformed with the type II Ag876 strain of EBV. This LCL is 
HLA-matched for the CD4+ T cell clone c93 but, due to sequence variations in the 
endogenous antigen, does not stimulate this CD4+ T cell clone by itself. This means 
that the amount of IFNγ induced by this LCL should be at the background level. 
However, being HLA-matched, this LCL can still present epitope peptides derived 
from conventional LCLs or corresponding exosomes to T cells.  
As expected, unmanipulated Ag876 LCL did not stimulate c93 but caused a 
substantial IFNγ secretion when pulsed with the antigenic peptide (PRS) prior to co-
incubation with T cells (Fig. 3.19A). Next, exosomes purified from control and 
CD63low-a LCLs were added to the Ag876 LCL (unmanipulated or peptide pulsed) 
prior to co-incubation with T cells. The Ag876 LCL supplemented with exosomes 
derived from either CD63low-a or control LCL stimulated c93 T cells to the same 
degree (Fig. 3.19B). The results of this experiment confirmed the equal stimulatory 
power of these two different classes of exosomes. Note, that exosomes were not 
washed off but co-incubated together with the T cells and the Ag876 cells. 
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Figure 3.19: Capability of CD63low exosomes to sensitise EBV-antigen negative LCL 
The LCL PER282 does not stimulate CD4+ T cells by itself but causes IFNγ release by the 
CD4+ T cell clone c93 when pre-pulsed with exogenous antigen-peptides (A). Exosomes 
purified from CD63low and control LCL were mixed with PER282 cells (unmanipulated or 
antigenic-peptide pulsed) prior to co-incubation with CD4+ T cells (clone 93, 2500 
cells/well). Both types of exosomes sensitised LCL282 to a similar degree which is seen by a 
comparable level of IFNγ release upon CD4+ T cells encounter. Exosomes were washed off 
the LCL before incubation with CD4+ T cells. (B). Negative controls were T cells incubated 
without any stimuli. 
 
Summary 
 
Here I have shown that LCLs secrete exosomes and have optimised the purification of 
LCL-derived exosomes by differential centrifugation. I found that it was first 
necessary to remove bovine microvesicles from the FBS and also use a low speed spin 
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to remove cells in order to minimise contamination with protein residents of other 
intracellular compartments (e.g. calnexin). After isolating exosomes of sufficient 
purity, I showed that exosomes purified from CD63low LCLs have a reduced level of 
CD63 compared to exosomes purified from a control LCL. MHC I and adhesion 
molecules remained constant over time. Seemingly contradictory results were 
obtained in MHC II quantification experiments when Western blotting and immune-
electron microscopy were used. This difference however, may be due to the effect of 
temporal fluctuations in the protein expression of the LCLs used in this study. 
Alternatively, the discrepancy with the WB data may be due to the differences in 
techniques. Immunolabelling of the exosomal surface measures what is available for 
the antibody to bind and would not recognise target epitopes of some of the MHC II 
molecules on the surface of the control exosomes if these are occluded by adjacent 
proteins. On the other hand, depletion of CD63 may somehow increase the avidity of 
MHC II to this antibody. LCL-derived exosomes were capable of directly stimulating 
CD4+ T cell clones in a HLA-restricted manner but depletion of CD63 in LCL-
derived exosomes did not affect the activation of CD4+ T cell clones by exosomes 
directly or added to a epitope-negative LCL prior to incubating with T cells.  
 
3.3 Influence of CD63 on T cell recognition of EBV positive LCLs 
 
3.3.1 The role of CD63 in cellular T cell stimulation 
 
To investigate the role of CD63 in antigen presentation by cells, both of the CD63 
depleted LCLs and the control LCL were co-incubated with CD4+ T cell clones c38 
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or c93. In contrast to the results obtained using exosomes, both CD63low LCLs 
stimulated markedly higher levels of IFNγ release by the two different T cell clones. 
These results suggested that depletion of CD63 increased levels of antigen specific 
CD4+ T cell recognition compared to the control LCL (Fig. 3.20). The enhanced T 
cell stimulation by the CD63 low LCL was also seen when the LCLs were loaded 
with synthetic epitope peptides.  
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Figure 3.20: CD63 knock down potentiates cellular CD4+ T cell activation by LCLs 
DQ5- (A) as well as DR52b- (B) specific CD4+ T cell clones exhibit an increased activation 
after co-incubation with CD63 low LCLs (CD63low-a and -b) compared to the control LCL. 
This is the case for peptide pre-loaded LCLs (peptide, 10
-5
M) as well as for unmanipulated 
cells. The graph shows a representative experiment out of 13 performed. The error bars 
represent the mean +/- standard deviation of the ELISA triplicate wells. Each incubation was 
conducted using 200 T cell/well. Negative controls were T cells incubated without any 
stimuli. 
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3.3.2 Titration of exogenous antigenic peptides 
 
As an enhancement of CD4+ T cell stimulation was seen for both, unmanipulated and 
peptide loaded (10
-5
M) CD63low LCLs, the next step was to titrate the peptides in 
order to identify the concentration for optimal T cell stimulation. In the range of 0 to 1 
x 10
-5
 M of peptide that was added to the LCLs prior to then being washed and mixed 
with CD4+ T cells, a concentration of 1 x 10
-7
 M was sufficient to cause a maximum 
IFNγ-release. Indeed, higher concentrations of peptide caused the T cell stimulation to 
actually decrease to a similar degree for all three LCLs (Fig. 3.21). A similar effect of 
high dose peptide inhibition was reported before for CD8+ T cells (Alexander-Miller 
et al. 1996) and has also been described for CD4+ T cells (Haigh et al. 2008;Long et 
al. 2005b). The fact that T cell recognition of exogenous peptide was increased upon 
CD63 knockdown was an unexpected observation since it suggests that the phenotype 
we have observed is more general than just an effect on the EBV epitopes themselves.  
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Figure 3.21: Titration of LCL-loading of exogenous antigenic peptides 
The LCLs, CD63low-a, CD63low-b and control, were pulsed with the antigenic peptides 
“SDD” and “PRS” prior to co-incubating with CD4+ T cell clones overnight (250 cells/well). 
For both T cell clones, c38 (A) and c93 (B), a peptide molarity of 1 x10
-7
 proved to be 
maximal stimulatory in addition to the innate LCL-derived T cell stimulation. 
 
3.3.3 CD8+ T cell stimulation 
 
In order to examine whether knocking down CD63 effects MHC class I driven 
antigen presentation, T cell assays were conducted as before but now using a CD8+ T 
cell clone (c6), This clone is specific for an epitope (GLCTLVAML) from the EBV 
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lytic protein BMLF1 which is known to be expressed by LCLs (Yang et al. 2000). C6 
is HLA-A0201 restricted and therefore HLA matched for the control and CD63low 
LCLs established from PER241. In contrast to the results observed using CD4+ T 
cells, CD63low LCLs stimulated CD8+ T cell clone to the same degree as the control 
LCL (regardless of whether the LCLs were preloaded with synthetic epitope peptide 
or left unmanipulated) (Fig. 3.22).  
 
 
 
Figure 3.22: Influence of CD63 knock down on CD8+ T cell activation 
CD63low-a, -b and the control LCL were tested for CD8+ T cell recognition; 500 T cells 
were used per ELISA well and 50 000 lymphoblastoid cells. CD8+ T cells did not show any 
difference in activation caused the by CD63low or control LCL. This applies to LCLs either 
non-treated or peptide loaded with the particular antigenic peptide (GLC) recognised by this T 
cell clone. The HLA-mismatched LCL PER213 was not recognised. Shown is one 
representative experiment out of two. The error bars show the mean +/- standard deviation of 
ELISA triplicates.  
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3.4 Mechanism how CD63 depletion enhances CD4+ T cell recognition 
 
3.4.1 Expression level of CLIP following CD63 depletion 
 
Since MHC class II expression, both total and surface, was unaltered in CD63 
depleted LCLs (Fig. 3.6), the enhanced CD4 T cell recognition observed was clearly 
not due to a quantitative change in MHC II levels. Rather, it may have reflected a 
qualitative change in MHC II. As a first step, the level of CLIP expression on the cell 
surface of the LCLs was examined. CLIP binds MHC II with low affinity. Therefore, 
the observation that peptide loaded LCLs are recognised better upon CD63 depletion 
could conceivably be due to the presence of more CLIP-containing MHC II molecules 
on the surface of CD63low LCLs and CLIP being more readily displaced by the 
higher affinity epitope peptides. Flow cytometry showed that staining with α-CLIP 
antibody was comparable for control and CD63low-a LCLs (Fig. 3.23A). As an 
additional control, the human T2 cell line was used. These cells lack almost all of the 
MHC regions from chromosome 6p (Trowsdale et al. 1990). T2 stably transfected 
with HLA-DR11, or HLA-DR11 and HLA-DM, kindly provided by Dr. J. Blum 
(Indiana University), were stained for CLIP and analysed by flow cytometry. As 
expected, T2-DR11 and T2-DR11-DM express HLA-DR11 but no HLA-DQ (Fig. 
3.23B). In terms of CLIP, T2-DR11 exhibits a noticeable expression of CLIP, 
whereas T2-DR11-DM, overexpressing HLA-DM (which chaperones the exchange of 
CLIP with antigenic peptides in the MIIC) does not. This control therefore confirmed 
the specificity of the anti CLIP antibody. Note that the CLIP expression of LCLs is 
substantially higher than of the T2 control cell line. Similarly, high levels of CLIP 
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were observed on LCLs established from other healthy lab donors (S. Sabbah, 
personal communication). The lower expression of CLIP on T2 cells is in 
correspondence with their lower expression of total HLA (here HLA-DR). 
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Figure 3.23: CLIP expression in CD63low and control LCL 
A) Flow cytometry was conducted using α-CD63 (left), α-CLIP (middle left), α-HLA-DQ 
(middle right) and α-HLA-DR (right). Surface expression of CLIP is equal in control LCL 
and CD63low-a LCL. Both HLA molecules, DQ and DR, are equally expressed as already 
shown in 3.1.4.4. B) The two T2 cell lines, T2-DR11 and T2-DR11-DM express equal 
amounts of CD63 and HLA-DR, HLA-DQ is not present in these cell lines. As expected, 
CLIP was only detectable for the T2-DR, not for the T2-DR-DM cell line expressing the 
chaperone protein HLA-DM that mediates the exchange of CLIP for antigenic peptides in 
MIICs.  
 
 
 
  
111 
3.4.2 MHC class II stability in CD63-low LCL  
 
While levels of cell surface CLIP were equivalent in control and CD63low cells, it 
was possible that MHC class II molecules in the latter are less stable and so better 
able to bind exogenously provided synthetic epitope peptides. This prompted a second 
experiment to examine stability of MHC II molecules in the different LCLs. Lysing 
cells in Triton X 100 (1%) for 30min at room temperature results in the disassembly 
of unstable MHC class II dimers into monomers that can be identified by non-
reducing SDS-PAGE. This experiment therefore allows the stability of MHC II to be 
determined by analysing the ratio of monomers to remaining dimers. The relative 
amounts of MHC class II dimers from control and CD63low LCLs was assessed by 
immunoblotting using an antibody specific for HLA class II (DA6-14) which can bind 
both dimers and monomers alike. CD63low-a, CD63low-b LCL and the control cell 
line did not show any substantial difference in the ratio of HLA mono- and dimers 
(Fig 3.24), which is in agreement with the previous result examining CLIP surface 
expression level (see Fig. 3.23A). The same experiment was also conducted after 
pulsing LCLs with antigenic peptides before lysis. As for the non-pulsed LCLs, the 
ratio of HLA monomers and dimers was equivalent for all LCLs tested (Fig. 3.24B).  
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Figure 3.24: Analysing HLA-stability in CD63low and control LCL  
A) LCLs were lysed for 30min on ice in Triton X-100 prior to incubating the lysates for 
30min at room temperature. Analysis by non-reducing SDS-PAGE and Western blotting 
revealed comparable dimer/monomer ratios of MHC class II in the control and CD63-
depleted LCLs. An aliquot of the lysates was reduced and boiled to detect the total amount of 
MHC II monomers; blotting for actin serves as a loading control. Shown are blots from one 
representative experiment out of four. B) Peptide pulsing of LCLs with antigenic peptide 
prior to lysis did not cause any change in the ratios.  
 
3.4.3 Total binding capacity of MHC II molecules in control and CD63low cells 
 
To test for potential differences in peptide binding properties, CD63low-a and 
CD63low-b as well as the control LCL were incubated with biotinylated PRS or SDD 
peptide sequences. Staining with PE-Avidin allowed quantification of bound peptides 
by flow cytometry (Fig 3.25C). In order to demonstrate that the process of 
biotinylation of the peptides did not sterically hinder the binding to MHC II 
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molecules, a standard T cell assay using the LCL PER241 and the CD4+ T cell clone 
c38 and c93 was conducted. The biotinylated and non-labelled SDD peptides were 
equally able to stimulate T cells (Fig. 3.25A). Biotinylated PRS showed a somewhat 
reduced ability to stimulate T cells (Fig. 3.25B). Nevertheless enough peptide bound 
to the cells to allow differences in binding to control or CD63low cells to be studied 
in subsequent experiments.  
Flow cytometry experiments showed that LCLs loaded with biotinylated peptides 
display low overall levels of fluorescence. Nonetheless, the enhancement of 
fluorescence after peptide loading was consistent and equal for the control and both 
CD63low LCLs after pulsing with biotinylated SDD (Fig. 3.25C), suggesting that 
depletion of CD63 did not affect peptide binding. Similar results were obtained when 
biotinylated PRS peptide was used (data not shown). Therefore, the enhanced T cell 
recognition that is seen for peptide pulsed CD63low LCLs is not due to just more 
synthetic epitope peptide binding to the CD63low LCLs but is likely to involve 
another mechanism(s). 
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Figure 3.25: Analysis of peptide binding properties 
A) Synthetic epitope peptides, unmodified or biotinylated, were tested for their ability to bind 
MHC II molecules. Peptides were loaded onto the LCL PER241 and analysed for their ability 
to increase T cell stimulation. The T cell stimulation was equal when loading LCL with non-
labelled or biotinylated SDD. B) The same experiment was conducted using PRS. Here, the 
biotinylation caused a app. 30% reduction in T cell activation compared to unmanipulated 
PRS. Error bars show the mean +/- standard deviation of ELISA triplicates. C) Peptide 
binding assays were conducted pulsing control LCL, CD63low-a and CD63low-b LCLs with 
biotinylated peptides and subsequently staining the peptide-labelled LCLs using PE-Avidin. 
LCL incubated with PE-Avidin but not pulsed with any peptides served as a negative control 
(-ve control). No difference in the amount of peptides bound to the surface was observed. The 
black and red numbers represent the mean fluorescence intensity of control cells without 
peptides and cells loaded with biotin-peptide complexes, respectively.   
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3.4.4 Compartmentalisation of MHC class II molecules  
 
To test whether CD63 depletion altered the compartmentalisation and distribution of 
MHC class II molecules on the cell surface, lysates of CD63low-a, CD63low-b and 
control LCLs were separated by rate zonal centrifugation on a sucrose gradient and 
detected by Western blotting after protein separation in SDS-PAGE. Three separate 
experiments were conducted, homogenising the cells without detergent. Consistent 
differences could not be detected in these experiments (Fig 3.26A, experiment 1-3). 
MHC II was not detected in the fractions 1 and 2 whereas fraction 3 and 4 showed 
strong MHC II presence throughout the experiments. The low staining of these lanes 
in CD63low-a lysates in experiment 3 can be rather attributed to poor antibody 
binding to this particular membrane than a true difference in protein 
compartmentalisation. For the fractions 5 to 8, contradictive results were obtained. 
Whereas an almost even distribution in experiment 1 and 2 was observed, experiment 
3 revealed a weaker staining of MHC II in these fractions. Also the result for fractions 
9 to 12 were not consistent as we saw a comprehensive presence of MHC II in these 
fractions for experiment 1, whereas MHC II seems to be less abundant in the same 
fractions when conducted experiment 2 and 3. Lane 13 exhibited a strong signal for 
MHC II throughout all 4 experiments. Staining for MHC class I and CD82 did not 
show any alteration in distribution in any of the four experiments. Shown are 
representative results from experiment 1 for the control and the CD63low-a LCL. 
MHC I was not or only scarcely present in lane 1 and 2 but abundantly found in 
fractions 3 to 8. Fraction 9 to 12 exhibited a lower amount of MHC I with an increase 
seen in fraction 13. CD82 was not present in the fractions 1 and 2 but abundantly 
found in the fractions 2 to 9 showing peaks in fraction 4 and 8. A weaker signal was 
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observed for CD82 in the fractions 10 to 13. Following fractionation experiments 
under lysis conditions using detergents focussed investigating the protein distribution 
of MHC II. The distribution of MHC II when the LCLs were lysed with Triton X-100 
(here: CD63low-a, control LCL, experiment 4) was almost indistinguishable (Fig. 
3.27B). An even distribution was seen for the CD63low LCL throughout the fractions 
8 to 12 and a lower signal in fraction 13. In control LCL this pattern was repeated 
with the exception of a light shift towards fractions of lower density. A faint signal 
was seen in fraction 7 whereas hardly any MHC II was detectable in fraction 13. 
Lysing cells in Brij98 prior to performing the sucrose centrifugation gave a similar 
result (Fig. 3.26C, experiment 5). Here, the most noticeable difference could be seen 
between the two CD63 knockdowns whereas the MHC II molecules of the control 
LCL were distributed in a pattern similar to those of the CD63low-a LCL (Fig. 
3.26C). No protein was detected in fraction 1, in fraction 2 MHC II was present in 
CD63low-a and control LCL but not in CD63low-b lysates. Heavy fractions combine 
fraction 2 and 3 in all three cell lines. Light fractions follow from fraction 5 to 
fraction 7 and medium fractions are remaining from fraction 8 to fraction 13. 
Additionally, the distribution of CD19 was analysed for all three LCLs. No apparent 
change under each of those three lysing conditions could be detected (data not 
shown). 
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Figure 3.26: Distribution of selected membrane proteins  
A) Three fractionation experiments were conducted after the control or CD63low LCLs were 
homogenised without detergent. The compartmentalisation of relevant proteins was then 
analysed by Western blotting. While MHC II was identified in different fractions in one 
experiment when control and CD63low LCLs were analysed, this was not observed in four 
other repeat experiments. Analysing the same cell lysates for compartmentalisation of MHC I 
and CD82 did not show any difference between CD63low and control LCL either (shown is 
one representative blot). B) MHC II does also appear in the same fractions when lysing 
CD63low-a and control LCL in Triton X-100 (1%).  C) A difference in MHC II distribution 
between CD63low-a and -b can be seen in the one experiment in which cells were lysed using 
Brij 98. However, comparing the pattern for the control LCL to the pattern of both CD63low 
LCLs does not suggest a CD63 knockdown-driven alteration in MHC II 
compartmentalisation. 
 
3.4.5 Analysis of protein compartmentalisation by chemical cross-linking 
 
In addition to rate zonal density gradient centrifugation, protein compartmentalisation 
can be analysed by protein cross linking using DSP (Dithiobis (succinimidyl 
propionate). Chemical crosslinking is used to determine proximal partners of a given 
molecule/protein. DSP is a homobifunctional, thiol-cleavable and membrane-
permeable protein crosslinker. It contains an amine-reactive N-hydroxysuccinimide 
(NHS) ester which reacts with lysine residues in protein side chains and the N-
terminus of each polypeptide. DSP cross-linked proteins can be cleaved in the 
presence of reducing agents. LCLs were treated with DSP prior to lysis in TritonX-
100 (1%). No difference in the patterns of crosslinked complexes was observed when 
Brij 98, MHC II 
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CD63low and control cells were treated with DSP (Fig: 3.27) Since staining for MHC 
II after cross linking resulted in equal bands for both LCLs, the interaction of MHC II 
with proximal partners seems not to be affected by the knockdown of CD63. 
However, it was noted that there was a slight difference in the mobility of MHC II 
molecules when non-crosslinked lysates separated by SDS-PAGE on a non-reducing 
gel. Such a difference in size could reflect a difference in post-translational 
modification, for example the degree of glycosylation. However, this size difference 
was not detected in repeated experiments suggesting it represents a subtle transient 
difference between the two cultures rather than a mechanism responsible for 
differential T cell recognition.  
 
 
Figure 3.27: MHC II multimer pattern after protein cross-linking  
MHC class II molecules in LCLs, either untreated (lane 1 and 2) or treated with the cross-
linking agent DSP (lane 3 and 4) were analysed by SDS-PAGE on a non-reducing gel using 
the α-MHC class II antibody DA6-14. An equal pattern of MHC II for both LCLs was seen 
after protein cross-linking (lanes 3 and 4) which suggests equal protein interaction partners 
for MHC class II in both LCLs. In contrast, analysing lysates from cells not treated with DSP 
revealed a small difference in the molecular weight for MHC II from control and CD63low 
LCLs (lanes 1 and 2). This difference was not seen in 3 subsequent experiments.  
 
 
 
  
120 
3.4.6 Immunological synapse (IS) formation between LCLs and CD4+ T cells  
 
Since no biochemical difference in MHC II molecules in control and CD63low LCLs 
were observed, the next step was to explore whether there was any difference in the 
interaction between MHC II on the surface of the LCLs with the TCR on the CD4+ T 
cell clone. When these cells interact, MHC II complexes are clustered within the 
immunological synapse. An immunological synapse (or immune synapse) is the 
interface between an APC and a lymphocyte which coordinates a number of 
signalling and adhesion molecules towards the contact area. This well structured 
assembly of molecules, also called supra-molecular adhesion complex (SMAC), 
facilitates an effective T cell activation (Cemerski and Shaw 2006;Kupfer and Kupfer 
2003).  
Control and CD63low LCLs were co-incubated with antigen specific CD4+ T cell 
clones and then fixed, allowing the cell conjugates to be studied by 
immunofluorescence microscopy. LCLs were additionally stained with the 
cytoplasmic, membrane permeant green fluourescent dye BCEFC (2′,7′-bis-(2-
carboxyethyl)-5-(and-6)-carboxyfluorescein) allowing LCLs to be differentiated from 
T cells when analysing conjugates. Staining was performed using monoclonal 
antibodies specific for MHC class II, the adhesion protein ICAM-1, which has been 
shown to be localised in the synapse (Almeida and Davis 2006;Batista and Saito 
2010;Goldstein et al. 2000;Jo et al. 2010) or the EBV membrane protein LMP-1, 
which has also been suggested to be recruited to the synapse (Dr. M. Pegtel, personal 
communication). A number of different permeabilisation protocols were tried 
including TritonX-100 (Fig. 3.28), Brij98 and CHAPS (data not shown). The 
experiments were also performed without permeabilisation. For each condition 10 to 
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12 images were taken and analysed by confocal microscopy. Images were taken from 
cell conjugates which demonstrate a clear intercellular interaction and a pronounced 
straining of the relevant protein. This enabled us to compare the exact distribution of 
the stained proteins between control or CD63low LCLs conjugated with T cells. MHC 
II was present on the outer membrane and internal vesicles which is seen by a mainly 
cortical staining. A clear localisation towards the intercellular contact area can be 
observed. ICAM1 appears to exhibit a more dispersed and even distribution with 
presence on the surface as well as in the cytoplasm. The localisation of LMP-1 
however resembles MHC II’s with a cortical distribution and presence on inner 
vesicles. However, a marked difference in synapse formation or protein distribution of 
these three proteins could not be detected between control and CD63low LCLs.  
  
122 
 
 
Figure 3.28: Analysis of the LCL-T cell IS after permeabilisation with Triton X-100 
Triton X-100 treated control or CD63low-a LCLs were labelled with BCEFC (2_,7_-Bis(2-
carboxyethyl)-5-carboxyfluorescein; green). As this weak green staining is difficult to see in 
the printed images these cells are identified with an arrow. LCLs were conjugated with 
antigen specific CD4+ T cell clones (arrowhead) and immunostained for ICAM-1, LMP-1 or 
MHC class II (all red stained). Cellular DNA was stained with Hoechst 33258 (blue). No 
apparent difference in protein recruitment to the IS could be seen in CD63low cells for any of 
the analysed proteins. This also applies to staining using no detergent or using Brij 98 or 
CHAPS to permeabilise cells (data not shown).  
 
3.4.7 Microfilaments and microtubules in LCL-CD4+ T cell conjugates 
 
While membrane proteins such as MHC II or ICAM-1 play a crucial role in the direct 
intercellular contact between APC and T cell, cytoskeletal proteins are also involved 
in the formation and maintenance of immunological synapses (Billadeau and 
Burkhardt 2006;Gomez et al. 2005;Rodriguez-Fernandez et al. 2010). Here, we 
investigated the distribution and organisation of the cytoskeletal proteins tubulin and 
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actin. CD63low-a and control LCLs were co-incubated with the CD4+ T cell clone 
c38 for 30min at 37ºC to allow the cells to form conjugates. The conjugates were 
resuspended in PBS and cytospun onto slides prior to fixation with paraformaldehyde. 
After permeabilisation, cells were stained with an anti-tubulin antibody (see 3.4.6) or 
with phalloidin which binds actin filaments. For both LCLs a pronounced localisation 
of tubulin in the microtubule organisation centre (MTOC) facing towards the contact 
area between the LCL and the T cell and even at the immune synapse itself could be 
observed. The overall tubulin organisation in CD63low and control LCLs appeared 
indistinguishable (Fig. 3.29A). Actin also shows polarisation towards the immune 
synapse for both the CD63low-T cell and the control LCL-T cell conjugates. Likewise 
tubulin, polarisation of actin fibres shows no difference in the CD63low LCL 
conjugated to the T cell clone compared to the control LCL (Fig 3.29B). Using 
confocal microscopy imaging to produce optical slices through the cell cytoplasm 
allowed more readily the analysis of actin polarisation and confirmed previous data 
(data not shown). In total three separate staining experiments were conducted and 10-
12 images taken from each experiment. 
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Figure 3.29: Analysis of cytoskeletal protein in the CD63low LCL conjugated to the 
CD4+ T cell clone c39 
Images of three representative cells from the CD63low and the control LCLs are shown. For 
each cell an image was taken in the blue (top left, shown in B), green (top right, shown in B) 
and red (bottom-left) channel as well as in transmitted light (not shown). A merged image is 
shown on the bottom right of each panel. Staining was conducted as for Fig. 3.27. A) 
CD63low-a and control LCL (arrow bar) were co-incubated with the CD4+ T cell clone c38 
(arrowhead) to allow the formation of cell conjugates. Subsequent staining of these 
conjugates using antibodies binding tubulin did not show any difference in the distribution of 
tubulin in either the CD63low or the control LCL whilst conjugated to a T cell. B) Similarly, 
actin distribution seems to be somewhat located towards the IS but does not show pronounced 
differences between control and CD63low LCL.  
 
3.4.8 Effect of CD63 depletion on co-stimulation activity of LCLs 
 
Another possibility is that the enhanced CD4+ T cell activation observed for 
CD63low cells is due to a difference in co-stimulation of the T cell by the LCL; that 
is, operating independently of the synapse. To test this, another CD4+ T cell clone 
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(c4) was used which is specific for an EBV EBNA1 epitope restricted through HLA-
DR1. As the control and CD63low LCL, derived from the same parental line, lack 
HLA-DR1, they cannot activate these T cells through MHC II-TCR interaction. Any 
differences observed using the LCLs would therefore be due only to differences in co-
stimulatory activity. In the same experiment it is still necessary to activate the clone’s 
TCR in MHC II independent way to allow co-stimulation to be studied. In order to 
activate the T cell clone’s TCR, different concentrations of α-CD3 antibody were 
added to the T cells in the presence or absence of what are now HLA-mismatched 
LCLs (either control or CD63low). In the absence of α-CD3, no T cell activity was 
observed as expected (Fig. 3.30). In the presence of α-CD3, the T cell clone was 
activated, producing IFNγ. However, no differences were observed in levels of IFNγ 
in the absence or presence of the LCLs. Even though different amounts of α-CD3 
antibody were tested, it has to be taken into consideration that T cell clones require 
little in the way of co-stimulation to be activated and subtle differences in co-
stimulation may not be detected in this experiment. A difference in co-stimulation 
between the control and CD63low cells can therefore not be fully excluded by this 
experiment. 
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Figure 3.30: Co-stimulation assay using CD4+ T cell clones 
LCL co-stimulatory activity was assessed by coating Maxisorp 96-well plates (Nunc) with α-
CD3 antibody to activate T cells and adding CD63low-a and control LCLs that are HLA-
mismatched to the particular T cell clone used for this experiment. The antibody 
concentrations used for coating were 0, 0.5, 1 or 2µg/ml. No difference in co-stimulatory 
activity was detected between CD63low and control LCLs. The graph shows a representative 
experiment out of two, the error bars indicate the mean +/- standard deviation of ELISA 
triplicate wells.   
 
3.4.9 Knock down of tetraspanins in HeLa CIITA cells 
 
CD63 has been suggested to interact with the EBV LMP-1 protein, localising LMP-1 
to the immunological synapse (Dr. M. Pegtel, personal communication). LMP-1 has 
been reported to have an immunosuppressive effect (Middeldorp and Pegtel 2008b). 
A model to explain the enhanced T cell recognition exhibited by CD63low cells could 
be that depletion of CD63 causes less LMP-1 to be present at the synapse, which in 
turn results in less LMP-1-mediated suppression of the T cells. While I had observed 
no difference in LMP-1 distribution following CD63 depletion in LCLs (Fig. 3.29) it 
was important to test this hypothesis by asking if CD63 depletion could enhance the 
CD4+ T cell recognition of a cell lacking LMP-1. 
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HeLa cells express MHC class II when transfected with the vector pXPG which 
express the MHC II transactivator CIITA. This cell line is commonly used for 
studying MHC II, for example MHC II trafficking, in a background of non-
professional APCs (Walseng et al. 2008). Since HeLa cells are HLA-DQ5 positive 
they could be used, along with the CD4+ T cell clone c38 (DQ5-restricted) already 
used on the LCLs, to investigate the influence of tetraspanins on antigen presentation 
in the background of a cell lacking EBV.  
HeLa CIITA cells were transduced with lentivirus encoding the two shRNA 
constructs used to target CD63 in LCLs (section 3.1.4.2, 3.1.4.4). As expected a large 
reduction in the expression level of CD63 was achieved with both shRNAs. Cells 
transduced with CD63low-a shRNA maintained low levels of CD63 (Fig. 3.31A, B). 
Cells transduced with the CD63low-b shRNA, however, did not maintain knockdown 
and were not used in subsequent experiments. HeLa CIITA cells transduced with a 
lentivirus not containing any shRNA construct served as a negative control cell line. 
The expression of other members of the tetraspanin family was tested by flow 
cytometry for these knocked down cells. The depletion of CD63 did not cause any 
difference in the level of other tetraspanins (data not shown). This experiment was 
particularly important as the expression of MHC II was not altered by the CD63 
shRNA lentivirus. 
In addition to CD63, we also targeted CD81 and CD151 with shRNAs cloned into 
lentiviruses. We used the same CD81 lentivirus that had previously been shown to 
function in HeLa cells (Fig. 3.4) but that had failed to knock down their respective 
gene targets in LCLs (Fig. 3.5). The CD151 shRNA lentivirus was kindly provided by 
Dr. F. Berditchevski and has been shown to work in other cell lines (Baldwin et al. 
2008). While CD81 and CD151 levels were reduced, in contrast to the CD63 shRNA 
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lentivirus, we observed a somewhat altered expression of MHC II for these two 
constructs. MHC II levels were increased slightly in the cell line transduced with the 
CD81 shRNA lentivirus. In cells transduced with the CD151 lentivirus two 
populations of cells, one with low the other one with higher MHC II, were observed 
(Fig. 3.31C). It is possible; therefore, that CD81 and CD151 affect MHC II, a possible 
avenue of research for future work. 
 
A                                                                                            B 
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Figure 3.31: Knock down of CD63, CD81, CD151 in HeLa CIITA 
A) Expression of tetraspanins CD63 was reduced in HeLa CIITA cells transduced by 
lentiviruses targeting the respective protein. MHC II levels were unaltered in the CD63low 
shRNA transduced cells. B) The knock down of CD63 and unchanged expression of MHC II 
expression upon CD63 depletion was confirmed by Western blotting. Actin serves as a 
loading control. C) Expression of tetraspanins CD81 or CD151 were also reduced using 
respective shRNA constructs cloned into lentivirus. MHC II was altered in these two lines. 
 
3.4.10 CD4+ T cell activation by HeLa CIITA cells 
 
Following generation of the CD63-, CD81- and CD151-low HeLa CIITA lines (Fig. 
3.31), these cells together with the control HeLa CIITA cell line were tested in T cell 
assays using CD4+ T cell clone c38. 
As expected, due to their lack of EBV antigen expression, HLA-DQ5 expressing 
HeLa CIITA cells by themselves were not recognised by CD4+ T cell clone c38 
However, tetraspanin knockdown cells and the control line did stimulate the clone 
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when exogenously loaded with the antigenic EBV peptide “SDD” (Fig. 3.32A). The 
key result is shown in Fig 3.32B. Importantly, in accordance with the results seen for 
LCLs, the CD63low HeLa cell line was much more efficient at stimulating the CD4+ 
T cell clone than the control cell line. Note that the two lines were pulsed in parallel 
with equal quantities of epitope peptide before their use as targets in the assay and the 
same result was seen in six independent experiments. This important result, showing 
that enhanced CD4+ T cell recognition occurs in the complete absence of LMP-1, 
strongly suggests an LMP-1 independent mechanism to be responsible for the 
phenotype observed in LCLs. Furthermore, HeLa cells, unlike LCLs, do not express 
the co-stimulatory molecule CD86 nor the adhesion molecule ICAM-1 (data not 
shown) suggesting these molecules are also not involved in the enhanced stimulation 
of CD4+ T cells. Interestingly, both CD81 and CD151 knockdowns also increased 
CD4+ T cell stimulation (Fig. 3.32C), albeit not to the same degree as the CD63 
knockdown. Since MHC II levels were altered in both the CD81 and CD151 
knockdown lines, some caution must be exercised in interpreting these data. After a 
few weeks of cell-culture upon virally infecting HeLa CIITA cells, we noticed the 
divergence into two populations in terms of MHC II expression. For the CD81 
knockdown we see the majority of the transfected cells expressing a somewhat higher 
level of MHC II compared to the control-HeLa cell line, whereas a small population 
exhibits a substantially reduced expression level. In the case of shRNA-CD151 
transfection, we obtained two populations of similar size showing comparable MHC 
II expression levels as seen for CD81 low HeLa cells. However, these results indicate 
that tetraspanins other than CD63 could also affect CD4+ T cell activation. 
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Figure 3.32: CD4+ T cell activation by HeLa CIITA cells 
A) HeLa CIITA cells were analysed via IFNγ ELISA for their ability to stimulate the CD4+ T 
cell clone c38. When exogenously loaded with antigenic peptide (1x10
-7
M), HeLa CIITA cell 
were recognised by the T cell clone whereas no T cell stimulation was observed for unloaded 
HeLa cells. B)  The control and CD63-deficient HeLa CIITA-cells were peptide pulsed (1x10
-
7 
M) and washed before use as targets in the assay as described in A. A much higher level of T 
cell stimulation was observed with the CD63 knockdown HeLa cell line compared to the 
control. C) Depleting CD81 and CD151 also increased the level of T cell stimulation by HeLa 
CIITA cells. The shown data are from one representative experiment out of six. The error bars 
show the mean +/- standard deviation of triplicate ELISA wells. 
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3.4.11 Reconsideration of the effect of exosomes and their impact on CD4+ T cell 
stimulation 
 
The above result clearly shows that CD63 depletion yields a robust increase in the 
ability of MHC II-positive cells to activate CD4+ T cells. Given that exosomes bear a 
very similar collection of membrane molecules, it was surprising that in earlier 
experiments there was no difference in CD4+ T cell activation when T cells were 
exposed to exosomes purified from control and CD63low LCLs. This lack of 
differential T cell activation exhibited by exosomes formed the basis of a final series 
of experiments seeking to discover the mechanism responsible for the observations 
made thus far.  
 
3.4.11.1 Quantification of exosome secretion by control and CD63low LCLs 
 
In all previous experiments with exosomes same quantities of exosomes (as 
determined by Bradford assay) were added to the T cells. For some of the experiments 
exosomes were prepared from the cells which were seeded exactly at the same 
density, and cells were recounted at the end of the 48 hours culture. The control and 
both CD63-low LCLs grew equivalently and similar cell numbers were recorded at 
the end of the culture period. Exosomes were purified in parallel from the three 
supernatants, resuspended in the same volume of PBS and quantitated by Bradford 
assay. The total amount of exosomes purified from a single experiment is shown in 
Fig. 3.33A. A larger amount of exosomes were prepared from the CD63-deficient 
LCLs. In total this experiment was repeated six times and the combined results, 
standardised per million cells (Fig. 3.33B), clearly shows that both the CD63low 
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LCLs secreted 50-70% more exosomes than the control. To confirm that the Bradford 
assay accurately reflected levels of exosomes, Western blotting was conducted 
running 10% of the exosome preparations made from the CD63low-a and control cell 
lines onto a reducing gel (Fig. 3.33C). Levels of both actin, which is present in the 
lumen of exosomes and MHC II, present on the surface of exosomes, were higher 
confirming the Bradford assay results. Western blotting was not performed on 
exosomes from CD63low-b cells. 
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Figure 3.33: Quantification of exosome release by LCLs 
A) Exosomes production was quantified by determining the protein concentration of the final 
exosome product. Both CD63low LCLs yielded more exosomes. The error bars represent the 
mean +/- standard deviation of the triplicate Bradford assay wells. B) The average amount of 
exosome secretion was determined by standardising the amount of exosomal protein produced 
by 1 x 10
6
 cells (counted after the 48 hours culture) for three independent experiments. 
Approximately 50-80% more exosomes were secreted by CD63low LCLs compared to the 
control LCL. The error bars show the mean +/- standard deviation of the amount of exosomes 
per million cells counted at the end of the 48 hour culture period. p<0.01; ns=not 
significant, analysed by unpaired Student’s t test. C) The increased exosome secretion by 
CD63low-a LCL was confirmed by Western blotting. For each lane the same proportion 
(~10%) of the exosomal sample were loaded onto the gel.  
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As exosomes are MHC II positive and themselves able to activate CD4+ T cells (see 
section 3.2.2.2), the observation that CD63low LCLs secrete larger quantities of 
exosomes suggested a number of possible mechanisms that could account for these 
cells’ enhanced ability to activate CD4+ T cells. These mechanisms are explored 
below.  
 
3.4.11.2 Exosome uptake by LCLs and CD4+ T cells 
 
One hypothesis suggested by the previous observation is that the increased amount of 
exosomes, released by CD63low LCLs, indicates an increased level of exosome 
processing and trafficking accompanied by an increased re-uptake of autologous 
exosomes. In order to study the cellular uptake of exosomes, LCLs were stained with 
DIL (1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate) prior to 
incubating the cells for 48 hours and purifying exosomes from their supernatant. DIL 
is a hydrophobic and lipophilic membrane integrating dye which stains the outer cell 
membrane as well as the membrane of subsequently generated endosomes, MVBs and 
exosomes. Unstained LCLs, were incubated for 15min with a mix of DIL-labelled 
exosomes, derived from the CD63low-a and control LCL, and analysed by confocal 
microscopy (Fig. 3.34A). No apparent difference in exosome binding or uptake was 
seen comparing both LCLs. However, in this experiment LCLs were co-incubated not 
with a pure autologous exosome preparation but a mixed population of exosomes 
derived from both control and CD63low LCL. The binding properties of CD63low 
exosomes onto CD63low LCLs would need to be investigated in future work. 
Furthermore, to assure comparability of the results obtained for both cell lines, the 
amount of exosomes given to LCLs was quantified and equalised prior to co-
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incubation. Note that this does not reflect the conditions seen under unmanipulated 
assays where CD63low LCLs were proven to release a higher quantity of exosomes 
into the medium than control LCLs. 
In the same experimental set-up CD4+ T cells were tested for their ability to bind 
these DIL-labelled exosomes. Two CD4+ T cell clones, one HLA-DQ5-restricted 
(c38) and the other not recognising any of the HLA-molecules present on these 
exosomes (c4, DR1-restricted) were co-incubated for 15min with exosomes either 
derived from CD63low or from control LCLs. Since optical slices were not taken 
from these samples a strict distinction between surface-bound and internalised 
exosomes cannot be made. But both CD4+ T cell clones appear to interact with 
exosomes derived from CD63low or from control LCLs equivalently (Fig. 3.34B). 
Moreover, the CD4+ T cell clone c38 whose TCR is capable of recognising HLA-
DQ5 molecules loaded with cognate peptide that are present on these exosomes did 
not appear to interact more strongly with exosomes than the other T cell clone which 
the exosomes are mismatched to. This result agrees with the observation that 
recruitment of exosomes by T cells is dependent on the interaction of LFA-1 and 
ICAM-1 rather than MHC and the TCR (Nolte-'t Hoen et al. 2009a;Segura et al. 
2007).  
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Figure 3.34: Interaction of exosomes with LCLs and CD4+ T cell clones 
A) CD63low-a and control LCLs were co-incubated with a mixture of DIL-labelled exosomes 
(red fluorescent) purified from both CD63low-a and control LCL supernatants. Both LCLs 
appear to interact equivalently with these exosomes. The cellular DNA was stained using 
Hoechst 33342. B) CD4+ T cell clones were separately co-incubated with exosomes derived 
either from CD63low-a or control LCL. Exosomes derived from any of these LCLs interacted 
equivalently with the HLA-matched and the HLA-mismatched T cell clones.  
 
3.4.11.3 Analysis of rebinding properties of exosomes to their mother cell 
 
To address the possibility that increased exosome secretion could subsequently lead to 
a higher amount of autologous exosomes bound to the LCL’s surface, flow cytometry 
experiments were undertaken using a slightly modified procedure. By avoiding cell 
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washing we allowed any weakly bound exosomes to remain bound to the LCL 
surface. Cells were fixed with PFA to immobilise exosomes onto the cell surface prior 
to staining with a specific antibody. Knowing that control and CD63low LCLs show 
an equal surface level of MHC II under conditions where surface bound exosomes are 
likely to be washed off the cell (Fig. 3.6), this modified procedure would reveal 
whether CD63low LCLs are binding back their own exosomes to a higher extent (Fig. 
3.35A) since they were shown to secrete more exosomes compared to the control LCL 
(Fig. 3.33). No difference in the level of MHC II expression could be seen between 
CD63low and control LCLs (Fig. 3.35B) suggesting that the increased secretion of 
exosomes by CD63low LCLs does not lead to an increased amount of exosomes 
binding back to the LCLs. 
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Figure 3.35: Analysis of exosomes binding to the surface of CD63low LCLs  
A) The increased release of exosomes by CD63low LCLs could lead to a higher amount of 
autologous exosomes bound back to their mother cell’s surface. B) Control and CD63low 
LCLs were gently washed only once and instantly fixed with PFA to ensure that any 
exosomes stuck to the LCL’s surface remain bound. To measure any difference in cell surface 
exosomes, flow cytometry detecting total MHC II was performed. The expression of either 
HLA-DR or HLA-DQ was indistinguishable between both cell lines suggesting that there is 
no difference in the capacity of control and CD63low LCLs to bind their autologous 
exosomes, despite the larger production of exosomes seen for the latter.  
 
3.4.11.4 Influence of increased exosome secretion upon CD4+ T cell activation 
 
Once released into the extracellular medium, LCL-derived exosomes are capable of 
stimulating T cells (see 3.2.2.1). Moreover, CD63low exosomes have been shown to 
exert a similar CD4+ T cells stimulation as control exosomes (see 3.2.3.2). Therefore, 
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an increased amount of exosomes released from CD63low LCLs could be directly 
responsible for the increased T cell activation exhibited by these cells. To test this 
hypothesis, T cell assays were performed as described in section 3.3.1 by co-
incubating both control and the CD63low-a LCL with the CD4+ T cell clones c38 and 
c93, respectively. This time however, previously purified exosomes derived from 
either the control or the CD63low-a LCL were added to the cell co-cultures. The 
rationale of this experiment was that if the enhanced recognition of CD63low LCLs 
was due to their increased release and binding of exosomes, an excess of exosomes 
would saturate the system causing the degree of CD4+ T cell stimulation by the 
control and CD63low cells to become equivalent.  
The previously shown effect of increased antigen-specific T cell stimulation by the 
CD63low-a LCL compared to control LCL was first verified (Fig. 3.36A). Adding 
exosomes to LCLs before co-incubation with T cells did not equalise the CD63-
related enhancement of stimulation. CD63low-a LCL, peptide loaded as well as the 
control, was still far better recognised by the CD4+ T cell clone c93 than the control 
LCL (Fig. 3.36B). Perhaps, the experimental design did not allow reaching saturation. 
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Figure 3.36: CD4+ T cell stimulation after incubation with LCL and exosomes 
A) A T cell assay with CD63low-a LCL and control LCL does confirm an increased antigen 
specific CD4+ T cell stimulation by CD63low-a LCL compared to the control LCL. B) 
CD63low-a and control LCL were mixed with their own, previously purified, exosomes prior 
to being added to the CD4+ T cell clone c93. The addition of high amounts of exosomes did 
not change the previously observed intensity pattern for T cell activation. CD63low-a LCL 
was still recognised much better than the control LCL.  
 
Summary 
 
We showed that knocking down the expression of CD63 in a LCL increases antigen 
specific recognition by CD4+ but not CD8+ T cell clones. Exosomes derived from 
CD63low LCL also exhibit a pronounced reduction in CD63 but do not show the 
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enhancement of T cell stimulation as CD63low cells do. In search for the 
mechanisms, underlying the CD63-related stimulation enhancing phenomenon, we 
investigated the process of antigen presentation from different angles. The data show 
that 1) CD63 does not interfere with HLA-loading and peptide binding efficiency; 2) 
it does not influence the compartmentalisation and surface distribution; 3) CD63 does 
not have an apparent effect on the process of glycosylation of MHC II. Furthermore, 
CD63 depletion does not seem to impair the formation of the immunological synapse 
or the localisation of proteins involved in APC-T cell interaction, including MHC II 
and ICAM-1. I did also show that co-stimulation appears not to be involved. The only 
difference which could be determined was a clear increase of exosome secretion by 
CD63low LCL compared to the control LCL. However, CD63low and control LCLs 
did not exhibit any difference in the amount of exosomes stuck to their surface. 
Neither did the addition of exosomes to their parental LCL in T cell assays cause a 
levelling of the elevated CD4+ T cell stimulation by the CD63low-a LCL. When 
interpreting the latter experiment, suggesting that the higher number of exosomes 
secreted by CD63low LCLs is not responsible for this elevation, it has to be taken into 
account that this assay was only conducted once and would have to be repeated to 
allow solid conclusions.  
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4 Discussion 
 
In order to study the role of the tetraspanin protein CD63 in the presentation of 
antigen to CD4+ T cells we firstly had to establish a model system. As APCs we used 
LCLs, B cells immortalised by EBV infection, which express EBV latent-cycle 
antigens. CD4+ T cell clones restricted through appropriate HLA molecules and 
specific for epitopes within those EBV-encoded antigens were used to detect changes 
in antigen presentation by the LCL. Antigen presentation by LCL-derived exosomes 
was also investigated. 
 
4.1 Purification of LCL-derived exosomes 
 
Depending on the purpose, different methods can be used for isolating exosomes. To 
purify exosomes suitable for clinical applications, techniques of filtering cell 
supernatant through a series of filters with gradually decreasing hollow size combined 
with separate ultracentrifugation steps are sometimes preferred (Lamparski et al. 
2002). For analysing exosomes by flow cytometry however, vesicles need to be 
isolated by affinity extraction, for example using antibody coated magnetic beads 
(Clayton et al. 2001). For the purposes of this study we decided to use differential 
centrifugation (Raposo et al. 1996;Wubbolts et al. 2003b) that in certain cases, for 
instance for each preparation of exosomes analysed by electron microscopy, was 
supplemented by an additional centrifugation step using a sucrose cushion (Skriner et 
al. 2006).  
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Purity of exosome preparations is commonly determined by looking for the presence 
of calnexin, a marker of the ER that should be absent from purified exosomes (Asea et 
al. 2008;Ramachandra et al. 2010;Saunderson et al. 2008). We found that even after 
months of optimising the purification procedure the amount of calnexin in the 
exosome pellet, as measured by Western blotting, could only be decreased and was 
never completely abolished even using the additional sucrose cushion purification 
step. Personal communication with Dr Aled Clayton (University of Cardiff, UK) 
revealed that this phenomenon had previously seen by him and co-workers when 
purifying exosomes from LCLs. One possibility is that calnexin is not limited solely 
to the ER in some cell types. In support of this idea are observations showing direct 
membrane contacts between the perimeter membrane of MVBs and the ER occur to 
promote particular signalling processes (Eden et al. 2010). Indeed, in the case of 
Pompe disease, a disease which causes a dysfunction in the formation of organelles 
including lysosomes or melanosomes, ER proteins including calnexin were even 
found in lysosomes and late endosomes (Zhang et al. 2007). Eventually, we had to 
accept the fact that exosomes purified from LCLs inevitably contain a certain amount 
of ER-derived cell material. In this context it is conceivable that intracellular 
trafficking and sorting of proteins is altered in LCLs and a certain amount of ER 
proteins is translocated to endosomal compartments and eventually also to exosomes.  
 
4.2 Recruitment of LCL-derived exosomes by CD4+ T cell clones 
 
After establishing a suitable exosome purification protocol, we went on to investigate 
the ability of purified exosomes to interact directly with T cells. It is known that DC-
derived exosomes can be recruited and bind to T cells, transfer molecules to T cells 
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and induce T cell activation (Andre et al. 2004a;Giri and Schorey 2008;Hao et al. 
2006a;Luketic et al. 2007;Quah and O'Neill 2005;Raposo et al. 1996). In this context, 
it has been demonstrated that initial ICAM-1/LFA-1 driven exosome recruitment to T 
cells is crucial for the actual MHC-TCR interaction, the transfer of exosomal 
molecules and the subsequent T cell activation (Nolte-'t Hoen et al. 2009b;Segura et 
al. 2005). Furthermore, tetraspanins such as CD9, CD151 and Tspan8 as well as 
integrins on tumour-cell derived exosomes have all been proposed to be involved in 
exosome binding and uptake (Nazarenko et al. 2010b;Rana et al. 2011). In our study, 
exosomes purified from the LCL PER241 express ICAM-1 as well as several 
tetraspanins and are recruited to the CD4+ T cell clone c38. This was shown by co-
incubating green-fluorescent LCL-derived exosomes with T cells prior to analysing 
the binding by flow cytometry. 
 
Following their initial interaction exosomes can bind and be taken up by cells. Since 
exosomes express phophatidylserine (PS), it is suggested that they could be captured 
by phagocytes via direct or indirect recognition of PS (Al-Nedawi et al. 2009). More 
importantly for our study other PS-ligands like Tim1 and Tim4 are also expressed on 
activated lymphocytes and are shown to mediate exosome capture (Miyanishi et al. 
2007). Whether the subsequent internalisation occurs via membrane fusion or 
endocytosis has been debated over the last decade (Morelli et al. 2004;Parolini et al. 
2009). In support of endocytosis are two recent studies using live cell microscopy 
(Tian et al. 2010). Internalisation of exosomes was also demonstrated by visualising 
exosomes in phagosome-like compartments using electron microscopy (Feng et al. 
2010). Membrane fusion and endocytosis is an energy dependent mechanism which is 
inhibited by low temperatures (Huth et al. 2006) whereas binding is energy 
  
147 
independent. We observed that co-incubation of exosomes and T cells at 37ºC 
resulted in a noticeably higher increase in T cell fluorescence than a 4ºC co-
incubation. This suggests that the interaction between T cells at 4ºC is limited to 
surface binding whereas the co-incubation at 37ºC supposedly enables T cells to also 
take up exosomes and reprocess exosomal molecules leading to a higher intensity in 
fluorescence of the T cells. Labelling exosomes with a dye incorporating into the 
membrane and co-incubating these exosomes with T cells as well as with LCLs prior 
to analysis by confocal microscopy clearly showed an interaction between cells and 
exosomes in our experiments. Furthermore, our confocal images (i.e. localisation of 
exosomal membrane and proteins in intracellular vesicles) point to internalisation of 
added exosomes by T cell clones. This is consistent with a previous observation that 
exosomes were transported to endosomes and lysosomes after cellular uptake 
(Parolini et al. 2009).   
 
4.3 Recognition of LCL-derived exosomes by CD4+ T cell clones 
 
Stimulation of T cells requires the presentation of antigenic peptides loaded onto 
MHC I or MHC II molecules by APCs. Exosomes derived from APCs also express 
antigenic peptide-MHC complexes, which makes them potential mediators of immune 
responses. In the case of CD8+ T cells, exosomes derived from virtually any cell type 
bear MHC I molecules. However, since naive T cells require two signals for their 
initial activation, namely MHC-peptide complexes in addition to co-stimulation, 
tumour cell derived exosomes can only activate CD8+ T cells when HLA-matched 
DCs are present as mediator cells to supply the second signal (Andre et al. 
2002;Wolfers et al. 2001). Exosomes from APCs such as DCs on the other hand, have 
  
148 
been shown to be capable of inducing CD8+ T cell’s response either directly (Admyre 
et al. 2006;Luketic et al. 2007;Utsugi-Kobukai et al. 2003) or in the presence of 
allogeneic DCs demonstrating exosomes contain functional MHC I-peptide 
complexes (Chaput et al. 2004;Hsu et al. 2003). Importantly the T cell activation was 
more efficient using exosomes from mature DCs underlining the importance of co-
stimulatory proteins in exosomal T cell activation (Admyre et al. 2006). In terms of 
MHC II, APC-derived exosomes bear functional MHC II molecules as they can be 
recognised by CD4+ T cells as allogenic antigens (Peche et al. 2003) and when 
antigen loaded directly stimulate cognate CD4+ T cell clones (Raposo et al. 1996), T 
cell lines (Admyre et al. 2007) or activated CD4+ T cells (Muntasell et al. 2007). 
Only the activation of naïve CD4+ T cells requires the uptake of exosomes by 
recipient DCs (Muntasell et al. 2007;Segura et al. 2005;Thery et al. 2002a). In 
accordance with this, exosomes secreted by LCL PER241 were capable of stimulating 
CD4+ T cell clones in an antigen-specific manner. As is the case with LCLs as target 
cells this exosome-mediated stimulation was due to the recognition of MHC II-
peptide complexes by T cell receptors. We examined whether exosomes were able to 
properly present MHC II-peptide complexes to the TCRs or whether the T cell 
stimulation was due to the transfer of antigenic peptides or even whole antigens via 
exosomes to T cells that then processed and presented the epitope peptides to 
neighbouring T cells in the culture. Two lines of evidence suggested that it was the 
former scenario responsible for T cell activation. First, the rather short time of co-
incubating T cells with exosomes (~18 hours) makes it unlikely that T cells can 
execute the whole process of exosome take-up and protein reprocessing. Second, and 
more importantly, by Western blotting we found that LCL derived exosomes 
contained EBNA2 but not EBNA3C protein. The presence of EBNA2, a nuclear 
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protein, in exosomes was surprising, nevertheless the fact that the EBNA3C-specific 
CD4 T cell clone was activated by exosomes in which EBNA3C protein could not be 
detected strongly suggests that T-cells were being directly stimulated by exosomes via 
pre-existing MHC-epitope peptide complexes.  
 
4.4 Characterisation of LCL-exosomes upon CD63 knockdown 
 
Tetraspanins are known to co-localise with MHC II molecules in MIICs and on 
exosomes of human B lymphocytes as shown by electron microscopy (Escola et al. 
1998) and flow cytometry (Rialland et al. 2006). Immunogold labelling using 
antibodies against MHC II and the tetraspanins CD63, CD81 and CD82 followed by 
analysis by transmission electron microscopy confirmed the presence and co-
localisation of these tetraspanins with MHC II on exosomes derived from LCLs used 
in this study. Considering that B-cell derived exosomes are capable of stimulating T 
cell responses (Admyre et al. 2007;Knight 2008;Raposo et al. 1996), the abundant 
expression of CD63 on our exosomes led us to examine the potential involvement of 
this tetraspanin in exosome-mediated T cell stimulation.  
 
We showed that knocking down CD63 in an LCL also caused a substantial reduction 
in the content of CD63 in exosomes derived from those cells. Depletion of CD63 did 
not affect the cellular expression levels of other relevant proteins including MHC II, 
MHC I, ICAM-I and CD86 in cells. This is in line with the previous observation that 
CD63 knockout mice did not exhibit any readily detectable alteration in lymphocyte 
function including lymphocyte stimulation, migration or interactions (Schroder et al. 
2009). A slightly different set of results were obtained when exosomes were analysed. 
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All marker proteins, analysed by Western blotting, including MHC I, ICAM-1, LMP-
1, CD82, CD86 and EBNA2 were unaltered in expression upon knockdown of CD63. 
However, while also total levels of MHC II, as measured by Western blotting, were 
unaffected by CD63 depletion, immunogold labelling and electron microscopy 
suggested that CD63 low exosomes had lower levels of MHC II. A possible 
explanation for the conflicting results regarding exosomal MHC II levels may be the 
differences in techniques. During immunolabelling of the exosomal surface with the 
antibodies, target epitopes of some of the MHC II molecules on the surface of the 
control exosomes could have been occluded by adjacent proteins and therefore would 
not have been available for binding of the antibody. Alternatively, epitope occlusion 
can occur where a modification on a nearby residue hinders the ability of the antibody 
to bind to its specific sites (Cheung 2004). CD81 is one example in which a 
tetraspanin has been shown to facilitate the accurate processing of its partner protein 
in the Golgi. In the absence of this tetraspanin, CD19, which is normally associated to 
CD81, migrates differently after reaching the surface. This is due to an alteration in 
the final N-glycan structure, suggesting that lack of CD81 has an effect on 
posttranslational modification of CD19 in the Golgi (Levy & Shoham 2005b). For 
CD63 such a role in posttranslational modification of its interaction partners is not yet 
shown but depletion of CD63 may somehow increase the avidity of MHC II to the 
antibody used in this study. To finally confirm this by electron microscopy 
quantification, a preparation of exosomes for TEM could be done in combination of 
Western blotting verifying an equal level of MHC II in this particular batch of LCLs. 
Unfortunately, this could not be performed in the limited time frame of this project. 
Nonetheless, we assume that the MHC II level was not altered by CD63 depletion. 
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This would be in line with the observation of an equal T cell stimulation by LCL-
derived exosomes following knockdown of CD63.  
 
4.5 Characterisation of LCL PER241 upon CD63 knockdown  
 
Several tetraspanins such as CD82 (Hammond et al. 1998), CD37 and CD53 
(Angelisova et al. 1994), CD81 (Kijimoto-Ochiai et al. 2004;Schick and Levy 1993b), 
CD9 (Unternaehrer et al. 2007;Zilber et al. 2005) as well as CD63 (Engering et al. 
2003;Engering and Pieters 2001) have been shown to be associated with MHC II 
molecules and play a role in MHC II sorting, clustering and organisation in 
lymphocytes. Kropshofer and colleagues reported that MHC II is partly incorporated 
into TERMs showing that a monoclonal antibody, CDw78 which binds a particular 
region of the MHC-II molecule, specifically recognises MHC-II associated with 
tetraspanins (Kropshofer et al. 2002b). However, in a subsequent study Poloso and 
colleagues showed that CDw78 does not define TERM-associated MHC-II, but 
instead recognises a peptide-bound MHC-II in a conformation acquired through 
trafficking to lysosomal Ag-processing compartments. Nonetheless, they confirmed 
the association of MHC II molecules with tetraspanins in DC as well as B cells 
(Poloso et al. 2006).  
 
We showed that the depletion of CD63 in an LCL itself, like in exosomes purified 
from these cells, does not affect the total cell or surface expression of MHC II (or any 
of the other relevant membrane protein tested in this work). Remarkably, we observed 
that CD63 low LCLs were able to stimulate two different CD4+ T cell clones to a 
much higher degree than control LCLs. Furthermore, this increased stimulatory 
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capacity was sustained even in the presence of high concentration of the exogenously 
added epitope peptide. Repeating this set of experiments in a different cell 
background, using HeLa-CIITA cells in which HLA-DQ5 expression is induced via 
stable expression of the class II transactivator (Gobin et al. 1997) showed that after 
pulsing with a limiting concentration of synthetic epitope peptide (as the HeLa cells 
do not express EBV proteins) T cell recognition of the CD63low HeLa cells was 
much higher than the control. This clearly showed the effect of CD63 depletion is not 
dependent on EBV-encoded proteins and therefore represents a much wider 
phenomenon. These data obtained for CD63 are in line with a similar observation 
obtained from experiments using mouse DCs from CD37 or CD151 knockout mice. 
These CD37- and CD151-deficient DCs were also hyperstimulatory to T cells (Sheng 
et al. 2009). In that study, the knockout of CD37 or CD151 appears to cause 
hyperstimulation by affecting different processes of T cell activation. CD151 
depletion appears to act through altering co-stimulation whereas CD37 was shown to 
interfere with MHC-peptide presentation itself. In a more recent study the tetraspanin 
Tssc6 also appears to be involved with CD37 and Tssc6 and CD37 may have 
cooperative roles in modulating cellular immunity (Gartlan et al. 2010). Both in vitro 
T cell proliferative responses and dendritic cell stimulation capacity are significantly 
exaggerated in CD37
−/−
/Tssc6
−/−
 mice compared with single knockout counterparts. 
An opposite regulatory function in MHC II-dependent antigen presentation was 
already shown for the tetraspanins CD9 in mouse DCs (Unternaehrer et al. 2007). In 
this report the superior capability of DCs compared to B blasts to stimulate T cells 
was proposed to be due to a distinctive organisation of MHC II on the DC’s surface 
mediated by CD9. 
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Since CD63 is incorporated into tetraspanin microdomains, it is conceivable that 
CD63 causes a similar deregulation of these microdomains followed by a diminished 
antigen presentation as observed for CD37 and Tssc6. Alternatively, CD63 may have 
a regulatory function in co-stimulation or induced inhibition of TCR activation. Apart 
from the MHC peptide-TCR mediated stimulatory signal, T cells require a second 
signal to become fully activated. This signal, the co-stimulatory signal, is antigen 
nonspecific and is provided by the interaction between co-stimulatory molecules 
expressed on the membrane of APC. One of the best characterized co-stimulatory 
molecules expressed by T cells is CD28, which interacts with CD80 (B7.1) and CD86 
(B7.2) on the membrane of APC (Lenschow et al. 1996). Another co-stimulatory 
receptor expressed by T cells is ICOS (Inducible Costimulator), which interacts with 
ICOS-L (Wang et al. 2000). T cell co-stimulation is necessary for T cell proliferation, 
differentiation and survival. Activation of T cells without co-stimulation may lead to 
T cell anergy, T cell deletion or the development of immune tolerance. Another way T 
cell stimulation is regulated is by the binding of programmed death ligand-1 or -2 
(PD-L1/-L2) on APC to PD-1 on T cells. PD-L1 binds to its receptor, PD-1, found on 
activated T cells to modulate activation or inhibition. Interestingly, PD-L1 also has an 
appreciable affinity for the co-stimulatory molecule CD80, but not CD86 (Butte et al. 
2008). The related molecule PD-L2 has no such affinity for CD80 or CD86, but 
shares PD-1 as a receptor. Engagement of PD-L1 with its receptor PD-1 on T cells 
delivers a signal that inhibits TCR-mediated activation of IL-2 production and T cell 
proliferation (Sheppard et al. 2004). There is no evidence of an interaction of 
tetraspanins and the above mentioned proteins CD80, CD86 or PD-L1/-L2 thus far. 
But the involvement of CD63 in sorting, trafficking and surface distribution of a 
number of proteins including MHC II (Pols & Klumperman 2008) makes also an 
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association of CD63 with CD80, CD86 and PD-L1/-L2 conceivable. To test these 
hypotheses a series of experiments investigating the qualitative properties of MHC II-
antigen presentation as well as potential co-stimulatory effects of CD63 depletion 
were conducted.   
 
4.5.1 Role of co-stimulatory molecules in stimulation of CD4+ T cell clones 
 
Exosomes derived from APCs, including B cells, are known to express co-stimulatory 
proteins (Galli et al. 2005;Thery et al. 2002a;Zitvogel et al. 1998) that provide 
exosomes with the ability to deliver a co-stimulatory signal. In this regard, exosomes 
secreted by mature DCs are more efficient at inducing CD4+ T cell activation than 
those of immature DCs indicating the importance of co-stimulatory molecules 
(Montecalvo et al. 2008;Segura et al. 2005). However, it is important to mention that 
the CD4+ T cell clones used in our study hardly needed any co-stimulation to be 
activated. Our T cell clones exhibited similar levels of IFNγ release upon inducing 
TCR-cross-linking using an α-CD3 antibody (Valitutti et al. 1995;Weiss 1991) with 
or without allogeneic LCLs to provide a second co-stimulatory signal. This was the 
case even when levels of anti-CD3 were reduced thus our T cell clones did not show 
any dependence upon co-stimulation, as has been observed using T cell clones in 
other settings  (Jenkins et al. 1990).  
Apart from that, LCL-derived exosomes were also able to sensitise HLA-matched but 
antigen-lacking B cells, indicating exosomes as a potent vehicle for antigen cross-
presentation. This phenomenon was previously shown especially for DCs in the 
context of presenting tumour derived antigens (Andre et al. 2002;Wolfers et al. 2001). 
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4.6 Mechanism how CD63 knockdown increases CD4+ T cell activation 
 
4.6.1 CLIP-antigenic peptide exchange and surface peptide presentation 
 
Since CD63 depletion did not affect levels of MHC II, yet increased the cell’s ability 
to stimulate CD4+ T cells, we investigated a possible qualitative change in MHC II.   
The invariant chain molecule transports newly synthesised MHC II molecules into the 
MHC II compartment whereupon it is degraded leaving the low affinity CLIP peptide 
in the MHC II groove. The exchange of high affinity peptides for CLIP is then 
catalysed by HLA-DM molecules. The process of CLIP exchange and peptide loading 
in MIICs is not 100% efficient and therefore a certain amount of CLIP is naturally 
found on the surface of APCs (Odorizzi et al. 1994;Roche et al. 1993;Wang et al. 
1997). HLA-DM is incorporated in tetraspanin-MHC II complexes (Levy & Shoham 
2005b;van Spriel and Figdor 2010b) and CD63 and CD82 bear internalisation signals 
which may enable them to contribute in MHC II (conventional HLA and HLA-DM) 
recycling from plasma membrane to peptide loading compartments (Kropshofer et al. 
2002b;Vogt et al. 2002). Hence, CD63 depletion could conceivably alter HLA-DM 
function. One possible scenario is that by altering HLA-DM function CD63 depletion 
increases the level of low-affinity MHC II-CLIP complexes which are readily 
replaced by exogenously added epitope peptides (Liu et al. 2010) that bind with 
higher affinity. This would account for the increased T cell stimulation observed 
when CD63 low LCLs are pulsed with exogenous epitope peptide.  
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Three separate approaches did not support this hypothesis. Firstly, flow cytometry 
using a CLIP-specific antibody detected similar surface expression levels of CLIP-
bound MHC for both CD63low and control LCLs. Secondly, adding biotinylated 
antigenic peptides to LCLs and subsequently staining with Avidin-PE allowed the 
binding of exogenous peptide to be compared (Busch and Rothbard 1990). These 
experiments showed that amounts of exogenously bound peptides did not vary 
between CD63low and control LCLs. Thirdly, biochemical analysis of the amounts of 
unstable (CLIP bound) and stable (epitope peptide bound) MHC II molecules showed 
no difference between CD63low and control LCLs whether untreated or pre-loaded 
with high affinity epitope peptide. Taken together these results indicate unaltered 
CLIP-antigenic peptide processing after CD63 knockdown. This in turn is in 
agreement with the observation that knocking down CD81 and CD82 in HeLa CIITA 
cell had no effect on the expression of MHC II-CLIP expression (Poloso et al. 2006). 
Moreover, tetraspanins are shown not to bind Ii-associated MHC II in endosomal-
lysosomal compartments (Hammond et al. 1998;Kropshofer et al. 2002b) and are only 
found on the cell surface (Kropshofer et al. 2002b;Rohn et al. 2004) indicating only a 
little if any participation of tetraspanins in peptide exchange processes.  
 
4.6.2 Compartmentalisation of MHC II on the LCL’s surface 
 
As demonstrated for CD82, tetraspanins can regulate the distribution and 
compartmentalisation of associated proteins on the outer membrane (Odintsova et al. 
2003). Moreover, CD82 and CD63 are shown to be present in MIICs and to interact 
with MHC II, HLA-DM and HLA-DO and with each other (Hammond et al. 1998). 
Therefore, it has been speculated that tetraspanins could play a role in MHC II 
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trafficking and maturation as well as influencing actual antigen presentation by 
sequestering MHC II-peptide complexes to areas of the cell membrane that are 
functionally more efficient (Kropshofer et al. 2002a;Unternaehrer et al. 2007). In this 
regard, mouse DCs deficient in CD37 or CD151 have both been demonstrated to be 
more stimulatory to T cells (Sheng et al. 2009). Interestingly, different mechanisms 
underpin this hyperstimulatory phenotype. CD151 does not appear to act through 
MHC II interaction but instead its knockout elevates DC’s co-stimulatory activity. In 
contrast, CD37 interferes directly with MHC II-peptide presentation (Sheng et al. 
2009). It is conceivable that CD37 sequesters MHC II-peptide complexes away from 
TERMS and hence impairs the formation of those speculated activation clusters. With 
this in mind we investigated the compartmentalisation of MHC II upon CD63 
depletion. This was done by performing a flotation of cell lysates prepared from 
CD63low or control LCLs on a sucrose density gradient and comparing the 
distribution of MHC II molecules within that gradient. The overall conclusion from 
these experiments was that CD63 knockdown does not influence MHC II 
compartmentalisation. This conclusion could be confirmed in future work by 
chemical protein cross-linking and subsequent analysis of the resulting protein 
complexes by Western blotting using an antibody recognising MHC II.  
 
4.6.3 MHC II, ICAM-1, actin and tubulin during immune synapse formation 
 
Tetraspanins are known to regulate cytoskeletal rearrangements as demonstrated by 
their influence on integrin signalling and cell spreading after adhesion 
(Delaguillaumie et al. 2004;Feigelson et al. 2003;Goschnick et al. 2006;Lammerding 
et al. 2003). This led us to investigate the potential influence of CD63 on the 
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regulation of immunological synapse (IS) formation and structure. The interactions 
between cells in IS are considered as stable cell junctions requiring a specific protein 
distribution and cytoskeletal polarisation (Dustin et al. 1998). After an exploratory 
contact between the APC and T cell (mediated by ICAM1 and LFA1 on the surface of 
APC and T cell respectively) a specific immune recognition of antigen presenting 
MHC molecules by TCR occurs. Subsequent signalling leads to the formation of 
robust, LFA-1 dependent, adhesions of the T cell to the APC and a selective 
redistribution of membrane molecules. The specific concentric pattern of this contact 
area, the IS, is divided into a central supramolecular activation cluster (cSMAC) and a 
peripheral SMAC (pSMAC) (Monks et al. 1998b). Microfilaments as well as 
microtubules play a crucial role in the formation of the immunological synapse since 
LFA-1 for example is linked to the actin cytoskeleton via talin (Sampath et al. 1998). 
In the way the actin cytoskeleton organises and regulates the IS, a positive feedback 
signalling from the SMAC does influence actin polymerisation and contraction 
(Ardouin et al. 2003;Gil et al. 2002;Krause et al. 2000).  
 
Tetraspanins CD81 (Mittelbrunn et al. 2002) and CD82 (Delaguillaumie et al. 2002) 
have been reported to localise to the IS, CD81 in particular is shown to cluster to the 
cSMAC. Since both these tetraspanins are taking part in the formation of TERMs, 
these observations indicate that TERMs may be redistributed to the IS in general. In 
agreement with this hypothesis is the observation that cross-linking of tetraspanins on 
the T cell surface causes co-stimulation. Antibodies specifically recognising and 
ligating CD9, CD53, CD81 or CD82 caused co-stimulation which is different from 
the mechanism known from the classical CD28-mediated co-stimulation pathway 
(Lagaudriere-Gesbert et al. 1997;Lebel-Binay et al. 1995;Tai et al. 1997;Witherden et 
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al. 2000). This antibody-mediated co-stimulation has been speculated to result from 
aggregation of tetraspanin microdomains which are components of the IS hence 
facilitating TCR engagement (Tarrant et al. 2003). This may not only be the case for 
the T cell side but also for the APC side of the IS since tetraspanins regulate MHC II 
clustering as well (Kropshofer et al. 2002b).  
 
Regarding the APC’s IS, most research so far focused on DCs. But the process of 
formation and maintenance of the IS seems to be very similar in B cells. Apart from 
MHC-TCR interaction, ICAM-1-LFA-1 binding is necessary for the formation of the 
IS between APC and T cell (Davis 2009). DCs (Barreiro et al. 2007) as well as B cells 
(Carrasco et al. 2004;Carrasco and Batista 2006a) are shown to recruit ICAM-1 to the 
IS to form the APC pSMAC opposite to the T cell pSMAC exhibiting the LFA-1. In 
terms of cell morphology and the influence of actin in IS formation abundant 
interactions between the actin cytoskeleton and the SMAC regulate efficiency of the 
IS (Al-Alwan et al. 2001;Billadeau & Burkhardt 2006;Riol-Blanco et al. 2009). For B 
cells in particular, it was demonstrated that Rap GTPase-regulated localised actin 
polymerisation (Lin et al. 2008) as well as F-actin dependent spreading of the B cell 
(Fleire et al. 2006) is required for B cell IS formation. Interestingly, a difference 
between the DC IS and the B cell IS seems to exist in terms of microtubule 
organisation and the microtubule-organising-centre (MTOC) polarisation. The MTOC 
is the site of microtubule nucleation in eukaryotic cells and one of its main functions 
is the organisation of the mitotic and meiotic spindle apparatus separating the 
chromosomes during cell division. In most animal cells during interphase the MTOC 
is usually located near the nucleus, and generally associated closely with the Golgi 
apparatus. MTOC-associated microtubules are therefore also of importantance for 
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membrane bound transport, as the motor proteins kinesin and dynein move along 
microtubules, allowing vesicles to be directed to or from the endoplasmic reticulum 
and Golgi apparatus. 
 For DCs, MTOC polarisation towards the contact area with T cells is well established 
and is thought to regulate the transport of cargo, including MHC and co-stimulatory 
molecules (Boes et al. 2002;Keller et al. 2007;Vyas et al. 2007) and control targeted 
delivery of cytokines at the IS (Pulecio et al. 2010). For B cells on the other hand, 
only little data exist demonstrating that the B cell’s MTOC is not particularly oriented 
to the IS upon contact with T cells (Kupfer et al. 1986). 
 
We investigated the structure of the LCL-T cell IS by immunostaining using 
antibodies against MHC II, ICAM-I and tubulin as well as phalloidin to label actin. 
Confocal microscopy allowed us to analyse protein distribution on the surface and in 
the cytoplasm, to analyse the actual IS for protein content, to study the localisation of 
MVBs and the polarisation of actin or tubulin fibres. As far as the distribution of 
MHC II, ICAM-1 and actin is concerned, we observed similar patterns of staining as 
described in the literature. However, in contrast to observations made by Kupfer et al. 
in LCL we found that tubulin filaments and the MTOC appeared to orientate 
somewhat towards the contact site of the interacting immune cells. While this is an 
interesting observation, more detailed analyses using specific antibodies, detailed 
quantification and statistical analyses of MTOC localisation in the different areas of 
the LCL-T-cell interface would be needed to allow more solid conclusions to be 
drawn. Especially considering the formation of the IS being a very dynamic process 
(Krummel and Cahalan 2010;Lee et al. 2002;Yokosuka and Saito 2009) future 
experiments exploring the kinetics of IS formation by life cell imaging over time 
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would be of interest. Regarding CD63, our data suggest that the depletion of CD63 
does not have any influence on the localisation, distribution and clustering of any of 
these analysed proteins. We did not find any differences between the control and the 
CD63 low LCLs when they were pre-mixed with CD4+ T cells. We do point out 
however that further investigations would be needed before a firm conclusion can be 
drawn from this work. 
 
4.6.4 LMP-1 distribution during immune synapse formation 
 
The same approach was used to study T cell activation in the context of LCLs 
expressing the EBV-derived membrane protein LMP-1 (latent membrane protein 1). 
LMP-1 has multiple functions during EBV infection including mimicking CD40 
signalling and hence maintaining B cell activation, affecting cell-cell contacts, 
cytokine and chemokine production as well as antigen presentation (Brooks et al. 
2009;Middeldorp and Pegtel 2008a). 
Discussions with another research group raised the possibility that the enhanced T cell 
stimulation exhibited by CD63 depleted LCLs could be due to the unique expression 
in LCLs of the EBV-encoded protein LMP1. Of interest to us were the findings that 
LMP1 co-localised with CD63 (Verweij et al. 2011). Since LMP1 also contains a 
motif that has immunosuppressive properties towards T cells (Dukers et al. 2000) this 
raised the possibility that CD63 localises LMP1 into the IS whereupon LMP1 
decreases T cell activity. If this was the case then depletion of CD63 could decrease 
the amount of LMP1 in the IS which in turn would allow such cells to stimulate T cell 
more effectively. Three pieces of experimental data argue against this model. First, 
using immunofluorescence microscopy as described above we could not see any 
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difference in LMP-1 localisation at the immunological synapse following CD63 
depletion. Furthermore we did not detect any change in the expression level of LMP-1 
upon CD63 knockdown in LCLs or LCL-derived exosomes. Second, we observed 
increased T cell stimulation upon knocking down CD63 in class II positive HeLa cells 
that lack LMP-1. 
 
4.6.5 LCL’s co-stimulatory capacity upon CD63 knockdown 
 
CD63 on T cells was previously shown to function as an activation-linked co-
stimulatory element in its own right in the context of DC encounter (Pfistershammer 
et al. 2004). Furthermore, Sheng et al. demonstrated that CD151 influences T cell 
stimulation by inhibiting murine DC’s co-stimulation of T cells (Sheng et al. 2009). 
Therefore, we also had to test whether CD63 knockdown in LCLs may have an effect 
on co-stimulatory capacity. An assay designed to determine the co-stimulatory 
capacity of APCs showed that the co-stimulatory activity of control and CD63low 
LCLs towards CD4+ T cells was the same. However, as stated in section 4.3, the 
CD4+ T cell clones used in our study, in common with all T cell clones, required little 
if any co-stimulatory signalling in order to be activated. In this regard, knocking down 
CD63 expression in HeLa CIITA cells was of particular importance as it did allow us 
to investigate the influence of CD63 on T cell stimulation in a non-professional, EBV-
negative APC. The fact that CD63low HeLa CIITA cells express the same level of 
MHC II but exhibited a strong hyperstimulation of the CD4+ T cell clone c38 
compared to control HeLa cells supported our previous results. CD86 was not 
detected in HeLa CIITA cells (data not shown) and no data so far report the 
expression of any other co-stimulatory proteins by this cell line. Therefore, the 
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observed increase in T cell stimulation by CD63low HeLa cells agrees with the 
outcome of our co-stimulation assay conducted with CD63low LCLs. CD63 appears 
to regulate T cell stimulation via MHC II-antigen presentation and not via co-
stimulation.  
Since knockdown of genes is considerably easier in HeLa cells compared to LCLs I 
made use of the HeLa CIITA system to perform some preliminary experiments on the 
effect of other tetraspanins on T cell stimulation. I was able to knock down both 
CD81 and CD151 in this cell line. Both knockdowns caused an enhanced stimulation 
of CD4+ T cell clones. Here, it has to be considered that these proteins, particularly 
CD151, may execute different regulatory functions in human cells (HeLa) than in 
mouse DCs. In this regard, CD151 is conceivable, apart from influencing the co-
stimulatory pathway as demonstrated by Sheng et al., to regulate T cell stimulation by 
modulating integrin mediated signalling in HeLa cells. CD151 is shown to directly 
interact with particular integrins (Berditchevski 2001;Sterk et al. 2000) and to regulate 
their activity through TERMs. Association with CD151 is critical for the recruitment 
of these integrins to TERMs, where they can cooperate with other TERM-associated 
transmembrane proteins (Stipp et al. 2003a). Thus, CD151 can affect the functionality 
of integrins, for example, by modulating ligand-binding properties (Hemler 2005) or 
regulating internalisation of associated integrins (Liu et al. 2007;Winterwood et al. 
2006). Due to the involvement of CD151-associated integrins in a number of 
processes, CD151 indirectly influences adhesion-dependent signalling and post-
adhesion events such as cell migration, cell motility, granule polarisation (Liu et al. 
2009), co-stimulating cytoskeletal processes that bring T cell signalling proteins to the 
IS (Wulfing and Davis 1998) and regulating the integrity of the IS and the duration of 
T cell contacts for optimal functional responses (Semmrich et al. 2005). 
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On the APC’s side, integrins such as LFA-1 or VLA-4 are mainly known to be 
responsible for processes such as cell migration and homing but also for antigen 
recognition (Arana et al. 2008) and also antigen presentation or T cell activation as 
they mediate the formation of the IS (Carrasco and Batista 2006b). For HeLa cells 
however, there are no data yet about an involvement of integrins in mediating T cell 
stimulation. Additionally, it has to be taken into consideration that we observed a 
heterogeneous MHC II expression in both CD81 low and the CD151 low HeLa 
CIITA cell lines, which makes interpretations of these findings difficult and further 
investigation into this phenomenon necessary to allow any solid conclusions. 
 
4.6.6 Quantification of exosome release following CD63 knock down 
 
Exosome trafficking and release is a complex intracellular process involving highly 
organised pathways (Keller et al. 2006;Thery et al. 2002b). Biogenesis of exosomes 
starts with clathrin- or non-clathrin dependent endocytosis and the formation of early 
endosomes. These endosomes then develop into late endosomes, also called MVBs in 
the context of APCs, incorporating intraluminal vesicles (ILVs), which correspond to 
exosomes once MVBs fuse back with the surface cell membrane and release their 
vesicles in an exocytic manner (Lakkaraju and Rodriguez-Boulan 2008;Schorey and 
Bhatnagar 2008;Van et al. 2006). ILVs are generated by segregation of cargo 
molecules within the limiting membrane of endosomes, followed by inward budding 
and the release of vesicles into the endosome’s lumen. ESCRT (endosomal sorting 
complex required for transport) is known to play a role in this process. ESCRT-0, -I, -
II recognise and associate with ubiquitinated proteins in the endosomal limiting 
membrane, possibly followed by ESCRT-III-mediated membrane budding (Hurley 
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2008;Williams and Urbe 2007). However, it has also been demonstrated that some 
proteins found on ILVs are being released via exosomes by an ESCRT-independent 
manner (Fang et al. 2007;Trajkovic et al. 2008). One of these pathways requires 
ceramide, a lipid exhibiting many structural and physical properties that may facilitate 
the generation of vesicles (Bianco et al. 2009;Trajkovic et al. 2008;Zhang et al. 2009). 
Ceramide mediated oligomerisation and stabilisation of exosomal membrane domains 
may lead, if beyond a critical size, to domain-induced budding (Baumgart et al. 2003) 
and may well be partitioned by tetraspanins.  
 
Due to the complexity, these processes of endosome formation and exosomes release 
can be affected at many different stages causing a quantitative alteration of exosome 
secretion. In blood cells, generally, stimuli causing an increase in intracellular calcium 
levels regulate the secretion of microvesicles including exosomes (Hugel et al. 2005). 
Such stimuli include the activation of thrombin receptor on platelets (Heijnen et al. 
1999), Toll-like receptor 4 by lipopolysaccharides (LPS) on DCs (Obregon et al. 
2006) or the cognate interaction with T cell clones (Buschow et al. 2009) on immature 
DCs. Moreover, the activation of P2X7 receptor (purinergic receptor P2X, ligand-
gated ion channel, 7) by ATP on neutrophils and monocytes (MacKenzie et al. 2001) 
or  diacylglycerol kinase-α on T cells (Alonso et al. 2005;Alonso et al. 2007;Alonso et 
al. 2011) has been shown to regulate exosome release whereas p53 influences this 
process on tumour cells (Lehmann et al. 2008). Regulation of exosome secretion does 
also depend on the microenvironmental pH (Parolini et al. 2009), premature 
senescence (Lehmann et al. 2008), dynein dysfunction (Kimura et al. 2009) or the 
overexpression of v-SNARE proteins, molecules involved in trafficking of endosomes 
to lysosomes (Fader et al. 2009).  
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In this context, tetraspanins expressed within the endosomal system are 
predominantly found in MVBs and lysosomes and particularly CD37, CD53, CD63, 
CD81 and CD82 are shown to be highly enriched on ILVs and exosomes, respectively 
(Escola et al. 1998). In the perspective of our study, CD63 has been reported to 
associate with PI 4-kinase in platelets where it influences phosphoinositide-dependent 
signalling and platelet spreading (Israels and McMillan-Ward 2005). Importantly, 
CD63 is suggested to function as a transport regulator (Pols & Klumperman 2008) 
and it is conceivable that CD63 somehow takes part in the formation, trafficking or 
release of exosomes. CD63 is thought to be linked with the generation of exosomes in 
at least two ways. Firstly, CD63 bears a YXXØ consensus motif required for 
endocytosis at the plasma membrane. This targeting motif is important for association 
with adaptor proteins (APs) and the recruitment of a clathrin coat (Bonifacino and 
Traub 2003). AP-2 associates with CD63 and regulates CD63’s clathrin-mediated 
endocytosis from the plasma membrane (Janvier and Bonifacino 2005;Peden et al. 
2004;Rous et al. 2002). Secondly, CD63 is speculated to be located towards ILVs by 
a pathway involving ceramide (Trajkovic et al. 2008) and in accordance with this, 
CD63 is found to be up to 7 times enriched in ILVs as compared to the endosomal 
limiting membrane and hence is highly enriched in exosomes as compared to whole 
cells (Escola et al. 1998). However, knocking down CD63 in monocyte-derived 
macrophages shows that this tetraspanin is not required for the integrity of MVBs and 
lysosomes in these cells (Ruiz-Mateos et al. 2008). Furthermore, CD63-knockout 
mice did not exhibit any obvious abnormalities in late endosomal/lysosomal 
compartments (Schroder et al. 2009). Although a role of other tetraspanins in the 
biogenesis of MVBs is not known, recently it has been reported that elevated 
expression of particular tetraspanins can change the protein composition of exosomes. 
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Overexpression of CO-029/TSPAN8 in a pancreatic cancer cell line regulates 
recruitment of other tetraspanins and integrins into exosomes (Gesierich et al. 
2006;Nazarenko et al. 2010b). Also CD82 and CD9 have been shown to influence the 
exosomal protein composition by facilitating recruitment of β-catenin, which plays a 
role in the Wnt- and E-cadherin signalling pathways (Chairoungdua et al. 2010). In 
addition to this, it has been demonstrated that CD9 knockout DCs produced less 
exosomes when compared to wild-type DCs (Chairoungdua et al. 2010). In relation to 
our data, this observed tetraspanin-dependent regulation of exosome secretion in DCs 
may represent a general mode of action of tetraspanins in APCs by which they 
influence antigen presentation.  
 
We showed in this study for the first time that CD63 exhibits a regulatory function in 
exosome release in LCLs. Our data clearly show that knocking down CD63 increased 
the release of exosomes in an LCL compared to the control LCL. This increase in 
exosomes secreted to the extracellular environment was quantified by measuring 
exosomal protein amount in exosome preparations derived from both these LCLs and 
confirmed by western blotting for MHC II. Actin is non-specifically sequestered by 
exosomes during their formation and was used as a loading control. Noteworthily, the 
level of CD63 knockdown as well as the hyperstimulatory capacity towards CD4+ T 
cells was higher for the LCL CD63low-b compared to CD63low-a. The increase in 
exosome release however, is somewhat lower for CD63low-b compared to the 
CD63low-a lymphoblastoid cell line. This indicates that the mechanism by which 
CD63 takes part in antigen presentation and T cell stimulation is more complex than 
just influencing the process of exosome formation and release. Nonetheless, this 
increase in exosome secretion following CD63 depletion is a promising candidate for 
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being the underlying mechanism responsible for the observed increase of CD4+ T cell 
activation we observed. If this is indeed the case, then how specifically does increased 
exosome release translate into increased CD4+ T cell activation? We perfomed 
preliminary experiments aimed to investigate two potential mechanisms. Firstly, we 
investigated the possibility that after their release to the extracellular milieu exosomes 
bind back onto the surface of the same or neighbouring LCL cells. If this was the 
case, then the increased amount of surface bound exosomes, each abundantly 
expressing MHC II-peptide complexes, would increase the stimulatory active surface 
area of CD63low LCLs available for T cell recognition in turn increasing recognition 
by T cells. Flow cytometry experiments seeking to detect an increased amount of 
exosomes weakly bound to the surface of LCLs did not show any difference between 
CD63low and control cells. Secondly, since LCL-derived exosomes are shown to 
directly stimulate T cells, the elevated secretion of exosomes could directly lead to an 
enhanced T cell activation (Fig. 4.1).  
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Figure 4.1: Model for how CD63 depletion causes CD4+ T cell hyperstimulation by 
increasing exosome secretion 
We have shown that exosomes are able to directly interact with and stimulate CD4+ T cell 
clones. In this model CD63 depletion leads to enhanced T cell stimulation by increasing the 
secretion of stimulatory exosomes.  
 
We tried to test this hypothesis by exogenously adding purified exosomes to LCL-T 
cell co-cultures. This was thought to mask the enhanced stimulation seen for the 
CD63low LCL. In one preliminary experiment that was performed, the CD63low 
LCL still stimulated the CD4+ T cell clone to a higher degree than the control LCL. 
Additional experiments, which could not be undertaken due to time pressure, would 
be needed in order to accept or reject the hypothesis. Since this theory explains the 
observed hyperstimulation by a quantitative change of exosome secretion rather than 
a selective qualitative change in antigen presenting molecules, it would be intriguing 
to investigate in more detail the MHC I dependent CD8+ T cell stimulation. More 
functional assays would be needed to substantiate our finding of CD63low LCLs not 
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being directly hyperstimulatory towards CD8+ T cells. Additionaly, CD63low 
exosomes purified from LCLs could be tested for their capability of stimulating CD8+ 
T cells antigen specifically.  
One way to test this hypothesis independently from the LCL system would be 
determining the exosome release by HeLa CIITA cells in the context of CD63 
depletion. 
Independently from the cell line used in the assay, blocking of exosome secretion by 
the addition of exosome-release blocking adjuvants would possibly provide 
meaningful insights. Amiloride for example is an inhibitor specific for H+/Na+ and 
Na+/Ca2+ ion channels resulting in an intracellular change in Ca2+ concentration and 
has been shown to inhibit exosome secretion in certain tumour cells in vivo and in 
vitro (Chalmin et al. 2010). Controlling exosomes release of LCLs in functional 
assays analysing T cells stimulation would enable us to specify the role of exosomes 
in T cell activation in the context of CD63. 
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